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Malaria is prevalent in humid tropics between 45°N and 45°S mainly in Africa, Asia, 
Central and South America. It is one of the most widespread infectious diseases found 
in 97 countries with estimated 198 million clinical cases and 584,000 deaths, 
representing a major global public health problem (WHO 2014).  A goal of 
eradicating malaria, once thought to be possible was abandoned decades ago and the 
present goal of malaria control is first to retard the accelerating rates of disease and 
death. Inspite of the decreasing number of malaria cases and mortality, highest 
numbers of cases were recorded in populations mostly living in countries of Sub-
Saharan Africa. Approximately 90% of deaths occur in the African region mostly in 
children under five years of age (WHO 2014). Among the four Plasmodium species 
(P. falciparum, P. vivax, P. ovale, and P. malariae) that are responsible for human 
malaria, P. falciparum has been the most prevalent overall, particularly in Africa 
(86%). Mortality due to P. falciparum which accounts for most of the deaths in Africa 
is associated with cerebral malaria and severe anaemia, especially in children in 
malaria holoendemic areas (Guerra et al. 2010). In Sub-Saharan Africa, pregnant 
women are also at a higher risk of cerebral malaria and anaemia, which are 
consequently the major causes of prenatal morbidity and mortality. Both of these 
malarial complications are responsible for a great number of spontaneous abortions, 
stillbirths, premature deliveries and low birth weight (Dicko et al. 2003). Because of 
the higher P. falciparum prevalence, morbidity and mortality, most of the researches 
are focused on this species. Malaria has been a serious problem in some parts of India 
due to the slow progress in its control. Since wide spread resistance has been reported 
against sulfadoxine-pyrimethamine and to some extent against artemether and 
artesunate plus SP. WHO has recommended artemisinin based combination therapies 
(ACTs) especially artemether plus lumefantrine as first-line treatment for 
uncomplicated P. falciparum malaria. During the past decade, most malaria-endemic 
countries shifted their national treatment policies to ACTs.  
 Aligarh is situated in the upper Ganga-Yamuna Doab. It extends from 27° 29´ 
N to 28° 11´ N latitudes and 77° 29´ to 78° 38´ longitudes. It has tropical monsoon 
type of climate with its highly attributed seasonal variation including the North-East 
and North-West monsoons. Aligarh experiences extreme cold during winters when 
there is a subsequent fall in temperatures, the maximum being 20°C and minimum 
being 4°C, respectively. The hot weather that starts from March and continues till 
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June is marked by a noticeable rise in maximum and minimum temperatures, in 
March being 34.7°C and 15.6°C, respectively. The temperature then continues to rise 
considerably in May and June. The maximum temperature rises to 38.7°C in May and 
39.6°C in June. The onset and retreat of monsoon differ considerably every year. 
Usually rain starts by the end of June or early July and continues till the end of 
September or early October. During this period of the year 90% of the total annual 
precipitation occurs. Excess rain in this part of the year may cause the low-lying areas 
or depressions and ditches to be water-logged. Relative humidity varies considerably 
throughout the year. With the onset of monsoon, the relative humidity increases 
ranging from 65 to 77%. January records the highest percentage of relative humidity, 
i.e. about 82% while during the summer season, particularly in May relative humidity 
is the lowest i.e. around 41%. 
 In India, 58 species of Anopheles have been recorded, out of which 6 are 
considered as primary vectors and 4 as secondary vectors. The primary vectors 
include An. culicifacies, An. stephensi, An. fluviatilis, An. dirus, An. minimus and An. 
sundaicus whereas An. annularis, An. philippiensis (nivipes), An. varuna and An. 
jeyporiensis are secondary vectors (Rao 1984). Among the primary vectors An. 
culicifacies has been established as a major vector of malaria in rural and peri urban 
areas of India (Subbarao et al. 1988). An. culicifacies is responsible for 60-70% of the 
total malaria cases reported annually in India (Sharma 1984). 
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Fig. 1. Pre-erythrocytic cycle of Plasmodium in man 
 
Fig. 2.  Erythrocytic cycle of Plasmodium in man 
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Fig. 3. Sporogonic cycle in mosquito. 
 Malaria is a febrile illness characterized by fever and related symptoms. The 
clinical manifestations of malaria are due to the erythrocytic phase of the parasite. 
Appearance of clinical symptoms of malaria after the pre-patent period is called the 
„„primary attack‟‟. It is usually a typical and may resemble any febrile illness. When 
the infection gets established, fever cycle becomes regular tertian type in the patients 
of P. falciparum and P. vivax. Fever with headache, chills, nausea and vomiting are 
the most frequent symptoms. In severe malaria cases prostration, convulsion, severe 
anaemia, impaired consciousness, respiratory distress and neurological deficits may 
occur. During the progression of the disease, the level of haemoglobin decreases in 
most of the patients. Severe anaemia is the leading manifestation followed by 
respiratory distress and prostration. Splenomegaly and hepatomegaly are infrequent. 
Jaundice is also reported in few malaria patients. Severe anaemia, cerebral malaria 
and metabolic acidosis are considered as the major clinical manifestations in severe 
childhood malaria. However, there is a remarkable shortage of clinical description of 
severe malaria in different endemic regions. Cerebral involvement is comparatively 
rare and seems to occur more frequently in older patients. This pattern resembles the 
situation in highly endemic regions and confirms previously reported age-related 
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differences in disease manifestation (WHO 2000b, Snow et al. 1994, Imbert et al. 
1997, Modiano et al. 1998). Respiratory distress, coma, multiple organ dysfunction 
are the major prediction of death in India (Tripathy et al. 2007). The disease pattern 
and the relative contribution of individual symptoms to mortality differ with 
endemicity, geographic location, access to health services and age among other 
factors (Marsh et al. 1995, Genton et al. 1997, Snow et al. 1997, Schellenberg et al. 
1999, Imbert et al. 2003, Maitland et al. 2003, Waller et al. 1995). 
 The infected RBCs in falciparum malaria, develop protuberance on their cell 
membranes, which results in cytoadherence and clumping. The occlusion of blood 
flow and damage to the vital organs like brain, kidneys, lungs, liver etc. leads to 
serious complications. In cerebral malaria basic defect is clogging of the cerebral 
microcirculation by the parasitized red blood cells. Surface knob proteins further 
increases the clogging of the microcirculation by forming rosette like structure by the 
infected RBCs. Obstructions to the cerebral microcirculations results in hypoxia as 
complete obstruction to blood flow is unlikely, since the survivors rarely have any 
permanent neurological deficits (Srinivas 2014). 
 Children with impaired consciousness and respiratory distress are at the 
highest risk of death (Marsh et al. 1995). Neurological involvement in falciparum 
malaria is common and nearly a quarter of children who survive cerebral malaria, 
develop neurological sequelae (Idro et al. 2007). P. vivax infection is responsible for a 
significant proportion of malaria cases worldwide and is also reported to cause severe 
disease in some cases. In the past few years, there is a changing trend in the clinical 
manifestation of vivax malaria, which has resemblance with falciparum malaria even 
causing death (Lanca et al. 2012). Young children are at high risk of vivax-associated 
severe anaemia, particularly in countries where transmission is intense and relapses 
are frequent. In such places vivax malaria may lead to unusual and fatal 
complications. P. vivax infection is being increasingly recognized as a cause of severe 
malaria in children (Singh et al. 2011). Despite having lower parasite densities than 
that of P. falciparum, P. vivax causes similar absolute reduction in RBC mass as it 
results in proportionately greater removal of uninfected RBCs (Douglas et al. 2012). 
P. vivax malaria though considered to be a benign entity can also have a severe and 
complicated course which is usually associated with P. falciparum malaria (Sharma 
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and Khanduri 2009). Recent findings indicate that P. vivax is also responsible for a 
dramatic toll in many endemic areas except Africa. Cerebral malaria, acute kidney 
injury, liver dysfunction, severe respiratory distress, abnormal bleeding, severe 
anaemia and multiple organ failures were the recently reported symptoms in vivax 
malaria (Prakash et al. 2003, Picot and Bienvenu 2009, Sonkar et al. 2011). 
 In India, P. vivax and P. falciparum cause benign and malignant tertian 
malaria, respectively. P. vivax infections are found in more than 50% cases (WHO 
2014). Of all species of human Plasmodia, P. falciparum is highly pathogenic causing 
malignant tertian malaria with comparatively high rate of morbidity and mortality. 
This parasite shows resistance against routine curative drugs such as chloroquine, 
amodiaquine, metakelfin, fansidar, mefloquine and even artemisinin which has 
recently been introduced in endemic areas and thus posing serious problems in the 
cure of this disease.  
 The increasing problems of drug resistance and availability of limited number 
of antimalarials in many parts of the world have increased the complexity of disease 
management. It has now become evident that most of the endemic countries are facing 
drug resistance problem against antimalarials used to treat uncomplicated malaria. 
Higher impact of resistance leading towards the drug failures contributes to the rise in 
resistance and increased morbidity and mortality due to malaria. The problem of drug 
resistance in Plasmodium may be minimized by sustained development of new 
antimalarials and their use in combinations with other existing effective antimalarials 
having different biochemical target. The strain of P. falciparum resistant to the 
antimalarials spread from areas with massive population movements, inadequate 
health services, improper use of antimalarials and limited resources and operational 
difficulties in implementing malaria control activities. 
  Resistance to chloroquine and amodiaquine in P. falciparum parasites that 
was first observed in 1950s in Colombia and Brazil spread to the Thai-Cambodian 
border in 1960s. Further resistance was reported in Africa in 1970s. Afterwards 
resistance against this drug was reported from Thailand, Malaysia, Cambodia, 
Philippines, Indonesia, Laos, Vietnam, Burma and other areas of South-East Asia 
(Behrens et al. 2010, Ganguly et al. 2013, Yuan et al. 2015) Chloroquine resistance is 
now common in practically all endemic countries of Africa, especially  East Africa 
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which poses increasing problems for the provision of adequate treatment. Resistance 
to the main alternative of chloroquine, sulfadoxine-pyrimethamine is widespread in 
South-East Asia and South America. Sensitivity of quinine was also declined in the 
border areas of Thailand, Cambodia and Myanmar (WHO 1993). Consequently, 
artemisinin and its derivatives were increasingly being used as first line of treatment 
in some of these areas.  
 As far as the status of drug resistance in India is concerned, like other 
countries it has also been reported in India. Malaria parasite has acquired its natural 
defense and developed widespread resistance against chloroquine and sulfadoxine-
pyrimethamine in a fairly good number of cases, warrants replacement as per 
instructions of WHO. Resistance to the cheapest and the most commonly used drug, 
chloroquine was first reported in India from Diphu of Karbi-Anglong district in 
Assam in 1973 (Arora et al. 2008). The Directorate of National Vector Borne 
Diseases Control Programme has been monitoring the efficacy of antimalarial drugs 
against falciparum malaria parasite in the country since 1978 through 13 monitoring 
teams in 11 regional offices for Health and Family Welfares with the objective to 
evaluate the efficacy of first and second line drugs used in the treatment of malaria 
and to provide the information for action to formulate revised drug policies. Drug 
resistance is suspected when acute cases of malaria do not respond to  proper dose of 
antimalarials or when parasites are seen in the blood after their temporary 
disappearance after such treatment. Criteria for recognition of suspected resistance of 
malaria parasites to chloroquine and amodiaquine were adopted in 1974 and a 
standard procedure for determining the response of malaria parasites to chloroquine in 
the field was recommended by the WHO. 
 An escalating number of malaria epidemics had been reported throughout the 
world which changed the scenario of malaria and the clinical profile of the disease. 
The classic paroxysms were observed in only 40 and 47% cases of P. falciparum and 
P. vivax infections, respectively (Hazra et al. 1998). Jaundice, hepatomegaly, 
splenomegaly, respiratory distress and oliguria with impaired renal function and 
convulsion or coma was also observed both in P. falciparum and P. vivax infections 
(Tripathy et al. 2007, Sharma and Khanduri 2009, Sonkar et al. 2011, Sharma et al. 
2015). P. falciparum has given rise to formidable drug resistant strain in Asia. The 
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problem of chloroquine resistance in P. falciparum is widespread and now it is 
leading towards multiple drug resistance against all major antimalarials. Sharma 
(1999) indicated that in high transmission areas of India there are about 30% cases 
which showed some level of drug resistance against standard dosage of curative 
drugs.  
 Antifolate drugs such as sulfadoxine–pyrimethamine combination interfere 
with folate metabolism, a pathway essential for malaria parasite survival. 
Unfortunately, the antifolates have proven susceptible to resistance in the malaria 
parasites. Its indiscriminate use resulted in point mutations in dhfr and dhps genes of 
P. falciparum and P. vivax. Resistance against this drug combination spread relatively 
rapidly, even though this drug remained first line of treatment in several countries as 
it was cheap and affordable. New combinations of these drugs with artemisinin 
derivatives have greatly enhanced their efficacy and reduce the ongoing development 
of resistance, as was observed by introduction of artesunate plus SP combination (Das 
et al. 2013, Mishra et al. 2014). 
 Resistance of the malaria parasite, especially to the antifolates, will continue 
to increase and pose a formidable challenge in future. In P. falciparum, point mutation 
in the dihydrofolate reductase (dhfr) and dihydropteroate synthetase (dhps) genes are 
the major cause of resistance to the antifolate drugs and such mutations are 
responsible for the reduction in their clinical effectiveness. Laboratory based studies 
have shown that specific point mutation affecting dhfr confer drug resistance. 
Epidemiological analysis has shown that these mutations can account for virtually all 
of the resistance observed in the field. Sulfadoxine-pyrimethamine combination 
seemed to be an effective and reasonable alternative to chloroquine, but resistance to 
sulfadoxine-pyrimethamine was rapidly gaining ground, facilitated by slow 
elimination from the body. Work related to resistance against sulfadoxine-
pyrimethamine which is used as second line treatment for P. falciparum malaria is in 
progress in India and abroad. dhfr mutations against sulfadoxine-pyrimethamine has 
been observed in Kenya, Tanzania, Thailand and India (Biswas et al. 2000, Nzila et 
al. 2000, Mutabingwa et al. 2001, Ahmad et al. 2004, Kaur et al. 2006, Sharma 2012, 
Pathak et al. 2014) showing mutations on one, two or three loci, resulting in treatment 
failures. Even though results are available regarding dhfr mutations separately for P. 
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vivax and P. falciparum from various countries, there is no information showing dhfr 
mutations of both species together from the same region at a given point, which can 
retrieve the cross-species effect of the antifolate treatment. Antifolate drugs 
sulfadoxine-pyrimethamine are commonly used to treat . falciparum malaria. 
However, they can also affect the P. vivax parasite, if it co-exists with P. falciparum 
as both the species have common drug targets.  
 Since resistance against sulfadoxine-pyrimethamine (SP) is widespread in 
most endemic countries, artemisinin based combination therapy was introduced. 
Unfortunately, resistance appeared comparatively more quickly against artemether, 
artesunate plus sulfadoxine-pyrimethamine and even in artemether plus lumefantrine 
in many countries including India (Valecha et al. 2009b, Saha et al. 2012, Malmberg 
et al. 2013, Das et al. 2013, Mishra et al. 2014). Looking at the widespread resistance 
against artesunate-SP in northeastern India expert committee of the National Vector 
Borne Diseases Control Programme formulated a sub national drug policy and 
selected artemether plus lumefantrine as the new first line treatment in the North-East 
India. 
 Available information in the literature indicates a lot of variations in the 
prevalence of malaria in  different regions of the same country and even in the same 
area over a passage of time. It is because of industrialization, urbanization and other 
developmental projects which created different ecological conditions. These changes 
have direct bearing on the breeding of vector populations and therefore on the 
transmission of the parasite. In the meantime, drug resistance became widespread in 
almost all the endemic countries, especially against chloroquine, sulfadoxine-
pyrimethamine and even against recently introduced artemisinin based combination 
therapy in endemic regions of almost all the tropical countries having malaria 
infection. It is a well known fact that P. falciparum is a malignant species which may 
cause pathological complications such as anaemia, thrombocytopenia, splenomegaly, 
acute renal failure, acute respiratory distress and neurological deficits and may 
terminate fatally in a few cases, if not treated on time. Recently, it has been reported 
that P. vivax is also moving towards malignancy which is evident from reports of 
different countries which has been cited above, indicating that complications like 
jaundice, renal disorders, acute respiratory distress and neurological deficits occur in 
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P. vivax patients but in a comparatively lesser number of cases.  Keeping these facts 
in view, present study entitled “Studies on the prevalence of malaria with special 
reference to drug resistance and mutations associated with antimalarials in Aligarh 
District” was undertaken which gave precise information regarding the prevalence of 
P. falciparum and P. vivax and the status of drug resistance, especially against 
sulfadoxine-pyrimethamine which was used very extensively uptill now. In my study 
area P. vivax is the dominant species which show relapse in many cases and therefore 
relapse pattern has also been observed in patients treated with chloroquine and 
primaquine. Recrudescence was observed in P. falciparum patients treated with 
sulfadoxine-pyrimethamine, artemether and artemisinin based combinations such as 
artesunate plus SP and artemether plus lumefantrine. Since drug resistance in the 
parasite helps their establishment in human host which may lead towards 
pathogenicity, liver enzymes and kidney markers were estimated in order to assess the 
extent of damage caused by P. falciparum and P. vivax in these vital organs of the 
patients especially in severe and complicated cases.    
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HISTORICAL REVIEW 
Malaria is known since ancient times and the most primitive reports were obtained 
from Egypt and various Papyri. Hippocrates in 400 BC gave the exact description of 
malaria (Boyd 1949). He also mentioned the basic symptoms like chills, fever and 
sweating and scrutinized the characteristic periodicity of different phases of malaria. 
The specific fever caused by malaria parasite known as "Agues" later on received an 
Italian name "Malaria" since then it was associated with the stinking air common near 
marshy areas. Scientists in the field of bacteriology and pathology were trying to find 
out cause of the infectious disease by examining the melancholic changes in the 
organs and the tissues. They suspected the role of insects in the transmission of some 
infections which was treated as milestone in the history of malaria towards the end of 
19th century. 
        Malaria parasite was first seen in red blood cell by Laveran in 1880. 
Marachiafava and Celli in 1885 gave the generic name Plasmodium. Grassi and 
Feletti in 1892 gave differential description for P. vivax and P. malariae whereas P. 
falciparum and P. ovale were described by Welch and Stephens in 1897 and 1922, 
respectively. A new method of staining the malaria parasites in the blood film was 
developed by Romanowsky (1890) in Russia. Mode of transmission of the disease 
from man to man was still unknown, although association among swamps, 
mosquitoes and fever was under the scanner by some workers. Manson in 1884 gave 
the theory of malaria transmission from man to man by mosquitoes. The actual mode 
of transmission involving Anopheles mosquito was described by Ross (1897), 
whereas the life cycle of human malaria parasite in Anopheles mosquito was 
described by Grassi, Bignami and Bastianelli in 1890. Grassi’s theory was 
reconsidered by James in 1931 who suggested that sporozoites after entering the 
human body invade reticulo-endothelial cells. Another study by Fairley in 1945 
revealed that the sporozoites vanished from peripheral circulation within 30 minutes 
after inoculation. Later it was described that the sporozoites first invade the liver and 
complete their pre-erythrocytic schizogony within few days and then enter into the 
blood circulation again to start the erythrocytic schizogony in RBCs followed by 
gametogony. 
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         As far as vector part of malaria is concerned, Challam in 1923 did the first 
anopheline survey in Kamrup district of Assam. Many more surveys were carried out 
by Christophers (1925), Stickland (1929), Ramsay (1930), Macdonald and Choudhury 
(1931), Gupta and Mazumdar (1932) and Rice and Savage (1932) in Assam. Further 
surveys were carried out in other parts of India such as Meghalaya, Manipur, Tripura, 
Arunachal Pradesh, Gujarat and Uttar Pradesh (Shortt 1924, Afridi et al. 1938, Singh 
and Jacob 1943, Mortimer 1946, Mishra and Dhar 1955, Mishra 1956, Bhatia et al. 
1958, Kalra and Wattal 1965, Sen et al. 1973, Rajagopal 1976). About 420 species of 
Anopheles are known throughout the world out of which, 70 are well known malaria 
vectors. 58 species of Anopheles are recorded in India, out of which six species are 
acting as primary vectors while four others are considered as secondary vectors (Rao 
1984). Sharma in 1984 reported that An. culicifacies is the most prolific primary 
vector which is responsible for about 60-70% transmission of malaria in India. This 
species is widely distributed in West Asia, Middle East and Indian subcontinent. In 
Aligarh, vectors responsible for malaria transmission are An. culicifacies and An. 
Stephensi (Wajihullah 2001).  
India is one of the major contributors to malarial morbidity and mortality in 
South-East Asia (World Malaria Report 2005). Malaria has been a problem in India 
for centuries with varying levels of endemicity. Most regions in the country have an 
unstable malaria situation except the North-Eastern region where stable malaria 
situation prevails. There are many endemic pockets of malaria in India particularly in 
North-Eastern states, Orissa, West Bengal and Madhya Pradesh. Situation of malaria 
in India till 1950’s was very serious, with over 75 million cases and 0.8 million deaths 
every year. Keeping the grave situation of malaria in view, National Malaria Control 
Programme (NMCP) was started in 1953 and encouraging results were obtained. 
After 5 years in 1958 National Malaria Eradication Programme (NMEP) was 
launched, this resulted in dramatic decrease in malaria cases. In 1965, cases came 
down to 0.1 million with no death record. Euphoria of success was so overwhelming 
that malaria was considered as a disease of the past. Resurgence of malaria occurred 
in 1970 because of administrative, financial and technical failures (Sharma and 
Mehrotra 1986). The implementation of Urban Malaria Scheme (UMS) in 1971-72 
and the Modified Plan of Operation (MPO) in 1977 improved malaria situation for the 
next 5-6 years which brought malaria cases down to approximately 2 million. The 
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impact was mainly on vivax malaria. Easy availability of drugs under the MPO 
prevented deaths due to malaria and reduced morbidity. P. falciparum Containment 
Programme (PfCP) was launched in 1977 to reduce falciparum malaria in the selected 
areas, but its general spread could not be contained. P. falciparum showed a steady 
upward trend during the 1970’s and thereafter. Malaria at one time considered to be a 
rural disease, later on diversified into various ecotypes. These ecotypes have been 
identified as forest malaria, urban malaria, rural malaria, industrial malaria, border 
malaria and migration malaria. In 1990s, malaria re-emerged and took the lives of 
several thousand people (Sharma 1996). Factors responsible for the re-emergence of 
malaria were vector resistance to insecticides and drug resistance in the parasite.  
Prevalence of malaria  
Malaria is accounting for around 198 million cases in 97 countries with an estimated 
584,000 deaths globally (WHO 2014). Malaria mortality rates have fallen by 47% 
globally. Mortality rates due to malaria among children in Africa have been reduced 
by an estimated 58% when compared with the data of 2000 (WHO 2014). Gusmao 
(1999) reported that about 50% of the population was exposed to some level of risk of 
malaria transmission in 21 countries of American continents. Brazil and Colombia 
experienced more than 60% of malaria burden out of these countries. Guerra et al. 
(2010) reported the risk of P. vivax and P. falciparum transmission in 21 countries in 
Latin America and Caribbean.  Approximately 60% of malaria cases were reported 
from Brazil in America, and rest 40% were reported from Colombia (14.2%), Peru 
(8.8%), Venezuela (5.4%), Bolivia (1.9%) and Ecuador (1.1%). Caribbean cases 
include those reported in Haiti (2.8%). In Central America, the occurrence of malaria 
cases reported in Guatemala, Panama and Honduras were 3.8, 0.4 and 1.5%, 
respectively. Species-wise distribution of malaria was 74% for P. vivax, 25% for P. 
falciparum and <0.01% by P. malariae.  Mortality rate was 0.1% of total malaria 
cases by all the species together (WHO 2009). 
 Malaria is a major burden for most of the resource poor nations of the world. 
Rehabilitation and resettlement programmes, socio-economic conditions and 
environmental factors play an important role in malaria epidemiology. Maximum 
work has been done on P. falciparum because of its association with malignancy and 
mortality in the patients. Various epidemiological studies related to P. falciparum 
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were conducted in different parts of the world like Gambella, Southern Ethiopia, 
Thailand and India (Nigatu et al. 1992, Thimasaran et al. 1995, Sharma 1996).  It was 
reported that P. falciparum infection was emerging in endemic areas (Mandal et al. 
1998).  Bashawri et al. (2001) gave the epidemiological profile of malaria in Al 
Khobar, Saudi Arabia, where 83% cases were of P. falciparum. 
 Unusual parasite genetic differentiation was noticed due to the bio-
geographical barriers which separate endemic areas on the pacific coast from those in 
the Amazon and Orinoco Basins. Due to the genetic differentiation of the parasite, 
spatial and sequential heterogeneity developed in the proportion of infections caused 
by each parasite population in P. falciparum (Cortese et al. 2002, McCollum et al. 
2007). This might have resulted in the isolation of the parasite population and limited 
spreading of mutation. It was more prominent in drug resistant population of P. 
falciparum that might have created problems in malaria control strategies. 
 P. falciparum was considered as the most prevalent species accounting for 
89% cases in Sub Saharan Africa (WHO 2014). The maximum mortality in this 
region was associated with cerebral malaria and severe anaemia (Guerra et al. 2010). 
In Africa, half of the malaria related deaths were caused by anaemia in P. falciparum 
infection. On contrary to this, there was less prevalence of malaria related anaemia in 
Latin America probably due to comparatively less parasite burden. P. vivax was the 
predominant species in this region which appears to display a different clinical 
spectrum but better health services limit severe malaria cases (Quintero et al. 2011). 
Majority of malaria morbidity and mortality is caused by P. falciparum infection in 
humans. High risk of cerebral malaria and anaemia was reported in pregnant women 
of Sub-Saharan Africa which was the major cause of prenatal morbidity and 
mortality. Most of the researches on malaria pathogenesis have been focused on P. 
falciparum species because of its high global prevalence, morbidity and mortality 
(Akhwale et al. 2004).  
 P. falciparum and P. vivax are epidemiologically and biologically different. 
Gametocytes which are picked up by the anopheline vector are responsible for the 
production of sporozoites. These sporozoites lodge themselves in the salivary gland 
and are finally transferred to human host when infected mosquito bites again. In P. 
vivax, gametocytes develop quickly and become available in the peripheral blood 
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within 5-6 days after the detection of the parasite in the blood. This helps transmission 
of gametocytes before diagnosis or initiation of the treatment. In P. falciparum it 
takes longer for the development of gametocytes which appear in peripheral 
circulation after 10 days. Besides this, P. vivax sporozoites develop faster than P. 
falciparum under similar conditions of temperature and humidity. The ability of P. 
vivax to relapse following primary attack favours its higher rate of transmission. The 
reactivation of hypnozoites which remain dormant for some time in the liver 
parenchyma is epidemiologically important and a favourable factor for P. vivax which 
enables them to propagate faster than that of P. falciparum. These advantageous 
factors probably help P. vivax to achieve higher numbers and cover wide geographic 
range compared to P. falciparum as earlier indicated by Gething et al. (2011).       
 P. vivax was the second most prevalent species with estimated 25-40% clinical 
cases world wide (Westerberger et al. 2010). Earlier it was believed that P. vivax 
causes a benign disease, but now there are growing evidences of its high prevalence 
and complexity along with severe anaemia (Genton et al. 2008, Tjitra et al. 2008, 
Kochar et al. 2009, Alexandre et al. 2010, Andrade et al. 2010). Public health 
importance of P. vivax became more significant because of its wider geographical 
range exposing more people to the risk of infection and its ability to relapse which 
makes its control more difficult (Tjitra et al. 2008). In Bikaner, North-Western India, 
blood of 303 admitted children was analysed by PCR which showed 61.01, 33.99 and 
4.95% cases of P. falciparum, P. vivax and mixed infection, respectively (Kochar et 
al. 2010). They observed greatest tendency to cause multiorgan dysfunction in 0-5 
years’ age group. Kochar et al. (2014) again recorded almost similar clinical features 
and prognosis, including mortality in severe P. falciparum and P. vivax patients in 
Bikaner.  
 An epidemiological study of children with severe malaria was carried out in 
2008 in Delhi, India. A total of 1,680 children were screened for malaria. On testing 
with peripheral smear examination 38 children were reported positive for malaria. 27 
(71%) were admitted and categorized as severe malaria according to WHO guidelines 
while remaining 11 (29%) received treatment on outpatients basis. Out of the 27 
severe cases 24 (88.8%) were infected with P. vivax (Kaushik et al. 2012). Further 
studies were conducted in Northern India in 2012 at a tertiary care hospital. 35 
children were diagnosed with severe malaria, out of which 51.4% were infected with 
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P. vivax and 22.8% with P. falciparum. Rest 25.7% were mixed infections (Gehlawat 
et al. 2013). In Uttarakhand P. vivax dominated over P. falciparum where these 
infections were 71.8 and 28.2%, respectively. Male to female proportion recorded in 
this study was 17:7 in falciparum patients while in P. vivax it was 42:19 (Singh et al. 
2013). Similar dominance of P. vivax infection over P. falciparum was noticed in 
Central India where these infections were 56.5 and 39.1%, respectively (Gupta et al. 
2013). 59.49% P. vivax and 40.50% P. falciparum infections with male to female 
ratio of almost 3:1 were observed in Gujarat, Western India in 2012 (Goyal and 
Makwana 2014). It was noted that P. vivax is the most widespread infection in India 
resulting in pronounced morbidity which may cause life threatening complications 
and even death in some cases (Joshi et al. 2008, Rizvi et al. 2013). 
Resistance and relapse against chloroquine and primaquine 
In malaria control programme, resistance is causing a challenging problem in most 
parts of the world. Drug resistance is the ability of the parasite species to survive 
and/or multiply regardless of the administration and absorption of a drug equal to or 
higher than that usually recommended but within the tolerance limit. Innovation of 
chloroquine for the treatment of malaria was a revolution, pushing quinine to 
sidelines. Two epicentres for the beginning of resistance were Colombia (South 
America) and Thailand (South-East Asia). 
 Numerous reports are available regarding resistance of P.  falciparum against 
standard dose of antimalarials. Resistance against chloroquine, amodiaquine, quinine, 
metakelfin, fansidar, mefloquine and artemisinin were reported in many endemic 
countries of the world such as Papua New Guinea, Thailand, Zimbabwe, India, 
Pakistan and Afghanistan. As far as resistance against chloroquine is concerned, it 
was observed for the first time in Cambodia in 1957 and spread along the Thailand-
Cambodia border in 1960s. After that, resistance spread worldwide and is now 
reported in about 80% of 92 countries where malaria continues to be a major killer. 
Kenya and Tanzania were the first countries to report chloroquine resistance in P. 
falciparum in 1978 which spread throughout Africa (Wellem and Plowe 2001). 
Chloroquine resistance was reported in the patients in Zimbabwe, Gambia, Thailand, 
Japan, Pakistan, Afghanistan and India (Vanojanonta et al. 1996, Mharakurwas et al. 
1997, Shah et al. 1997, Bojang et al. 1998, Mitra et al. 2006, Sharma et al. 2012). 
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Chloroquine was replaced by the combination of sulfadoxine-pyrimethamine (SP) as 
first line drug for the treatment of uncomplicated malaria in Thailand and many other 
African countries in 1973. Sulfadoxine-pyrimethamine too was replaced by 
mefloquine in 1985 because of appearance of resistance. The rapid development of 
resistance against mefloquine compelled to the introduction of artemisinin based 
combination therapy in these countries by mid-1990s (Farooq and Mahajan 2004).  
 Reports regarding the failure of primaquine in preventing relapse in P. vivax 
patients were widespread in Western Pacific and South-East Asia, and later in Central 
America (Signorini et al. 1996). After administration of the standard primaquine 
therapy, relapse in vivax malaria was reported from various countries such as Japan, 
New Guinea, Thailand, Indonesia, India, Nepal and Pakistan. Course of therapy used 
to successfully treat the relapsed cases was either 20 mg/day for 7 days or 15 mg/day 
for 14 days or 15 mg/day for 21 days or two courses of standard primaquine therapy 
at one month interval without noticeable side effects in the above countries. A lot of 
variations were observed in different parts of India as for efficacy of primaquine is 
concerned. Sharma et al. (1999) conducted a study on relapse pattern of P. vivax in 
Kheda and observed relapse in only 2.6 % patients treated with 5 days course of 
primaquine whereas Prasad et al. (1991) conducted a study on the relapse pattern of 
P. vivax in district Shahjahanpur where they observed relapse in 70.2% males and 
29.8% females. 
 Srivastava et al. (1996) studied relapse pattern in the Kheda hospital where 
one group of patients was treated with 600 mg chloroquine and other with 600 mg 
chloroquine and 50 mg primaquine and showed 28.3 and 27.3% relapse rates, 
respectively. Few long term relapse and more short term relapse (within 2-3 months) 
were noticed by them. Adak et al. (1998) conducted a five years epidemiological 
study of patients attending malaria clinic in Delhi and observed 23 to 44% relapse 
cases, depending upon the duration of the follow up. 
 Resistance to P. vivax malaria was noticed in Australia when routine treatment 
of chloroquine failed to treat the patients (Rieckmann et al. 1989). In Myanmar, 
resistance to standard chloroquine therapy was noticed by Marler-Than et al. (1995). 
During his follow up 50 patients with P. vivax infection were treated with standard 
regimen of chloroquine phosphate (1500 mg for 3 days) followed by 45 mg 
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primaquine immediately and then weekly for 8 weeks. Recrudescence was noticed in 
a few patients between days 3 and 14 with RI, RII and RIII patterns. Baird et al. 
(1997) reported chloroquine resistant strain of P. vivax in Indonesia where 21 patients 
infected with P. vivax were treated with chloroquine and 3 of them showed asexual 
phase of P. vivax parasitaemia between days 14 and 18 despite effective levels of 
chloroquine at the time of recurrence. 14% cases showed resistance to the standard 
chloroquine therapy. There were many more reports of chloroquine resistance in P. 
vivax which had been documented from Indonesia, Vietnam, Myanmar, Thailand and 
India (Baird et al. 1991, Collignon 1991, Schuurkamp et al. 1992, Kyaw et al. 1993, 
Phan et al. 2002, Sunawinata et al. 2003, Ratcliff et al. 2007, Tanwar et al. 2013, 
Ganguly et al. 2013, Price et al. 2014, Yuan et al. 2015, Kumar et al. 2015). 
Resistance against Sulfadoxine-pyrimethamine 
Sulfadoxine-pyrimethamine (SP) which is an antifolate was introduced to treat the P. 
falciparum patients in many countries where resistance against chloroquine was 
widespread. Antifolates interfere with the folate metabolism, a pathway essential for 
the survival of malaria parasites. Due to indiscriminate use for a long duration, 
susceptibility of this drug combination gets reduced and resistance against 
Plasmodium appeared in fairly good number of cases. SP resistance was reported on 
the Kenyan coast and in North-East Tanzania with 45% treatment failure during 1997-
2001 (Nzila et al. 2000, Mutabingwa et al. 2001). Point mutation occurred in 
dihydrofolate reductase (dhfr) and dihydropteroate synthetase (dhps) genes in P. 
falciparum isolates from India and Thailand where mutation was higher in dhfr gene 
compared to dhps (Biswas et al. 2000, Ahmad et al. 2004). They concluded that even 
though sulfadoxine-pyrimethamine (SP) is prescribed as a second line of treatment in 
India, the mutations associated with SP resistance continue to increase progressively. 
Gregson and Plowe (2005) reported that first mutation occurs at S108N codon 
followed by C59R, N51I and I164L. There was occurrence of single, double, triple 
and quadruple pfdhfr mutations depending on the level of drug resistance. Higher 
degree of pyrimethamine resistance was showed by P. falciparum isolates with 
increased numbers of pfdhfr mutations. The patients with falciparum malaria 
containing quadruple mutations showed treatment failure against this drug (Wang et 
al.1997). Kaur et al. (2006) observed mutations in dhfr gene of P. vivax against 
antifolate drugs. 
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 Even though results are available regarding dhfr mutations separately for P. 
vivax and P. falciparum from various countries, there is no information showing dhfr 
mutations of both species together from the same region at a given point, which can 
retrieve the cross-species effect of the antifolate treatment. Sulfadoxine-
pyrimethamine is commonly used to treat falciparum malaria. However, it can also 
affect P. vivax parasite, if it co-exists with P. falciparum, since both the species have 
common drug targets. Resistance to this drug combination is rising fast, with 
treatment failure being reported in Kenya, Tanzania, Mbeya, Malawi, Tanga and 
Orissa and North-Eastern parts of India (Bousema et al. 2003, Bwijo et al. 2003, 
Msyamboza et al. 2007, Schonfeld et al. 2007, Menard et al. 2008, Gesase et al. 
2009, Sharma 2012, Mishra et al. 2014). 
 The level of pyrimethamine resistance in P. vivax has also increased with the 
sequential addition of each mutation in dhfr gene and S117T mutation was seen in 
extremely resistant parasites (Hastings et al. 2004, 2005). Valecha et al. (2006) 
reported double mutations in dhfr gene in vitro in Indian isolates of P. vivax.  Alam et 
al. (2007) studied cross species impact of antifolate drug treatment and observed that 
the overall mutation rate of dhfr in P. vivax was lower than that in P. falciparum. 
They concluded that both the species of Plasmodium followed similar trends of dhfr 
mutations. 
 Additional mutations reported in pvdhfr were I13L, P33L, F57L/I, T61M, 
S117T, I172V and I173L (Imwong et al. 2003, Brega et al. 2004, de Pecoulas et al. 
1998, 2004, Hastings et al. 2005, Schunk et al. 2006). Various other workers reported 
similar pvdhfr mutations at above codons except for I13L, P33L, I172V and I173L in 
India (Imwong et al. 2001, Kaur et al. 2006, Valecha et al. 2006). 
 Highest level of pyrimethamine resistance was due to quadruple mutations in 
the P. falciparum dihydrofolate reductase (pfdhfr) enzyme leading to treatment 
failure. Ahmed et al. (2006) described the presence of quadruple mutations in 
majority of P. falciparum isolates from Car Nicobar (Andaman and Nicobar) Island, 
India. It was concluded from their work that the pressure of antifolate drug was high 
in the island, which is a matter of concern for malaria control programme. Ahmed et 
al. (2006) further described dihydropteroate synthetase (dhps) mutations on the P. 
falciparum isolates to assess the sulfadoxine-pyrimethamine resistance. In isolates 
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from Car Nicobar Island, majority showed double dhps mutations whereas isolates 
from Uttar Pradesh (U.P.) and Assam showed wild type dhps. dhfr-dhps mutations 
were lowest in U.P., higher in Assam and highest in Car Nicobar.  
 Lumb et al. (2009) studied the origin and evolution of pyrimethamine 
resistance in the isolates of Indian subcontinent for which microsatellite flanking of 
the pfdhfr gene was mapped. They described the genetic hitchhiking around the pfdhfr 
gene among 190 P. falciparum isolates collected from different geographical regions 
of India (Uttar Pradesh, Madhya Pradesh, Assam, Orissa and Andaman and Nicobar 
Islands) where there were different levels of malaria transmission and drug resistance. 
They observed a significant reduction in genetic variation in the ±20-kb vicinity of the 
mutated pfdhfr alleles due to hitchhiking. This reduction in the genetic diversity was 
more prominent around quadruple pfdhfr alleles (heterozygosity [He]= 0.23) than 
around double (He= 0.365) and single (He= 0.465) mutant alleles. It was observed 
that all the pfdhfr alleles share a single microsatellite haplotype and seem to have 
originated from a single progenitor similar to that of South-East Asian (Thailand) 
pfdhfr mutants. Thus, the emergence of drug-resistant alleles is recent phenomenon in 
India and that can be compared to South-East Asian countries. 
 Lumb et al. (2011) assessed 193 P. falciparum isolates from India and 
analysed 15 microsatellite loci around dhps gene to investigate genetic lineages of the 
mutant dhps alleles in different parts of the country. After analysing the genetic 
lineages of the resistant dhps alleles on Andaman and Nicobar Islands and mainland, 
India was considered as a significant contributor in Asia, considering intercontinental 
spread of sulfadoxine-pyrimethamine resistance. Kuesap et al. (2011) examined the 
prevalence and pattern of mutations in P. vivax isolates collected from Mae Sot, Tak 
Province, Thailand. The study was done on P.vivax dihydrofolate reductase (pvdhfr) 
and P. vivax dihydropteroate reductase (pvdhps). The single nucleotide sequence-
haplotype was examined for amino acid positions 13, 33, 57, 61, 117 and 173 of 
pvdhfr and 383 and 553 for pvdhps. The most common alleles out of the mutant 
pvdhfr were triple mutants (99%). Eight different types of combinations of pvdhfr 
alleles were found at loci 57, 58 and 117. For pvdhps allele, most prevalent was single 
mutation in amino acid 383 (82.5%) and wild-type A383/A553 (17.5%) allele. It was 
concluded that all the isolates have some or the other type of mutant alleles either in 
pvdhfr or pvdhps gene. Molecular analysis was done in malaria endemic pockets in 
Historical Review 
21 
 
Pakistan where resistance was detected in pvdhfr gene at codon 57, 58, and 117, with 
highest mutation frequency of 93.5% at codon 117N in P. vivax. 
 The in vivo and in vitro data on pvdhfr mutations clearly showed the 
association between pyrimethamine resistance and point mutations (Imwong et al. 
2001, Tahar et al. 2001, Leartsakulpanich et al. 2002, Tjitra et al. 2002 and Hastings 
et al. 2004, 2005). The dhfr mutation of both Plasmodium species have now been 
used as markers to assess antifolate drug pressure in the field (Wang et al. 1997, 
Imwong et al. 2001, Tjitra et al. 2002, Ahmad et al. 2004, 2006, de Pecoulas et al. 
2004, Hastings et al. 2004, Gregson and Plowe 2005, Nayak et al. 2014, Kar et al. 
2015, Schunk et al. 2006, Valecha et al. 2006). Resistance of P. falciparum at the 
molecular level to sulfadoxine-pyrimethamine was done by the molecular markers of 
mutations in the dihydrofolate reductase and dihydropteroate synthetase (Ghani et al. 
2013). 
 Widespread SP resistance in many endemic areas was explained by the 
invasion of limited resistance lineages which was shown by the application of 
microsatellite markers flanking pfdhfr. Multiple origins of triple mutation of pfdhfr 
were confirmed in Africa (Mita 2010). Zakai et al. (2013) observed higher rate of 
pfdhfr mutation compared to pvdhfr in isolates of India and Saudi Arabia. 
Resistance against artemisinin derivatives. 
Due to indiscriminate use of sulfadoxine-pyrimethamine high level of resistance 
appeared in P. falciparum against this drug and the treatment strategy was shifted to 
artemisinin based combination therapy (ACT). In Afghanistan, a slow rate of spread 
of resistance and improved treatment outcomes were recorded by the use of 
artemisinin based combination therapy (ACT). It was reported that the therapeutic and 
parasitological cure rates with AS/AQ were inadequate and the decisive factor for 
deploying ACT to prevent further selection of drug resistance in Afghanistan. In 
Tanzania, it was reported that Artemisinin based combination therapy is most 
effective and safe for the treatment of uncomplicated malaria. A higher rate of 
resistance ranging from 9.5-16% against artesunate-SP combination has been reported 
in Thailand and Cambodia (Saha et al. 2012, Das et al. 2013 and Mishra et al. 2014). 
Valecha et al. (2009a) observed cure rate of 90% in Assam and Orissa where strains 
of multiple drug resistance of P. falciparum are quite prevalent. But in the rest of 
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India this drug combination is highly effective as for the treatment of uncomplicated 
and complicated cases of falciparum malaria is concerned.  Artemether and 
lumefantrine (AL) proved better combination in Africa where failure rate was 2.82-
5.58% (Sisowath et al. 2007, Malmberg et al. 2013). The efficacy of artemether-
lumifantrine (AL) was recorded up to 100% in uncomplicated P. falciparum patients 
(Shayo et al. 2015). Though resistance against this drug combination has also been 
documented as is evident from the above findings, it is still comparatively a better 
option for treating falciparum malaria with maximum efficacy rate. 
Clinical manifestations:  
Malaria is a febrile disease with clinical symptoms such as headache, fatigue, chills, 
malaise and myalgia followed by nausea, vomiting and anorexia. In severe cases 
especially in falciparum malaria patient may suffer from jaundice, renal failure, 
neurological disorders and even coma. The clinical course of malaria varies with 
geography, epidemiology, immune status and the age of the patient. Young children 
and pregnant women in endemic areas are generally at highest risk of developing 
severe illness and anemia. Repeated infections in older children and adults develop 
partial immunity in the endemic pockets where malaria is transmitted throughout the 
year thereby decreasing the risk for severe disease. Patients with no exposure to 
malaria parasite are generally at a very high risk especially when infected with P. 
falciparum. In malaria, paroxysm begins with shivering and chills followed by high 
fever and drop in body temperature to normal or even below normal. In a fairly good 
number of patients classical paroxysm is not experienced in the beginning because of 
multiple broods emerging in the bloodstream. Synchronous infections are more likely 
to be present with classic fever patterns. However, the occurrence of typical 
periodicity of fever in falciparum and vivax malaria is no more a reliable clue to the 
diagnosis of malaria as symptoms in viral fever also shares a few similarities. 
Hypnozoites in P. vivax infection which remain dormant in hepatocytes for shorter 
duration in tropical regions and for longer duration in temperate regions result in short 
term and long term relapses in the patients. 
 It was reported that the erythrocytes of malaria patients have a decreased half-
life compared to those of healthy individuals (Looareesuwan et al. 1991). The 
released merozoites either from the liver or from erythrocytes enter the new 
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erythrocytes. P. vivax has special preference for immature red blood cells 
(reticulocytes), while the merozoites of P. falciparum invade any stage (Simpson et 
al. 1999, Rayner et al. 2005). A noticeable outcome of the parasite multiplication and 
the periodic burst of schizonts is the rupture of the infected erythrocytes. Though it 
contributes to the development of anaemia but is not sufficient explanation of the 
level of anaemia in the patients exposed to the infection. Severe malaria was indicated 
by the level of infection with parasitaemia >50,000 parasites/µL (WHO 2000). 
Rigidity is caused by the transfer of parasite antigens to the infected erythrocyte 
membrane. It is followed by the deformation of the membrane, opsonisation by 
antibodies and complement and macrophage activation (Wickramasinghe and Abdalla 
2000). Acute malaria infection in the adult may be supplemented by a reduction in 
total erythropoietic activity.  The two most horrifying complications of malaria that 
are associated with mortality, especially in children and pregnant women, are cerebral 
malaria and severe anaemia with mortality rates 5.6-16%  in children and 
approximately 6% in pregnant women (Marsh et al. 1995, Granja et al. 1998, 
Manandez et al. 2000, Weatherall et al. 2002).  
 Approximately 60-80% of Hb is degraded during the intra-erythrocytic cycle, 
liberating haemozoin (HZ) and amino acids that are used by the parasites to produce 
its own proteins. The presence of HZ in the cytoplasm of polymorphonuclear 
leukocytes and monocytes, may be linked with the severity of the malaria infection, as 
cytoplasmic HZ is more frequently found in the complicated malaria cases than in the 
uncomplicated cases (Nguyen et al. 1995, Amodu et al. 1998, Lyke et al. 2003, Lopez 
et al. 2004). Besides the known importance of anaemia as a cause of morbidity and 
mortality in malaria endemic areas, little is known about its prevalence and burden in 
malaria endemic regions. Specific haematological changes associated with malaria 
infection may vary with the level of nutritional status (Friedman et al. 2005), malaria 
endemicity (Idro et al. 2006a), demographic factors (Barcus et al. 2007), malaria 
immunity (Langhorne et al. 2008) and parasite species. 
 Anaemia is one of the prominent clinical features in malaria. Repeated 
haemolysis of infected red blood cells is the most common cause for the reduction in 
haemoglobin levels. Anaemia depends on the degree of parasitaemia, duration of 
acute illness and the number of febrile paroxysms. Anaemia becomes evident after a 
few paroxysms (Srinivas 2015). It is more prominent in P. falciparum infections 
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compared to P. vivax as former infect RBCs both young and old, while the latter 
invades only younger cells. Massive destruction of red blood cells in P. falciparum 
infection results in rapid development of anaemia. The clearance of uninfected RBCs 
is increased due to extrinsic and intrinsic changes to the RBCs that enhance their 
recognition and phagocytosis (Dondorp et al. 1997, 2002). Moreover, non-parasitized 
RBCs are also removed from the circulation by complement-mediated lysis and 
phagocytosis resulting from immune complex deposition and complement activation 
(Claire 2004). In response to parasite infection host immune system gets activated and 
immunoglobulins and complement play an important role of marking uninfected 
RBCs for the clearance by phagocytes (Facer et al. 1979, 1980). Clearance of 
uninfected RBCs in such a large numbers was certainly due to activation of splenic 
and other macrophages for the phagocytosis of RBCs which increased significantly 
during malaria (Brown et al. 1990, Mohan et al. 1995, Ladhani et al. 2002 and 
Jenkins et al. 2006). The increased clearance of infected red blood cells is believed to 
be due to opsonisation. It was estimated that approximately 10 uninfected cells are 
cleared from the circulation for every infected cell and therefore the clearance of un-
infected cells play an important role in the development of anaemia (Jakeman et al. 
1999). This theory was proved authentic when the surface of RBCs was found 
positive for immunoglobulins and/or complement in malaria patients (Facer 1979). 
Antibodies giving rise to the positive Direct Coomb’s Test (DCT) were directed 
against malaria antigen (Facer 1980, Kai and Roberts 2008). It may include the IgG 
complexes against malaria antigens including ring stage protein 2 (Layez 2005). It is 
believed that anaemia and haemolysis of red blood cells is also linked with age-
dependent increase in the capacity of RBCs to inactivate complement components 
absorbed or deposited directly onto the surface of the RBCs (Odhiambo et al. 2008).  
Complement receptor 1 (CR1 or CD35), decay accelerating factor (DAF or CD55) 
and the membrane inhibitor of reactive lysis (MIRL or CD59)  enhance binding of 
C3b in immune complexes (CR1), which enhance the inactivation of C3 convertases 
(CR1 and CD55) and interfere with the assembly of the terminal components of 
complement that form the membrane attack complex (CD59) (Devine 1991). Splenic 
macrophages may remove the immune complexes and CR1 and the RBCs depleted of 
immune complexes CR1 (CD35) and CD55 and back to the circulation. CR1 and 
CD55 associated with cell surface of RBCs show a decrease while IgG tagged with 
cell surface increases in children with severe malaria (Waitumbi et al. 2000). The 
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difference in surface IgG levels appeared to be functionally significant as RBCs from 
children with severe anaemia were more susceptible to phagocytosis in vitro than 
RBCs from controls (Kai and Roberts 2008). Decrease in the CD35 or CR1 
expression and elevation in immune complexes bound on uninfected RBCs were 
related with anaemia but the decline in CD35 (CR1) and CD55 expression was only 
briefly related with malaria infection and levels returned in CD35 and CD55 
expression when bound immune complexes are cleared by phagocytes. Anaemia in 
malaria patients is generally normocytic and normochromic type (Phillips et al. 1986). 
In endemic countries high frequencies of haemoglobinopathies and iron deficiency 
leads to microcytic and hypochromic type of malaria (Bashawri et al. 2001). 
Reticulocytosis is another clinical feature which develops along with anaemia. The 
haematocrit level may be normal during the first 24 hours after the onset of fever in 
uncomplicated falciparum malaria patients, but there may be a progressive decline in 
the haematocrit level afterwards after a few paroxysms (Wickramasinghe & Abdalla 
2000). Some factors released by the parasites in malaria infection induce bone 
marrow dysfunction by causing pathogenesis (Silverman et al. 1987, Miller et al. 
1989).  It has been observed that many children who suffer from malaria had low Hb 
levels and reticulocyte counts than expected (Kurtzhals et al. 1999, Wickramasinghe 
& Abdalla 2000). In P. vivax infection destruction of erythrocytes is marked with 
decreased level of haemoglobin which takes sufficient time to return to its original 
figure, despite the elimination of the infection. This is probably because of P. vivax 
invasion to reticulocytes, which prevents the establishment of the normal erythrocyte 
population (Collins et al. 2003). 
 Thrombocytopenia is one of the clinical symptoms which may occur in both 
P. falciparum and P. vivax infections. Association between severe malaria and 
thrombocytopenia was reported in some studies, most of which include both children 
and adults (Gerardin 2002, Rogier 2004).  In few cases minor bleeding was reported 
in P. vivax cases as well which may be explained by medullary damages with the 
discharge of mega platelets in the peripheral circulation by megakaryocytes. The 
hypothesized mechanisms leading to thrombocytopenia were mainly coagulation 
disturbances, bone marrow alterations, antibody-mediated platelet destruction, 
oxidative stress and platelets activation as cofactors in activating malaria (Lacerda et 
al. 2011). 
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 Thrombocytopenia and its prognostic value have not been addressed in 
children who suffer from P. vivax infection and present this symptom in a fairly good 
number of cases (Muley et al. 2014). Adult P. vivax patients were also reported to 
have thrombocytopenia (Kochar et al. 2009). It was highest in children of 1-5 years 
age and decreased with increase in age, whereas in P. falciparum infection it was 
reverse. Low rate of thrombocytopenia was also reported from the patients having 
complications like hyperparasitaemia and acute renal failure, compared to the 
uncomplicated patients (Saravu et al. 2011). Significant association between platelets 
and severe malaria in children was reported by Tanwar et al. (2012). It was also 
observed that neither bleeding nor the mortality was reported even in case having 
severe thrombocytopenia where platelet count was <50,000/µL (Lacerda 2007, Silva 
2009). Thrombocytopenia may not be the direct cause of mortality but may be the 
marker for increased severity and needs appropriate management (Muley et al. 2014). 
Thrombocytopenia may not be considered to be a severity criterion due to its inability 
to cause death (WHO 2000b). 
 The early enlargement of the spleen is due to engorgement, oedema of the 
pulp and later due to lymphoid and reticulo-endothelial hyperplasia with an increased 
haemolytic and phagocytic function of the organ. Frequent relapses and re-infections 
lead to pulp sclerosis and dilated sinuses. Splenomegaly is commonly observed in 
malaria patients after a few paroxysms but did not receive any special attention as it is 
usually resolved with standard antimalarial therapy. Inside the spleen, the supply of 
the splenic and gastric arteries is segmented, occlusion of their secondary branches 
results in wedge-shaped infarct which is generally associated with haematological 
disorders such as leukaemia, lymphoma and other hypercoagulable states. Splenic 
infarct may also be caused by systemic embolisation in endocarditis or prosthetic 
heart valves. Very few cases of malaria showing splenic infarct are documented 
(Agarwal et al. 2005, 2014). Splenic infarct can be diagnosed by a CT showing 
multiple wedge-shaped areas of low attenuation, which are characteristically different 
from those noticed on CT images of splenic rupture or sub capsular hematoma (Miller 
et al. 2004). 
 The main procedure of infarction in malaria especially in P. falciparum is the 
phenomenon of sequestration of RBCs containing mature stage of parasites (Mohanty 
et al. 2006). Sequestration mainly occurs in the venules of vital organs which were 
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not uniformly distributed, being greatest in the brain, mainly white matter, followed 
by heart, eyes, liver, kidneys, intestine, adipose tissue and least in the skin. Similar 
tendency is not observed in vivax malaria where splenic infarct is caused by 
hyperplasia of reticular cells situated inside the walls of venous sinuses (Agarwal et 
al. 2005). Splenic infarct is generally observed in falciparum malaria with high 
parasitaemia and microvascular sequestration of parasitised RBCs (Bonnard et al. 
2005). Splenic infarction, a rare complication mainly caused in P. falciparum was 
reported in 34 years old patient who had fever for five days and was treated with 
chloroquine (Kim et al. 2007). Splenic infarction was observed in acute cases of P. 
falciparum, P. vivax and mixed infections in the northwest Rajasthan (Gupta et al. 
2010). 
 Liver plays a key role in the life cycle of malaria parasites which gets 
seriously affected and enlarged in some cases. Hepatocellular dysfunction ranging 
from mild derangement of liver function to liver failure was observed as a major 
complication of falciparum malaria patients (Joshi et al. 1986, Ahsan et al. 1993, 
Ayyub et al. 2000, Premratna et al. 2001). Malaria hepatitis is the term frequently 
used for the hepatocellular jaundice in patients infected with malaria but its clinical 
significance is still to be highlighted (Anand 2001, Anand 1996, Anand et al. 1994). 
 Lots of variations were observed as far as occurrence of jaundice in malaria is 
concerned. It was reported in 2.53-5.3% patients of falciparum malaria (Mehta et al. 
1989, Anand et al. 1992). Mild elevation of enzymes and hepatomegaly were 
observed in some cases.  Involvement of liver leading to acute hepatitis or liver cell 
necrosis is rare complication in P. falciparum malaria which was reported by Mishra 
1992. Hepatocellular jaundice or malarial hepatitis with the incidence of 
approximately 2.6% was reported from Northeast India (Anand et al. 1992). Jaundice 
was observed in 7-8% children having complicated falciparum malaria (Bag et 
al.1994, Seth et al. 1997). Cases of jaundice as high as 32-37% were reported in 
falciparum malaria from Thailand and South India (Wilairatana et al. 1994, Harris et 
al. 2001). Higher rate of jaundice ranging from 11.5% to 62% was also reported in 
endemic pockets of tropical countries (Kochar et al. 1997, Murthy et al. 1998, 
Mazumder et al. 2002). 
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 Jaundice is more common in falciparum as compared to vivax malaria. Hazra 
et al. 1998 reported jaundice in 40% and 9.09% cases in P. falciparum and P. vivax, 
respectively. 22% malaria hepatitis was reported in falciparum malaria in Hyderabad 
(Murthy et al. 1998). 72% of patients with jaundice were reported to have 
hyperbilirubinaemia, elevated liver enzymes and hepatocellular damage (Harris et al. 
2001). Echeverri et al. (2003) reported 15% jaundice in P. vivax malaria from 
Colombia. Above findings indicate a wide variation in the range of jaundice which 
vary in complicated and uncomplicated cases of P. falciparum and P. vivax in 
endemic and non endemic areas.   
 Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are 
mainly caused by malaria in the tropics. ARDS, an important complication of severe 
and complicated falciparum malaria, is also reported in vivax malaria. It is more 
common in adults than in children. In malaria, the development of ARDS can start 
either at the initial stage or during the time of treatment when the parasitaemia 
declines. Death may occur due to acute respiratory disorders as it was reported in 
2.88% P. falciparum patients in Vienna (Losert et al. 2000). In the earlier years the so 
called "adult respiratory distress syndrome" is now known as "acute respiratory 
distress syndrome" because of its presence in children also. It is a disease with high 
mortality rate throughout the world (Gupta et al. 2001, Jindal et al. 2003, Dellinger et 
al. 2008, Sharma and Mohan 2005, Sharma and Mohan 2007, Wheeler and Bernard 
2007). Patients having acute onset of dyspnoea can swiftly proceed to respiratory 
failure (Mohan et al. 2003, 2008). 
 Parasite sequestration in the cerebral microvasculature may be the principal 
cause of neural dysfunction in severe malaria patients. Other than sequestration there 
might be some other factors which are responsible for complications and death in 
falciparum malaria (Mac Pherson et al.1985). The adherence of parasitized red blood 
cells (pRBCs) to the endothelial lining leads to sequestration using protein derived 
from parasites exposed on the erythrocytes surface (Newbold et al. 1999). 
 Parasite antigens including P. falciparum erythrocytes membrane protein-
1(PfEMP-1) mediated binding to host receptors, of which, intercellular adhesion of 
molecule-1 (ICAM-1) and its expressions is up regulated in the areas adjacent to 
sequestrated parasites. By the agglutination of adjacent erythrocytes with pRBCs, the 
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sequestrated parasite mass gets further increased, and form rosettes with non-
parasitized erythrocytes or use platelets-mediated clumping to bind with each other 
(Rowe et al. 2009, Idro et al. 2010). Due to sequestration there is damage perfusion 
and exuberate coma through hypoxia.  In parasitized red blood cells, its capability to 
deform and pass through the microvasculature might be the cause of hypoxia and 
inadequate tissue (Dondorp et al. 2002). One third of the acute seizures in children 
having cerebral malaria manifest as eye deviation not convulsion (Ogutu et al. 2002). 
Prolonged convulsions are associated with neurological deficits in survivors of 
children with severe malaria. Effective and regular management of convulsion 
associated with falciparum malaria may result in better outcome in children who 
suffer from severe malaria (Ogutu and Newton 2004). Hypoxia and insufficient 
perfusion play a vital role in convulsions, but there are remote chances of necrosis in 
nerve tissue. In hypoglycaemic patients neural injury may occur (Idro 2006b). 
 P. falciparum is responsible for almost all the mortalities caused in malaria 
which mainly affects the central nervous system (Carter et al. 2002, Mung'Ala-Oder 
et al. 2004). The most severe neurological appearance of acute falciparum malaria is 
cerebral malaria which generally leads to coma (Newton et al. 2000).  In Kenya 
children suffering from acute falciparum malaria showed neurological involvement. 
The associated symptoms were metabolic distress, impaired consciousness, high 
parasitaemia and neurological sequelae (Idro et al. 2007). An elevated risk of 
neurological and cognitive deficits, behavioural difficulties and epilepsy were seen in 
the surviving patients. Multiple mechanisms lead to brain injury and coma, the exact 
mechanism by which intravenous parasites cause brain damage is not well understood 
in which mortality rate is very high (Idro et al. 2010). 
 Neurological sequelae such as hemiplegia, speech problems, cortical blindness 
and epilepsy were reported in 3-31% cases (Brewster et al. 1990, Bondi 1992, Carter 
et al. 2004). Multiple seizures associated with cerebral malaria have been reported to 
be linked with epilepsy in later stages (van Hensbroek et al. 1997). Neurological 
sequelae are common complications of cerebral malaria which is generally observed 
in survivors of childhood cerebral malaria, but there is no association between the risk 
factors for neurological deficits and persistent neurological sequelae (Oluwayemi et 
al. 2013). 
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 Acute renal failure (ARF) is a common cause of morbidity and mortality in 
severe malaria patients of South-East Asia and Indian subcontinents where 
transmission rate is low but there are occasional bursts in malaria transmission in 
small pockets during post monsoon, resulting in an increased creatinine level in the P. 
falciparum and P. vivax patients having high parasitaemia. Acute renal failure (ARF) 
is described as one of the most important manifestations of severe falciparum malaria 
(Das 2008, Kochar et al. 2010, Al-Rohani et al. 2011, Thanachachartwet et al. 2013). 
Higher rates of  ARF were reported from India, Pakistan and Thailand which ranged 
between 12.5- 21% in P. vivax infections in the higher transmission regions (Mehta et 
al. 2001, Prakash et al. 2003, Manan et al. 2006, Tripathy et al. 2007,  Vannaphan et 
al. 2010).  There are many other reports which showed low rates of ARF (2.5-3.5%) 
from Pakistan and India (Naqvi et al. 2003, Maheshwari et al. 2004). Acute renal 
failures are comparatively more common in P. falciparum malaria, but there are 
reports which showed acute renal failures along with electrolyte abnormality and 
increased urinary protein excretion in children suffering from vivax malaria (Ahmad 
et al. 1989, Kaur et al. 2007, Devidayal et al. 2008, Saharan et al. 2009, Sharma & 
Khanduri 2009). 
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INTRODUCTION 
Malaria has been a problem in India for centuries with varying levels of endemicity. 
Situation of malaria in India till 1950’s was very serious, with over 75 million cases 
and 0.8 million deaths every year. In 1965, cases came down to 0.1 million with no 
death record.  Resurgence of malaria occurred in 1970 because of administrative, 
financial and technical failure (Sharma and Mehrotra 1986). Plasmodium falciparum 
Containment Programme (PfCP) was launched in 1977 to reduce falciparum malaria 
in the selected areas but its general spread could not be contained. P. falciparum 
showed a steady upward trend during the 1970’s and thereafter. Malaria at one time 
considered a rural disease, later on diversified into various ecotypes. These ecotypes 
have been identified as forest malaria, urban malaria, rural malaria, industrial malaria, 
border malaria and migration malaria. Urbanization, industrialization and other 
developmental projects created numerous breeding sites which increased the vector 
populations as well as malaria transmission. In 1990s malaria re-emerged and took the 
lives of several thousand people (Sharma 1996). Factors responsible for the re-
emergence of malaria were insecticide resistance in anopheline vector and drug 
resistance in P. falciparum against the antimalarials. Most regions in the country have 
an unstable malaria situation, except in the North-Eastern states where stable malaria 
situation prevails. There are many endemic pockets of malaria in India particularly in 
North-Eastern states, Orissa, West Bengal and Madhya Pradesh. Majority of malaria 
morbidity and mortality is caused by P. falciparum followed by P. vivax which was 
believed to be a benign species causing only morbidity. Now it has been proved that 
P. vivax is also causing severe disease and may prove fatal (Tjitra et al. 2008, Genton 
et al. 2008). This species is epidemiologically and biologically different from P. 
falciparum. In P. vivax gametocytes develop quickly and become available in the 
peripheral blood within 5-6 days after the detection of the parasite in the blood. This 
helps in the transmission of gametocytes before diagnosis or initiation of the 
treatment. In P. falciparum, it takes longer for the development of gametocytes which 
appear in the peripheral circulation after 10 days. Besides this, P. vivax sporozoites 
develop faster than P. falciparum under similar conditions of temperature and 
humidity. The ability of P. vivax to relapse following primary attack by hypnozoites 
which remain dormant for some time in the liver parenchyma and gets reactivated 
after few weeks or a few months, is epidemiologically important and a favourable 
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factor which helps P. vivax to multiply faster than P. falciparum. These advantageous 
factors probably enable P. vivax to achieve higher numbers and cover wide 
geographic range compared to P. falciparum as earlier indicated by Gething et al. 
2011.       
 Drug resistance in P. falciparum against antimalarials especially chloroquine 
and sulfadoxine-pyrimethamine worsened the situation and transmission rate of 
malaria was increased (Sharma 1996). Rajasthan, Gujarat, Karnataka, Goa, southern 
part of Madhya Pradesh, Chhattisgarh, Jharkhand, Orissa and north-eastern states 
have highest infection rate with API more than 5. Among these, Orissa with a 
population of 36.7 million contributed 25% of reported annual malaria cases in India 
(Kumar et al. 2007). Recent World Malaria Report indicated that 275.5 million people 
in India (22%) still live in high transmission area where API is more than 1. Incidence 
of malaria in India is about 58% of the total cases recorded in South-East Asia 
(Srinivas 2014). In 2014 a total of 1.07 million cases and 535 deaths were recorded in 
India (WHO 2014).  
 In India, the epidemiology of malaria is complex because of geo-ecological 
diversity, multi-ethnicity and wide distribution of anopheline vectors transmitting 
three Plasmodium species.  Overall, P. vivax dominated over P. falciparum, but in 
some parts of India like North-Eastern states situation is reverse where P. falciparum 
is the major species.Keeping in view the above complexity of insecticide resistance in 
vector and drug resistance in the parasite against antimalarials which has direct 
bearing on the transmission, prevalence of malaria in Aligarh was explored in this 
study. 
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MATERIALS AND METHODS 
This study is based on the cases of malaria admitted in the medical college and few 
other hospitals in Aligarh during the years 2011- 2013. Thick and thin blood smears 
were prepared on glass slides by pricking the finger of patients complaining for fever 
and headache. Thin films were fixed with methanol before staining. After fixation, 
slides were stained with Giemsa and JSB stains, and the probabilities of P. falciparum 
and P. vivax was microscopically confirmed by Nikon Eclipse-600 research 
microscope at 100x.  Quantitative Buffy Coat (QBC) test was also performed to 
observe the positivity of malaria. 
Blood Smear Preparation and Fixation:  
Clean glass slides of about 1.2 mm thickness were used for making smears. For smear 
preparation, the tip of the middle finger of the left hand was cleaned with a swab and 
allowed to dry completely before pricking. Two drops of blood were placed on each 
slide, one for thick smear and the other for thin. The thick smear was made in such a 
way that the edge of the smear remains approximately 1.0 cm away from the edge of 
the slide. The distance between the edge of thick and thin smears was about 0.75 cm. 
Only thin smear was fixed with methyl alcohol. Thick smears were 
dehaemoglobinized and allowed to dry. After drying, slides were stained with Giemsa 
and JSB as described by Singh (1956).  
Stain Preparation:  
Preparation of Giemsa Stain: 
For the preparation of Giemsa stain 3.8 gm powdered Giemsa was transferred to a 
completely dry brown bottle in which few glass beads were added. In this bottle, 250 
ml of methanol was added and mixed well. This solution mixture was placed in a 
water bath at 37ºC overnight for complete dissolution. Finally, it was filtered and 
stored in a brown bottle in dark place. It was left for two months for maturation before 
use. 
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 The diluents used were buffer solution having pH 7.2 which was prepared by 
mixing 28 ml of KH2PO4 (9.08 g/L) and 72 ml of Na2HPO4.2H2O (11.78 g/L) in 
deionised water. 
 Working solution was prepared by adding 6 ml of stock Giemsa stain with 94 
ml of buffer solution in a staining dish. 
Staining procedure:  
Slides were stained in JSB in the following steps: 
1. Thin smears were fixed in methanol for 30 seconds by waving in hand, while 
thick films were dehaemoglobinised prior to putting in the stain and allowed to 
dry. 
2. Dried slides were transferred in staining dish having working solution of Giemsa 
stain for 3-5 min 
3. Now the slides were transferred in the same stain diluted with equal amount of 
buffered water (pH 7.2) and allowed to stain for 10-15 min 
4. They were then washed in slow running tap water to remove excess of stain. 
5. Finally, the slides were dried in air before microscopic examination. 
Preparation of JSB stains: 
JSB-I solution: 
Methylene blue (0.5 mg) was dissolved in 500 ml distilled water and 3 ml of 1% 
sulphuric acid (H2SO4) was added drop by drop, followed by 0.5 gm of potassium 
dichromate (K2Cr2O7).  Addition of potassium dichromate led to the formation of 
purple precipitate and at this step 3.5 gm of disodium hydrogen phosphate dihydrate 
(Na2HPO4.2H2O) was added which dissolved the precipitate. The mixture was now 
boiled in a flask with a reflex condenser for 1 hour. The stain was allowed to cool at 
room temperature and was ready for use as JSB-1 solution. This solution when used 
after maturation of 2-3 weeks gave better results. 
JSB-II solution:  
JSB-II solution was prepared by dissolving 1 gm of water soluble eosin in 500 ml of 
distilled water. A freshly prepared eosin solution, though can be used immediately, 
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may not yield result as satisfactory as the one which has turned deep red after some 
storage. 
Preparation of buffer water: 
0.22 g of disodium hydrogen phosphate dihydrate (Na2HPO4.2H2O) and 0.74 g of 
potassium acid phosphate (KH2PO4) were added to 1000 ml of distilled water or 
filtered tap water. To maintain pH buffered water was kept in glass bottles. 
Staining procedure: 
Slides were stained in JSB in the following steps: 
1. Slides were dipped 2-3 times in JSB-II. 
2. These slides were washed for 10 mins in buffer water. 
3. Now the slides were dipped in JSB-1 for 45 seconds. 
4. These slides were again washed for 10 mins in buffer water. 
5. Now the slides were allowed to dry before microscopic examination. 
Preparation of Leishman’s Stain solution:  
0.6 g of Leishman powder was transferred to a completely dry brown bottle in which 
a few dry glass beads were added. 400 ml of methanol was poured in the bottle 
containing stain powder and mixed well until the dye was completely dissolved. 
Prepared stain was stored at room temperature in dark for 2-3 weeks for maturation.  
Staining procedure: Slides were stained with Leishman’s stain in the following 
steps: 
1. Blood smears were dried in air. 
2.  Leishman’s stain was poured on the thin blood films and allowed to stain for 
2 min. 
3. The same stain was diluted with twice the amount of distilled water and mixed 
by swirling and allowed to stain for 10 min in diluted stain. 
4. These slides were rinsed thoroughly with distilled water. 
5.  Finally, the slides were allowed to dry before microscopic examination. 
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Slides Examination:  
Stained blood films were examined under the microscope at 10x, 40x to record the 
positivity of malaria parasite. For specific diagnosis of P. falciparum and P. vivax, 
positive slides were thoroughly examined by Nikon Eclipse-600 research microscope 
under oil immersion lens (100x).  
Quantitative Buffy Coat (QBC) Technique for blood analysis:  
QBC is the most efficient fluorescence microscopy-based malaria diagnostic test by 
which as little as 1 parasite per µL of blood can be detected (Ponsilaptip et al. 1990). 
Acridine orange stains used in QBC makes malaria parasites more easily visible 
through the use of fluorescence microscopy. Centrifugation concentrates parasites in 
specific areas of the tube for improved detection.  Sensitivity of QBC is 
predominantly notable in case of low parasitaemia and is more sensitive than 
microscopic examination of Giemsa stained thick blood film (Bentio et al. 1994). This 
technique is time saving and completes in 8 min. Even though peripheral blood smear 
examination is considered as the gold standard technique, QBC test is widely used 
and more sensitive in detecting malaria parasite. 
  
Fig.1. QBC malaria detection kit. 
Role of acridine orange stain: 
The interior of the capillary used in QBC malaria test is coated with fluorescent 
acridine orange stain, which bonds with the nucleic acid of any malaria parasite 
present in the sample during preparation. When viewed under blue light (~460 nm), 
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parasites stained with acridine orange will fluoresce brightly against a dark 
background increasing visibility (Fig 3).  
Centrifugation: 
       
Fig. 2. Microhaematocrit centrifuge used for the QBC kits. 
 In QBC technique, components of blood separate into distinct layers based on 
their differing densities when centrifuged at 14,400 × g (12,000 rpm) for 5 mins. 
During this process, parasites contained in the sample get separated according to 
density. This simplifies detection for users, as the parasites concentrate into specific 
(easy-to-locate) areas of the tube. 
Procedure for detection of Plasmodium by QBC:  
1. 50 microliters of blood was taken into a capillary tube coated with acridine 
orange and fitted with a cap. 
2. A plastic float was inserted inside the tube and then spun in the QBC 
microhaematocrit centrifuge at 12000 rpm for 5 min. 
3. Now the tube was mounted on a small plastic holder and examined through an 
ordinary light microscope with customised fluorescence. 
       4.  During centrifugation parasites get concentrated within specific areas of the 
tube and could easily be detected to the viewer.  
Positivity of malaria and the monthly incidence of P. falciparum, P. vivax and mixed 
infections were recorded for the years 2011, 2012 and 2013.  
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RESULTS 
Month wise prevalence of P. falciparum, P. vivax and mixed infections in Aligarh for 
the years 2011, 2012 and 2013 is shown in Tables 1-3 and Figs 3-5.. Predominance of 
P. vivax was recorded in almost all the months of the year with almost similar 
seasonal pattern throughout the study. A gradual increase was noticed from July-
August onwards in P. vivax with a peak in September, immediately after the rainy 
season and then showed a decline in December which continued up to April, May and 
June due to pre-monsoon showers. P. falciparum infections showed increased trend 
from August onwards and showed a peak in October and then declined in November 
with the onset of winter and continued to decline till April. Low rate of transmission 
was recorded during May, June and July (Table 1- 4 & Fig.6). 
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Table 1: Prevalence of malaria showing Plasmodium  falciparum, Plasmodium  vivax 
and mixed infections during 2011. 
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Fig. 3. Prevalence of malaria showing P. falciparum, P. vivax and mixed infections 
during 2011 
Month 
            
Prevalence 
Total Slide 
Examined 
Total  
Positive 
Sample 
Slide 
Positivity 
Rate (%) 
Pf (%) Pv (%) Mixed 
infection  
(%) 
January 92 7 7.60 4 (57.14) 3(42.85) - 
February 88 8 9.09 4(50.00) 4(50.00) - 
March 58 5 8.62 2(40.00) 3(60.00) - 
April 169 17 10.06 6(35.29) 11(64.70) - 
May 250 31 12.4 4(12.90) 27(87.09) - 
June 448 90 20.08 9(10.00) 81(90.00) - 
July 495 94 18.98 20(21.28) 74(78.72) - 
August 586 216 36.86 77(35.65) 129(59.72) 10(4.63) 
September 1228 473 41.93 154(32.56) 307(64.90) 12(2.54) 
October 495 190 38.38 85(44.74) 100(52.63) 5(2.63) 
November 347 89 25.64 22(24.72) 65(73.03) 2(2.25) 
December 284 26 9.15 15(57.69) 11(42.31) - 
Total 4540 1246 (27.44) 402 (32.26) 815 (65.40) 29 (2.32) 
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Table 2: Prevalence of malaria showing Plasmodium falciparum, Plasmodium vivax 
and mixed infections during 2012. 
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Fig. 4. Prevalence of malaria showing P. falciparum, P. vivax and mixed infections 
during 2012. 
Month 
          
Prevalence 
Total 
Slide 
Examined 
Total 
Positive 
Sample 
Slide 
Positivity 
Rate (%) 
Pf (%) Pv (%) Mixed   
infection  
(%) 
January 65 4 6.15 1 (25.00) 3 (75.00) - 
February 38 2 5.26 1 (50.00) 1 (50.00) - 
March 12 1 8.33 - 1 (100.0) - 
April 169 14 8.28 - 14 (100.0) - 
May 285 37 12.98 - 37 (100.0) - 
June 312 48 15.38 - 48 (100.0) - 
July 298 46 15.43 6 (13.04) 40 (86.96) - 
August 286 64 22.37 18 (28.12) 43 (67.19) 3 (4.69) 
September 448 205 45.75 75 (36.58) 124 (60.49) 6 (2.93) 
October 405 173 42.71 53 (30.64) 115 (66.47) 5 (2.89) 
November 247 40 16.19 10 (25.00) 27 (67.50) 3 (7.50) 
December 195 16 8.20 6 (37.50) 10 (62.50) - 
Total 2760 650 (23.55) 170 (26.15) 463 (71.23) 17 (2.61) 
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Table 3: Prevalence of malaria showing Plasmodium falciparum, Plasmodium vivax 
and mixed infections during 2013. 
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Fig. 5. Prevalence of malaria showing P. falciparum, P. vivax and mixed infections     
during 2013. 
Month 
            
Prevalence 
Total Slide 
Examined 
Total 
Positive 
Sample 
Slide 
Positivity 
Rate (%) 
Pf (%) Pv (%) Mixed 
infection  
(%) 
January 85 7 8.23 2 (28.57) 5(71.43) - 
February 58 3 5.17 - 3(100) - 
March  36 2 5.55 - 2(100) - 
April 69 3 4.34 - 3(100) - 
May 198 21 10.60 - 21 (100) - 
June 228 39 17.10 - 39 (100) - 
July 295 32 10.84 - 32 (100) - 
August 206 52 25.24 4 (7.69) 46 (88.46) 2 (3.85) 
September 325 170 52.30 44 (25.88) 122 (71.76) 4 (2.35) 
October 299 128 42.80 46 (35.94) 80 (62.50) 2 (1.56) 
November 147 37 25.17 8 (21.62) 28 (75.67) 1 (2.70) 
December 64 5 7.81 2 (40) 3 (60) - 
Total 2010 499 (24.82) 106 (21.24) 384 (76.95) 9 (1.80) 
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Table 4: Prevalence of malaria showing Plasmodium falciparum, Plasmodium vivax 
and mixed infections during 2011-2013. 
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Fig. 6. Prevalence of malaria showing Plasmodium falciparum, Plasmodium vivax 
and mixed infections during 2011-2013. 
Month 
            
Prevalence 
Total Slide 
Examined 
Total 
Positive 
Sample 
Slide 
Positivity 
Rate (%) 
Pf (%) Pv (%) Mixed 
infection  
(%) 
January 242 18 7.43 7 (38.89) 11 (61.11) - 
February 184 13 7.06 5 (38.46) 8 (61.53) - 
March 106 8 7.54 2 (25.00) 6 (75.00) - 
April 407 34 8.35 6 (17.64) 28 (82.35) - 
May 733 89 12.14 4 (4.49) 85 (95.50) - 
June 988 177 17.91 9 (5.08) 168 (94.91) - 
July 1088 172 15.80 26 (15.11) 146 (84.88) - 
August 1078 332 30.79 99 (29.81) 218 (65.66) 15 (4.51) 
September 2001 848 42.37 273 (32.19) 553 (65.21) 22 (2.59) 
October 1199 491 40.95 184 (37.47) 295 (60.08) 12 (2.44) 
November 741 166 22.40 40 (24.09) 120 (72.29) 6 (3.61) 
December 443 47 10.60 23 (48.94) 24 (51.06) - 
Total 9210 2395 (25.72) 678 (28.30) 1662 (69.39) 55 (2.29) 
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 Out of 4540 slides examined during the year 2011, only 1246 (27.44%) were 
found positive for malaria. Majority of the cases (815, 65.40%) belonged to P. vivax, 
402 (32.26%) to P. falciparum, while 29 (2.32%) were mixed infection. In 2012, a 
total of 2760 slides were examined, out of these 650 (23.55%) were positive for 
malaria infection, out of which 170 (26.15) were P. falciparum, 463 (71.23%) P. 
vivax and 17 (2.61%) mixed infections. In 2013 out of 2010 total slides examined, 
499 (24.82%) were positive for malaria. Out of these 499 positive cases 106 (21.24%) 
belonged to P. falciparum, 384 (76.95%) to P. vivax and 9 (1.80%) were mixed 
infection (Tables 1-3). Overall positive cases during the years 2011-2013 for P. 
falciparum, P. vivax and mixed infection were 678 (28.30%), 1662 (69.39%) and 55 
(2.29%), respectively (Table 5 & Fig. 7).  
Table 5: Year wise slide positivity rate and prevalence of Plasmodium falciparum, 
Plasmodium vivax and mixed infection for years 2011, 2012 and 2013. 
Year Total slides 
examined 
Total positive 
slides (%) 
Pf (%) Pv (%) Mixed 
infection (%) 
2011  4540 1246 (27.44) 402 (32.26) 815 (65.40) 29 (2.32) 
2012  2760 650 (23.55) 170 (26.15) 463 (71.23) 17 (2,61) 
2013  2010 499 (24.82) 106 (21.24) 384 (76.95) 9 (1.80) 
Total 9310 2395 (25.72) 678 (28.30) 1662 (69.39) 55 (2.29) 
 
Fig. 7.   Plasmodium falciparum, Plasmodium vivax and mixed infections in years 
2011, 2012 and 2013. 
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The seasonal pattern of P. falciparum, P. vivax and mixed infections in 
Aligarh showed least malaria transmission from January to April, which was low 
during the months of May, June and July. Malaria transmission was high in the 
months of August, September and October, reaching a peak soon after rains, which 
finally showed a declining trend in the months of November and December. There 
were slight fluctuations in the number of cases in the same month of the years 2011, 
2012 and 2013 which was probably due to pre-monsoon showers and variable rainfall 
in the monsoon season. (Figs. 3-5). During peak transmission season, mean 
temperature and relative humidity ranged somewhere around 26-28°C and 77-88%, 
respectively which was quite favourable for the sustenance of vector population, 
responsible for malaria transmission. Almost similar trend was shown by P. 
falciparum, P. vivax and mixed infection during 2011, 2012 and 2013 where P. vivax 
infection showed its dominance over P. falciparum. A considerable degree of 
fluctuation was observed during peak transmission season (i.e. September and 
October) when SPR was comparatively high and ranged from 38.38-52.00%. During 
this period, the transmission rates of P. falciparum and P. vivax infections were quite 
high ranging between 25.88-44.74% and 52.63-71.76%, respectively. Fluctuations 
were more prominent in these respective infections, especially during peak season.  
Male predominance was observed in the infected patients. In nearly all the 
months, the proportion of infection was more in males as compared to females. Out of 
2395 total positive cases 1412 patients were males and 983 were females, accounting 
for 58.95 and 41.05%, respectively (Table 6 & Fig. 8.). 
Chapter -1 
 
45 
 
Table 6: Sex wise distribution of malaria during 2011-13. 
Month Male (%) Female (%) Total 
January 12 (66.67) 6 (33.33) 18 
February 8 (61.54) 5 (38.46) 13 
March 4 (50.0) 4 (50.0) 8 
April 20 (58.82) 14 (41.17) 34 
May 50 (56.18) 39 (43.82) 89 
June 98 (55.37) 79 (44.63) 177 
July 88 (51.16) 84 (48.84) 172 
August 171 (51.50) 161 (48.49) 332 
September 539 (63.56) 309 (36.44) 848 
October 302 (61.51) 189 (38.49) 491 
November 95 (57.23) 71 (42.77) 166 
December 25 (53.19) 22 (46.81) 47 
Total 1412 (58.95) 983 (41.05) 2395 
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Fig. 8. Distribution of malaria in male and female patients in Aligarh. 
Percent parasitaemia was also recorded in P. falciparum and P. vivax 
infections for the years 2011, 2012 and 2013. On the basis of parasitaemia, the disease 
was classified as uncomplicated and complicated severe malaria. Out of 752 total P. 
falciparum cases, 289 (38.43%) were placed under the category of uncomplicated 
malaria where parasitaemia was <10%, whereas 463 (61.57%) under severe malaria 
with parasitaemia >10%. In P. vivax, 1588 cases were positive having 932 (58.69%) 
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uncomplicated malaria with parasitaemia  <6 and 656 (41.31%) severe complicated 
malaria with parasitaemia >6. 55 cases of mixed infection were observed with 16 
(29.09%) uncomplicated and 39 (70.91%) severe malaria with similar parasitaemia as 
found in P. falciparum patients (Table 7 & Fig. 9). 
Table 7: Uncomplicated and complicated severe malaria cases on the basis of 
parasitaemia during the study period 2011-2013. 
Plasmodium species Uncomplicated cases Severe cases Total 
P. falciparum 289 (38.43%) 463 (61.57%) 752 
P. vivax 932 (58.69%) 656 (41.31%) 1588 
Mixed infection (Pv&Pf) 16 (29.09%) 39 (70.91%) 55 
Total 1237 1158 2395 
 
 
  
Fig. 9. Ratio of uncomplicated and complicated malaria on the basis of parasitaemia. 
           Efficacy of the Quantitative Buffy Coat (QBC) technique was compared with 
routine microscopic thick and thin blood smear examination of 400 samples. QBC 
technique showed positive results in 360 (90%) samples which was higher than that of 
thick film examination result where 340 (85%) smears were positive. Thin film 
examination gave the lowest positivity rate of 74.5% as the parasite was seen in only 
298 slides (Table 8 and Fig. 10). 
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Table 8:  Results of microscopic examination of blood film and  QBC technique  
Result Thick (%) Thin (%) Q.B.C. (%) pLDH 
Positive 340 (85) 298 (74.5) 360 (90.0) 162 (40.5) 
Negative 60 (15) 102 (25.5) 40 (10) 238 (59.5) 
Total 400 400 400 400 
 
    
Fig. 10. Showing Ring stage of Plasmodium falciparum by QBC Technique  (100x) 
Different stages of P. falciparum and P. vivax were obtained by observed 
under microscope after staining the thick and thin blood film on the class slides. 
Various blood stages like signet ring stage, gametocyte stage, trophozoite stage and 
schizont stage were  seen in thick and thin blood films for the detection of parasites. 
(Figs 11-24 and Plate 1-2.) 
 
Fig. 11. Signet ring stage of Plasmodium falciparum in red blood cell of thin film 
(100x) 
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Fig. 12. Signet ring stage of Plasmodium falciparum in thick blood smear (100x) 
 
Fig. 13. Signet ring stage of Plasmodium falciparum in thick blood smear (100x) 
 
Fig. 14. Female gametocyte of Plasmodium falciparum (100x) 
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Fig. 15. Male gametocyte of Plasmodium falciparum (100x) 
 
Fig. 16. Signet ring stage of Plasmodium vivax in thin blood film (100x) 
 
Fig. 17. Mixed infection showing signet ring stages of Plasmodium falciparum and 
Plasmodium vivax in red blood cells (100x) 
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Fig. 18. Trophozoite stage of Plasmodium vivax in thin blood film (100x) 
 
Fig. 19. Advanced trophozoite stage of Plasmodium vivax in thin blood film (100x) 
 
Fig. 20.  Early schizont stage of Plasmodium vivax in thin blood film (100x) 
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Fig. 21. Mature schizont of Plasmodium vivax in thin blood film (100x) 
 
Fig. 22. Female gametocyte of Plasmodium vivax (100x) 
 
Fig. 23. Female gametocytes of Plasmodium vivax (100x) 
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Fig. 24. Male gametocyte of Plasmodium vivax in thin blood film (100x) 
 
Plate 1. Showing ring stages and gametocytes of Plasmodium falciparum (100x) 
 
     
   
Plate 2. Showing ring, trophozoite, schizont and gametocytes of Plasmodium vivax 
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DISCUSSION 
As far the efficacy of conventional microscopic examination and QBC technique for 
the diagnosis of malaria is concerned, QBC was the most efficient technique during 
my study as its positivity rate was 90%. Similar positivity rates of 89.7-90.9% were 
recorded by other workers (Bentio et al. 1994, Craig and Sharp 1997, Garung et al. 
2010). In contrast higher rates ranging from 94.45-98% were observed in few other 
studies (Baird 1992, Bhandari et al. 2008, Bhat et al. 2012, Benito et al. 2014). Parija 
et al. (2009) recorded only 78% positivity by QBC technique which is much low 
compared to my value. As for thick smear is concerned, its positivity was 85%  in the 
present study which was slightly less than  that of Craig and Sharp (1997) and Parija 
et al. (2009) who recorded positivity rates of thick film during their study as high as 
91.4 and 100%, respectively. Positivity rate in thin smears was 74.5% in my slides 
which is less than that of Craig and Sharp (1997) and Bhat et al. (2012) and more than 
that of Parija et al. (2009) who observed positivity in only 54.8% slides.  
 In the present study, seasonal analysis demonstrated the maximum number of 
P. vivax cases during the months July-November, while P. falciparum cases were 
comparatively less in number and showed maximum transmission during August, 
September and October. In Aligarh, generally rain starts in July and after the rains 
plenty of water bodies become available for the breeding of vector species in the 
preceding months. During these months temperature remained moderate (i.e. 26 to 
28°C) and optimum humidity ranged between 77 to 88% which were ideal for 
mosquito breeding, that might have influenced increase in vector population which 
must have contributed maximum transmission as earlier observed by Adak et al. 
(1998) in Delhi. Similar increase in transmission of malaria was recorded during 
September and October in Assam in areas having streams where vector species which 
happens to be An. minimus was in abundance due to favourable temperature and 
humidity (Jana-Kara et al. 1995). Breeding places for vectors increased due to rains in 
preceding months, leading to water logging, moderate temperature and optimum 
humidity. In Karnataka incidence of malaria increased from June onwards because 
monsoon starts earlier in that part of the country (Muddaiah & Prakash 2006). Similar 
higher transmission was recorded from September to November in Uttarakhand where 
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almost similar meteorological conditions prevail as in my study area (Verma et al. 
2014). 
 In Aligarh low transmission rate for both P. falciparum and P. vivax was 
recorded during November and December as temperature drops down during these 
months. Lowest transmission rate of both falciparum and vivax malaria was recorded 
in the months of January, February, March and April during the years 2011-2013. 
This extremely low transmission was because of adverse environmental factors which 
caused reduction in the number of vector species. During these months either extreme 
dry cold or dry heat conditions prevail which affect vectors adversely either by 
making water bodies unsuitable or very slow for the breeding or by making them 
scarce as a result of high temperature which even kill the vector. June and July again 
showed low transmission which may be correlated with pre-monsoon showers during 
the months of March and April which resulted in water stagnations and vector 
breeding.  
 P. falciparum infection showed a declining trend and slide positivity rate 
decreased from 32.26-21.24% when the data of 2011 was compared with that of 2013. 
Almost similar rates of transmission were recorded for this parasite which ranged 
from 25.85 and 33.99% in central India, Rajasthan, Karnataka and Manipur in 
Northeastern states (Muddaiah and Prakash 2006, Kochar et al. 2010, Singh et al. 
2013, Joshi and Govardhan 2013, Sharma 2015). A much higher percentage of P. 
falciparum infection ranging from 61.01-73% was recorded in Rajasthan, Madhya 
Pradesh and Assam (Singh et al. 2008, Kochar et al. 2010, Sharma et al. 2015). Both 
these places are treated as endemic home especially for P. falciparum. The slow 
progressive decrease in the number of P. falciparum cases in our study area might be 
due to the introduction of artemisinin and its combination therapy which has high 
efficacy rate of around 99-100% and causes a reduction in falciparum malaria. 
Contrary to this, P. vivax cases showed a progressive increase from 65.40% in 2011 to 
76.95% in 2013. Almost similar prevalence rates (52.4-80%) for the P. vivax infection 
were reported from Karnataka, Uttarakhand, Arunachal Pradesh, Nagaland and central 
India (Muddaiah and Prakash 2006, Joshi and Gowardhan 2013, Singh et al. 2013, 
Verma et al. 2014, Sharma et al. 2015). The increase in P. vivax infection might be 
due the treatment with Lariago (Chloroquine) which is still given in P. vivax infection 
along with primaquine. Chloroquine and primaquine both have lowered their efficacy 
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rate as for radical treatment of P. vivax is concerned and this might be the probable 
reason for increasing number of vivax malaria cases. Mixed infections recorded 
during August-November ranged from 1.80-2.61 which coincides with peak 
transmission of both the species. In other parts of India, mixed infections ranged from 
13-13.9% (Muddaiah and Parakash 2006, Joshi and Gowardhan 2013, Verma et al. 
2014) which is much higher as compared with my average figures of 2011-2013. Low 
rate (4.95%) of mixed infection was recorded by Kochar et al. (2010) which is 
slightly higher than what I observed in my study area. When transmission rate was 
compared, fluctuations were recorded in both P. falciparum and P. vivax infections 
during 2011-13. The probable reason for this fluctuation might be due to the 
occurrence of a particular infection in a localised area from where more cases of 
either P. falciparum or P. vivax were registered in a particular month. Such sporadic 
infections might be the reason for increase or decrease in the number of P. falciparum 
and P. vivax cases during high transmission season.  
 In P. falciparum infection 61.57% cases who had high parasitaemia of more 
than 10% were treated as complicated, while 38.4% cases were placed in 
uncomplicated category with parasitaemia less than 10%. A comparatively higher 
number of P. falciparum cases were recorded in Uttarakhand with 75% severe 
complicated cases (Singh et al. 2013). In P. vivax about 58.9% patients had no 
complications and rest 41.31% patients had complications in my study area. But 
parasitaemia was low as compared to falciparum malaria. In uncomplicated P. vivax 
cases parasitaemia was less than 6%, while in complicated ones it was more than 6%. 
Singh et al. (2013) reported 62.3% severe and 37.7% uncomplicated cases of P. vivax 
malaria, just reverse what I have observed in my study. In mixed infections a 
maximum of 70.91% cases were complicated type with parasitaemia more than 10% 
compared to uncomplicated type which represented 29.09% cases with percent 
parasitaemia less than 10. 
 As far sex wise distribution is concerned, malaria was more common in males 
as compared to females, representing 58.95 and 41% cases, respectively. Almost 
similar infection rates of 57% in males and 43% in females were recorded in Rajkot, 
Gujarat (Goyal and Makwana 2015).  Nahum et al. (2007) recorded malaria in 51.2% 
males and 48.8% females in West Africa which is very close to the values recorded in 
my area of study. In contrast, proportionately higher number of cases of malaria were 
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recorded in males (66.4-81%) in Rajasthan, Maharashtra, Karnataka and Orissa 
(Muddaiah and Prakash 2006, Gupta et al. 2009, Chetan et al. 2014, Nayak et al. 
2014, Kar and Bhatta 2015). However rate of infection in females reported by these 
workers was less than what I have reported from my study area. Looking at these 
figures it may be concluded that malaria is affecting males more as compared to 
females. It is probably because the males are having much exposure to mosquito bites 
compared to females as they remain in contact with mosquito for comparatively 
longer duration and mostly in the places where mosquito can bite them. 
 
  
 
 Chapter 2 
Relapse and Resistance in Malaria 
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INTRODUCTION 
Recurrence of symptoms of malaria can be classified as recrudescence, relapse or re-
infection. In recrudescence which generally occurs in Plasmodium falciparum 
infections, symptoms return after a latent period during which the parasites remain in 
blood in a very low density due to inadequate or ineffective treatment (WHO 
2010). Relapse, which usually occurs in P. vivax, clinical symptoms reappear after the 
disappearance of the parasites from the blood. Some hypnozoites which remain 
dormant for some time in liver cells get reactivated and generally cause short term 
relapse. Long term relapses in P. vivax due to over wintering of hypnozoites were also 
recorded in the temperate regions (White 2011).  In re-infection, new sporozoites 
enter the host and cause clinical disease after the elimination of past infection. It 
cannot be distinguished from recrudescence, although recurrence of infection within 
two weeks of treatment for the initial infection is typically attributed to treatment 
failure (WHO 2010). As per the definition of WHO, drug resistance is of three types 
(RI, RII and RIII). In RI type, parasitaemia disappears after the treatment followed by 
recurrent parasitaemia, while in RII type, parasitaemia gets decreased by more than 
75% followed by a subsequent rise of parasites in the blood. In RIII type, decrease in 
parasitaemia ranged between 0-75 % following treatment. 
 Recently it has been reported that P. vivax infection is found in more than 50% 
of total malaria cases in India (WHO 2014). Chloroquine (CQ) at the rate of 25 mg/kg 
body weight over 3 days remains the recommended first-line treatment for all 
uncomplicated vivax malaria in India (NDPM 2013).  Many countries such as 
Indonesia, Vietnam, Thailand, Myanmar and Northeastern parts of India witnessed 
chloroquine resistance in P. vivax (Phan et al. 2002, Sumawinata et al. 2003, Ratcliff 
et al. 2007, Ganguly et al. 2013, Price et al. 2014, Yuan et al. 2015) which is a matter 
of concern and there is an urgent need to implement a preventive measure to check 
the invasion of any resistant P. vivax strain from the aforesaid countries along with 
travellers and/or migrants. There are many endemic pockets of malaria in India 
particularly in Orissa, Jharkhand, Madhya Pradesh, Chhattisgarh, and Northeastern 
states. Ethnic tribes living in the forested pockets of these states contribute to the bulk 
of morbidity and mortality (Das et al. 2008). P. vivax infection remains a major cause 
of childhood illness. In most endemic areas P. vivax co-exists with P. falciparum and 
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mixed infection of these species is not infrequent. Control of P. vivax infection is 
more difficult compared to P. falciparum because of its tendency to relapse after the 
treatment of primary infection. In endemic areas relapse of P. vivax infection is a 
major cause of malaria in young children, which provides a source for malaria 
transmission to healthy individuals. 
 Resistance in P. falciparum against chloroquine was first observed in 
Cambodia in 1957 which spread along the Thailand-Cambodia border in 1960s, 
followed by Kenya and Tanzania in 1978 and spread throughout Africa (Wellem and 
Plowe 2001). Chloroquine was replaced by the combination of sulfadoxine and 
pyrimethamine as first line drug for the treatment of uncomplicated malaria in 
Thailand and many other African countries in 1973. Sulfadoxine-pyrimethamine too 
was replaced by mefloquine in 1985 because of appearance of resistance. The rapid 
development of resistance against mefloquine compelled to the introduction of 
artemisinin based combination therapy in these countries by the mid-1990s. (Farooq 
and Mahajan 2004). In India, chloroquine resistance in P. falciparum was reported 
from Karbi Anglong district in 1973 (Sehgal et al.1973) and then from Nowgaon in 
1974 in the Northeastern state of India i.e., Assam. Many more cases were reported 
from Assam, Arunachal Pradesh, Mizoram and Nagaland during the next 3–4 years.  
In 1982, National Drug Policy was introduced suggesting sulfadoxine-pyrimethamine 
for the treatment of P. falciparum cases in chloroquine resistant regions. In the year 
2005, artesunate along with sulfadoxine-pyrimethamine was introduced as second line 
of treatment for chloroquine resistant cases, and in 2007 this combination therapy 
became the first line of treatment in high endemic regions. At the moment, most 
malaria endemic countries including India have shifted their national treatment 
policies to artemisinin based combination therapy (ACT). As for relapse in P. vivax 
infection against chloroquine and primaquine is concerned, it has been reported both 
in patients treated with curative dose of chloroquine alone and in those treated with 
chloroquine along with primaquine (Adak et al. 1998, Valecha et al. 2001). 
         High levels of sulfadoxine-pyrimethamine resistance and treatment failures were 
reported from Western Kenya, Southern Malawi, Southern Nigeria, Tanzania and 
North-Eastern states in India (Bousema et al. 2003, Msyamboza et al. 2007, Matondo 
et al. 2014, Mishra et al. 2014). Recrudescence was also reported in patients treated 
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with artemether-lumifantrine combination in Africa (Sisowath et al. 2007, Malmberg 
et al. 2013). Keeping in mind the widespread resistance in P. falciparum against 
sulfadoxine-pyrimethamine and in few cases against artemisinin and artemisinin 
based combined therapy and relapse in P. vivax against chloroquine and primaquine 
from different parts of the country, the present study was undertaken to assess the 
level and types of resistance and relapse in Aligarh. 
 
MATERIAL AND METHODS 
To study the phenomena of relapse, recrudescence and resistance in P. vivax and P. 
falciparum different protocols were followed as for the treatment and follow up 
periods are concerned. 
Relapse in P. vivax infections: To study the relapse in P. vivax, following treatment 
regimens were followed. 
1. First group of patients was given 1500 mg chloroquine base in divided doses 
(i.e. 600 mg on day 0, followed by 300 mg daily for 3 days).  
2. Second group of patients was administered with 1500 mg of chloroquine in 
divided doses (i.e. 600 mg on day 0, followed by 300 mg daily for 3 days) 
followed by 15 mg primaquine daily for 5 days. 
3. Third group of patients was treated by giving  1500 mg of chloroquine in 
divided doses (i.e. 600 mg on day 0, followed by 300 mg daily for 3 days)  
followed by 15 mg of primaquine/day for 14 days. 
4. Doses for both the drugs were calculated according to the age and body weight 
of the patients as per the National Drug Policy of India. Children below 4 
years and pregnant women were not included in this study. 
           Follow up of the patients was done for 12 months.  In order to determine the 
relapse pattern in P. vivax each patient was identified individually by name, address 
and subsequent treatment. On reporting back, blood smear was prepared from the 
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patient and examined microscopically as well as by QBC technique for the presence 
of malaria parasite and recorded against her/his name. 
          Differentiation was made in relapse and non-relapse cases by follow up of the 
patients. Those patients reporting for the first time with no earlier history of malaria 
and positive for P. vivax were treated as primary cases. The patients who had no 
clinical symptoms of malaria or parasitaemia after primary infection post- treatment 
with standard dose of antimalarials during the entire period of follow up were 
considered as non-relapsing cases. The patients who reported back to the 
hospital/clinic within follow up period of one year post-treatment with renewed 
clinical symptoms along with a periodic fever every third day and were positive for P. 
vivax infection  were considered as relapse cases. If the patient suffered from malaria 
after the treatment within 3 months with more regular paroxysm, he/she may be 
treated as a case of short term relapse. But if it happened after 3 months then the case 
will be considered as long term relapse.  P. vivax patients who did not respond to 
1500 mg chloroquine and 75 mg and 210 mg primaquine were recorded as 
chloroquine resistant cases. 
Recrudescence and resistance in P. falciparum infections: To study the 
recrudescence in P. falciparum, following treatment regimens were followed. 
1. Sulfadoxine-pyrimethamine (Fansidar) was given as a single dose of 3 
tablets (1500 mg sulfadoxine + 75 mg pyrimethamine) in P. falciparum 
patients. 
2. Artemether alone was given 200 mg/day for 3 days. 
3. ACT + SP combination: In this artemisinin based combination therapy 
artesunate was given for 3 days at the rate of 200 mg/day, while SP 
(Sulfadoxine 750 mg and pyrimethamine 75 mg) was given on the first day 
only. 
4. ACT comprising of artemether and lumefantrine (artemether 20 mg and 120 
mg lumefantrine) was given twice a day for three days in case of resistant P. 
falciparum cases.  
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5. Doses for all the above drugs were calculated according to the age and body 
weight of the patients as per the National Drug Policy of India. Children 
below 1 year and pregnant women were not included in this study. 
 
          For recrudescence, follow up of the patients was done after treating P. 
falciparum patients with sulfadoxine-pyrimethamine, artemether alone and 
artemisinin based combination therapy ACT (i.e. artemether-lumifantrine). The cases 
where parasitaemia disappeared after the treatment with standard dose of aforesaid 
antimalarials, followed by recurrent parasitaemia were placed in RI type, while those 
cases where parasitaemia was decreased by more than 75% followed by a subsequent 
rise of parasites in the blood were documented as RII type. In RIII type decrease in 
parasitaemia ranged between 0-75% following treatment. 
RESULTS 
Results of the present study are summarised in tables 1-4. Out of 233 P. vivax patients 
53 (22.74%) showed relapse. As far as recrudescence in P. falciparum infection is 
concerned, it was 24.32% against sulfadoxine-pyrimethamine, 2.04% against 
artemether and 1.28% against artemisinin based combination therapy 
(artesunate+sulfadoxine-pyrimethamine). None of the P. falciparum patients showed 
recrudescence when treated with ACT-LA (Table 1).    
Table 1. Relapse and resistance against the antimalarials used to treat Plasmodium 
vivax and Plasmodium falciparum infections. 
Treatment Given No. of 
Plasmodium 
falciparum 
patients 
No. of 
Resistance 
(%) 
No. of 
Plasmodium 
vivax patients 
No. of 
Relapse 
(%) 
Chloroquine & Primaquine - - 233 53 (22.74) 
Sulfadoxine/Pyrimethamine 185 45 (24.32) - - 
Artemether alone 98 2 (2.04) - - 
Artesunate + Sulfadoxine/ 
Pyrimethamine 
78 1(1.28) - - 
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As far as relapse is concerned, it was evident in all the three groups of P. vivax 
patients treated with 1500 mg chloroquine alone and those who were treated with 
1500 mg of chloroquine along with 75 and 210 mg of primaquine for 5 and 14 days, 
respectively. Out of 108 patients treated with chloroquine alone relapse was shown in 
34 (31.48%) cases. Short term relapse was recorded in 28 (25.92%) cases, while long 
term relapse was observed in only 6 (5.55%) patients. In the second group of patients 
who were treated with 1500 mg chloroquine and 75 mg primaquine showed relapse, 
majority were of short term (15%) and rest 5% were of long term type. In the third 
group, where primaquine was administered at the rate of 15 mg/day for 14 days, 
relatively less number of patients relapsed (6.66%) which were of short term type 
only and none of the patients had long term relapse (Table 2). Last combination was 
comparatively more effective, but still showing relapses (Fig. 1). Resistance in 3 P. 
vivax patients was observed as low grade parasitaemia recorded after 4 days of 
chloroquine treatment.  
Table 2: Relapse pattern in Plasmodium vivax patients after treatment with 
chloroquine and varying doses of primaquine. 
Group Chloroquine Primaquine Follow 
up(month) 
No. of 
patients 
Relapse/ 
reinfection 
(%) 
Short 
Term 
Relapse 
(%) 
Long 
Term 
Relapse 
(%) 
A 1500 mg over 
3 days 
No 12 108 34 (31.48) 28(25.92) 6(5.55) 
B 1500 mg over 
3 days 
5 days PQ 
(15 mg/day) 
12 80 16 (20.00) 12(15.00) 4(5.00) 
C 1500 mg over 
3 days 
14 days PQ 
(15 mg/day) 
12 45 3 (6.66) 3(6.66) - 
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Fig. 1 Relapse pattern in Plasmodium vivax with chloroquine and primaquine 
            Patients who reported back with fever after complete medication were 
recorded as resistant cases, if found positive for P. falciparum infection. Level of 
resistance (i.e. RI, RII and RIII) was ascertained on the basis of late and early 
recrudescence. During the study period highest level of resistance was recorded 
against sulfadoxine-pyrimethamine due to its indiscriminate use against P. 
falciparum. Drug resistance in P. falciparum against sulfadoxine-pyrimethamine (SP) 
was recorded in 24.44% cases during 2011-2013. All the three levels (RI, RII and 
RIII) of resistance were observed in patients treated with a single dose regimen of SP 
(Table 3). RI level of resistance with recurrent parasitaemia post-treatment was more 
prominent and observed in 15.35% patients followed by RII level of resistance where 
decrease in parasitaemia was more than 7.50% followed by a subsequent rise in the 
number of parasites in peripheral circulation. RIII level of resistance was relatively 
less compared to RI and RII types and was recorded in only 1.58% cases where there 
was a slight decrease in parasitaemia following which clinical symptoms again 
became evident. RII and RIII levels of resistance were responsible for SP treatment 
failures.   
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Table 3: Level of resistance in Plasmodium falciparum patients against sulfadoxine-
pyrimethamine  
Years Plasmodium 
falciparum 
patients 
observed 
Resistant Patients 
Total 
Resistant 
patients 
(%) 
RI (%) RII (%) RIII (%) 
2011 73 16 (21.91) 9 (12.32) 5 (6.84) 2 (2.74) 
2012 50 12 (24.00) 8 (16.00) 3 (6.00) 1 (2.00) 
2013 62 17 (27.42) 11 (17.74) 6 (9.67) - 
Total 185 45 (24.44) 28 (15.35) 14 (7.50) 3 (1.58) 
 
Recent drugs used for the treatment of P. falciparum as suggested by WHO is 
artemisinin combination therapy (ACT). Artemisinin derivative that is mainly used in 
Aligarh is artemether alone and with other drugs in combinations such as 
artesunate+sulfadoxine-pyrimethamine and artemether-lumefantrine. As far as 
artemisinin and artemisinin based combined therapy (ACT) is concerned, it was 
observed that all the 84 patients who were treated with ACT-AL were cured 
completely (Fig. 2).  
 
 
 
 
 
 
 
 
Fig. 2 Resistance against SP and ACT in Plasmodium falciparum 
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98 patients who were treated with artemether alone showed recrudescence in 
2.04% cases compared to 1.28% of 78 patients who were treated with artesunate and 
sulfadoxine-pyrimethamine combination (Table 4). The rate of recrudescence is 
negligible but it appeared more quickly as compared to earlier antimalarials used to 
treat resistant cases of P. falciparum.  
Table 4: Recrudescence in Plasmodium falciparum against artemisinin and 
artemisinin combination therapy during 2011-2013. 
Antimalarials used P. 
falciparum 
patients 
observed 
Resistant Patients 
Total 
(%) 
RI (%) RII (%) RIII 
(%) 
Artemether 98 2 (2.04) 2 (2.04) - - 
Artesunate+SP 78 1 (1.28) 1 (1.28) - - 
Artemether+Lumefantrine 84 - - - - 
 
 Artemether-lumefantrine combination was proved most effective drug 
showing no resistance. Maximum level of resistance was observed in P. falciparum 
against sulfadoxine-pyrimethamine but the level of resistance was very low against 
artemether and ACT (artesunate+SP). 
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DISCUSSION 
Artemisinin based combination therapy (ACT) is recommended in place of pre-
existing antimalarials especially the cheap and easily available sulfadoxine-
pyrimethamine by the World Health Organization (WHO 2014). Due to the 
indiscriminate use of SP in most endemic regions of the tropical countries drug 
resistance appeared in a fairly good number of P. falciparum cases, but the 
introduction of ACT reduced the selection pressure and slowed the rate of increase in 
the frequency of triple mutants (Briggs et al. 2014).   
 It is believed that in relapse, symptoms reappear after the elimination of 
parasites from the blood, since hypnozoites which remain dormant in hepatocytes 
restart their multiplication and infect RBCs again (Nadjm and Behrens 2012). Craig 
and Kain (1996) were also of the same opinion and indicated that relapse is caused by 
the same inoculum of the parasite which was responsible for the initial infection and 
not by a genetically different strain of the parasite. But another group of workers 
believed the other way and postulated that the P. vivax parasites which emerge from 
hypnozoites were heterologous population that cause relapse and were different from 
those which were responsible for primary infection (Imwong et al. 2007). There is 
another theory regarding relapse indicating that both number as well as genetic 
variations of the strain decide the duration and frequency of relapse. If inoculum is 
high incubation period will be short and relapses will occur early. In normal course 
multiple strains of hypnozoites may be activated during primary attack but in 
subsequent relapse few strains will be detected.  Still few others might have been 
suppressed by the immune response of the host and may or may not reach patency 
(White 2011). 
         During this study, seasonal transmission occurred in both P. vivax and P. 
falciparum with peak in September-October. Both relapse as well as recrudescence 
was observed in these respective infections during the follow up of the patients. 108 
patients who were treated with 1500 mg chloroquine in divided doses showed relapse 
in 34 (31.48%) patients out of which 28 (25.92%) were of short term type and 6 
(5.55%) were of long term type.  Relapse rate of 31% in P. vivax patients was 
observed in Gujarat and Kolkata (Roy et al. 2013, Kim et al. 2013), which was 
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exactly the same what I observed in Aligarh. Higher rate of 40.10% relapse was 
recorded in Delhi when P. vivax patients were treated with 1500 mg chloroquine over 
a period of three days (Valecha et al. 2001),  which is slightly higher compared to my 
results where same amount of the drug was administered. Adak et al. (1998) recorded 
23.3% relapse when the patients were treated with only 900 mg chloroquine in two 
doses (600+300 mg) and followed up for one year.  Comparatively low rates of 
relapse were observed in Haridwar and Mandla which were 6.9 and 10.3%, 
respectively when treated with similar dose (Sinha et al. 1989, Singh et al. 1990). 
Yadav et al. (2002) reported relapse in only 8.6% cases following treatment with full 
dose of chloroquine (i.e., 1500 mg) in Sundargarh, which is much less in comparison 
to my results although the dose of drug was the same.  
        In my study area, relapse rate was 20% in P. vivax patients who were treated 
with 1500 mg chloroquine followed by 15 mg primaquine/day for 5 days. Almost 
similar relapse rate (22.22%) was observed in Timor, Australia in the patients treated 
with both chloroquine and primaquine (Chen et al. 2007). Valecha et al. (2001) 
reported a slightly higher rate of relapse (29.6%) in patients who got exactly similar 
treatment in Delhi in 2001. Much higher rates of relapse ranging from 43-55% were 
recorded in Indian, Nepalese and Somalian patients who received standard dose of 
chloroquine and primaquine (Smoak 1997, Imwong et al. 2007, Manandhar et al. 
2013).  In contrast, lower rates of relapse ranging from 5.20-13.2% were reported 
from India, Myanmar and Australia (Dua and Sharma 2001, Yadav et al. 2002, 
Townell et al. 2012, Yuan et al. 2015). Numbers of relapsing cases during my study 
were least (6.66%) when the patients were treated with 1500 mg chloroquine followed 
by 15 mg of primaquine daily for 14 days. Comparable relapse rate of 5.45% was 
recorded in Thailand in patients who followed the same treatment regimen (Walsh et 
al. 2004). In contrast, much higher rate of relapse documented as 26% was observed 
in Thailand after treating the patients with similar doses of chloroquine and 
primaquine (Myint et al. 2011).  
         Nearly one-third patients (31.48%) relapsed within a year when treated with 
1500 mg chloroquine. Relapse rate decreased to 20% when chloroquine was 
supplemented with primaquine at the rate of 15 mg/day for 5 days and further 
decreased to 6.66% when the duration of treatment with primaquine was extended to 
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14 days during the present study. Similar decrease in the relapse rate was observed by 
other workers as well (Srivastava et al. 1996, Valecha et al. 2001, Walsh et al. 2004, 
Townell et al. 2012, Yuan et al. 2015). Almost five times short term relapses were 
observed compared to long term when patients were treated with chloroquine only. 
The ratio changed when five days regimen of 75 mg primaquine was supplemented 
with chloroquine and short term relapses observed were three times higher than long 
term relapses. Those who were treated with 210 mg of primaquine for 15 days 
experienced 6.66% short term relapses. .Patients treated with only 1500 mg 
chloroquine showed maximum relapses which were more frequent, indicating 
ineffectiveness of this drug on hypnozoites. As far as the role of primaquine is 
concerned, it reduced the relapse rate in the patients treated with primaquine. Relapse 
rate was comparatively higher in patients treated with 75 mg primaquine in 
comparison to those treated with 210 mg primaquine which indicates decrease in its 
efficacy on hypnozoites and confirms that shorter primaquine regimens at the same 
daily dose are associated with higher relapse rates as earlier observed by Galappaththy 
et al. (2013). Primaquine could not prevent relapse completely even after 14 days of 
treatment indicating progressive decline in its efficacy. It is therefore  appropriate to 
implement the 14-day regimen recommended by the World Health Organization, 
although this regimen could not eliminate hypnozoites completely but reduces relapse 
to a minimal level. 
          Long survival of P. vivax during lean period of transmission following 
primary infection and relapses ensures transmission in the next season through the 
existence of a reservoir of P. vivax. During this dormancy in hepatocytes P. vivax 
might have escaped host immune response and survived for the reappearance in next 
transmission season. 
 Different strains of P. vivax might be responsible for different relapse patterns 
in different ecosystems with reference to space and time, which are probably not 
constant and likely to be time dependent. In addition to this, the degree to which these 
parasite strains interact with each other have an impact on the maintenance of genetic 
diversity and regulation of the parasite population as a whole. However, amplification 
of specific DNA sequences by the polymerase chain reaction using specific 
oligonucleotide probes from different parasite isolates of relapsing and non-relapsing 
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patients could be used to analyse the genetic diversity of P. vivax which may help in 
differentiating relapse and reinfection cases of P. vivax (Saifi et al. 2010).  
          Chloroquine resistance in P. vivax has been confirmed in only ten countries 
across the globe, excluding India (WHO 2013). During the present study 3 (1.28%) 
patients of P. vivax did not respond to chloroquine and primaquine as low grade 
parasitaemia was observed after 7, 9 and 13 days of treatment. Almost similar 
observation was made by earlier workers who recorded recrudescence between 3 and 
14 days following chloroquine and primaquine treatment (Marler-Than et al. 1995, 
Baird et al. 1997, Baird et al. 2009), which is in corroboration with the present 
finding. Similar other treatment failures were observed recently in P. vivax infections 
by other workers (Ganguly et al. 2013, Price et al. 2014, Yuan et al. 2015, Kumar et 
al. 2015) 
         Drug resistance is a complex phenomenon, where a parasite acquires the 
ability to resist the effect of one or more antimalarial drugs partially or fully by 
genetic mutation. If the parasites are resistant to the drugs, patients may not respond 
to the treatment. Resistance is widespread in P. falciparum against sulfadoxine-
pyrimethamine, a synergistic drug used to inhibit dihydrofolate reductase and 
dihydropteroate synthase which act on the erythrocytic stage of P. falciparum and P. 
vivax. The combination product may be used in areas where there is chloroquine 
resistance (Drug bank 2005). This drug combination acts at different steps to block 
two key enzymes which are required for the synthesis of folate in a biochemical 
reaction. Dihydrofolate reductase (dhfr) gets inhibited by pyrimethamine whereas 
dihydropteroate synthetase (dhps) by sulfadoxine (Farooq and Mahajan 2004). 
 In the present study resistance rate against sulfadoxine-pyrimethamine ranged 
from 21.91% to 27.42% during the years 2011-2013. RI  type of resistance which 
accounted for 12.32-17.74% was 2-3 times more than that of RII type which ranged 
from 6.84 -9.67%, whereas  RIII type of resistance was found in only 2.00 -2.74% of 
P. falciparum patients. This result showed a progressive increase in RI and RII levels 
of resistance. The reason for this increase seems its indiscriminate use in most of the 
endemic countries as it is cheap as well as easily available drug which caused varying 
levels of mutation in different countries depending on the duration of its use. Similar 
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and much higher rates of resistance and treatment failures against SP were 
documented from Kenya, Tanzania, Mbeya, Malawi, Tanga and Orissa and 
Northeastern parts of India (Bousema et al 2003, Bwijo et al. 2003, Msyamboza et al. 
2007, Schonfeld et al. 2007, Gesase et al. 2009, Sharma 2012, Mishra et al. 2014, 
Pathak et al. 2014). These authors verified the resistance by mutation study and 
recorded double, triple and quintuple mutations which ranged from 64-84% cases. 
 In the present study only RI level of resistance was observed in 2.04 and 
1.28% patients treated with artemether and artesunate and sulfadoxine-pyrimethamine 
(AS-SP) combination, respectively. The low percentage in the resistance rate of these 
drugs are indicative of the fact that artemether alone as well as (AS-SP) combination 
are still quite effective in our study area but must be used with caution as resistance 
has already appeared in India as well as other endemic tropical countries.  Resistance 
rates of 9.5-16% have been reported against AS-SP from Thailand and Combodia 
(Saha et al. 2012, Das et al. 2013). In contrast, ACT (artemether-lumefantrine) 
cleared the parasitaemia from all the 84 patients successfully without recrudescence in 
a single case during this study which is in corroboration with the findings of Shayo et 
al. (2015) who reported cure rate of 91-100% in uncomplicated P. falciparum cases in 
Tanzania. Resistance against artemether-lumefantrine combination has also been 
documented in 2.82 and 5.58% cases in Africa (Sisowath et al. 2007, Assefa et al. 
2010, Malmberg et al. 2013). Resistance rate as high as 9.5% was recorded from 
Orissa and Assam (Valecha et al. 2009a), but it is still effective in the rest of India 
and many other endemic countries, and therefore may be considered as safe and 
comparatively more effective drug for the treatment of acute uncomplicated and as 
well as severe resistant falciparum malaria as a viable alternative of artesunate, 
artemether and artesunate+SP combination. However, its rational use and periodic 
monitoring is necessary as this drug combination may also fail, if used 
indiscriminately. 
 
 
 
 Chapter 3 
Mutations in dihydrofolate reductase gene of 
Plasmodium falciparum and Plasmodium vivax 
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INTRODUCTION 
Malaria is one of the most prevalent parasitic diseases worldwide with estimated 198 
million cases and 584,000 deaths (WHO 2014). It mainly affects children, pregnant 
women and non-immune adults who frequently die as victims of cerebral 
manifestations and anaemia (Quintero et al. 2011). This disease is managed by 
antimalarial drugs as no effective vaccine is yet available. However, the parasite has 
developed resistance against most commonly used antimalarial chloroquine (CQ), 
posing a major problem for malaria control programme (Mitra et al. 2006). In case of 
Plasmodium falciparum infection and in doubtful species diagnosis, sulfadoxine-
pyrimethamine (SP) combination was usually prescribed by clinicians to avoid any 
risk on the life of the patient and thereby, increases SP pressure in the parasite 
population. With the spread of chloroquine resistant malaria in different countries 
including India, this drug was replaced with SP which was used indiscriminately for 
more than a decade. Resistance started appearing against drug and became widespread 
in many endemic countries such as Kenya, Tanzania, Mbeya, Malawi, Tanga and 
Orissa and Northeastern parts of India (Bousema et al. 2003, Bwijo et al. 2003, 
Msyamboza et al. 2007, Schonfeld et al. 2007, Menard et al. 2008, Gesase et al. 
2009, Sharma 2012, Mishra et al. 2014, Pathak et al. 2014). This drug combination 
targets the folate biosynthetic pathway of Plasmodium species blocking the nucleic 
acid biosynthesis and thus causing parasite death (Peterson et al. 1988, Triglia et al. 
1997). Pyrimethamine acts on the dihydrofolate reductase enzyme of P. falciparum 
(pfdhfr) and inhibits the folate biosynthesis pathway of the parasite (Yuvianiyama et 
al. 2003, Gregon and Plowe 2005). Point mutation in pfdhfr reduces its binding 
capacity with SP which results in resistant parasite strains (Mbugi et al. 2006, Gesase 
et al. 2009). There are mutations at more than three loci in the parasite enzyme in 
endemic countries (Peterson et al. 1988, Sirawaraporn et al. 1997). Pyrimethamine 
resistance developed in a progressive manner and treatment failures were recorded 
(Wang et al. 1997). As both P. falciparum and P. vivax contain the same target 
enzymes, the antifolate drug affected both these species (Imwong et al. 2003, de 
Pecoulas et al. 2004, Hastings et al. 2004, Kaur et al. 2006, Barnadas et al. 2008).  
 Since resistance was reported against SP combination in most of the endemic 
countries of the world, artemisinin based combined therapy (ACT) was introduced. 
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Resistance against artesunate plus sulfadoxine-pyrimethamine (AS-SP) combination 
has been reported in a few countries, including India (Saha et al. 2012, Das et al. 2013 
and Mishra et al. 2014). But there are many countries where sulfadoxine-
pyrimethamine and AS-SP combinations are still effective. In India, sulfadoxine-
pyrimethamine showed varying level of resistance which is highest in Andaman 
Nicobar and North-Eastern States where treatment failures were recorded against this 
drug. However, the level of resistance is comparatively much lower in plain areas 
including Uttar Pradesh (Alam et al. 2007). AS-SP combination is still effective in 
most parts of the country and is given to treat falciparum malaria all over India as per 
antimalarials drug policy of India except for the North-Eastern States where 
artemether plus lumefantrine is recommended. Keeping these facts in mind, study on 
the prevalence of mutations and phenotypic expressions associated with sulfadoxine-
pyrimethamine resistance in P. falciparum and P. vivax was attempted in the samples 
obtained from Aligarh, India.  
 
MATERIALS AND METHODS 
Blood samples collected from the febrile patients who attended the Medical College 
and other malaria clinics of Aligarh, India during 2011-2013. Thick and thin blood 
smears of these patients were screened by Nikon Eclipse-600 research microscope at 
different magnifications and specific diagnosis was made at 100x. The patients were 
treated according to National Drug Policy of India. Prepared slides from Aligarh, 
India were observed for phenotypic variations in P. falciparum. Mutation studies were 
conducted in pfdhfr and pvdhfr genes, using the above blood samples. DNA 
extraction, amplification and nucleotide sequencing were done as described earlier by 
Alam et al. (2007). DNA was extracted from the blood of patients that were infected 
with P. falciparum and P. vivax using Accu Prep Genomic DNA extraction kit 
(Bioneer Corporation of Korea). 
Isolation of DNA from whole blood:  
The protocol followed for the isolation of DNA was as follows:  
1. 20 μl of proteinase K was added to a clean 1.5 ml tube.  
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2. 200 μl of whole blood was added to the tube containing proteinase K.  
3. 200 μl of binding buffer was added to the sample and mixed immediately by 
vortex mixer.  
4. Above mixture was incubated at 60oC for 10 min. 
5. 100 μl of isopropanol was added and mixed well by pipetting. 
6. Lysate was then transferred carefully into the upper reservoir of the binding 
column tube  (fit in a 2 ml tube) without wetting the rim 
7.  Tube was closed and centrifuged at 8,000 rpm for 1 min. If the lysate was not 
completely  passed through the column after centrifugation, it was again 
centrifuged at a higher speed  (>10,000 rpm) until the binding column tube is 
empty.   
8.  Tube was opened and the binding column tube was transferred to a new 2 ml 
tube for  filtration.    
9. Now 500 μl of washing buffer 1 (W1) was added without wetting the rim, tube 
was closed and centrifuged at 8,000 rpm for 1 min.   
10. Tube was opened again and the solution was poured from the 2 ml tube into a 
disposal  bottle 
11. 500 μl of washing buffer 2 (W2) was added carefully without wetting the rim, 
tube was closed and centrifuged again at 8,000 rpm for 1 min.   
12. It was centrifuged once more at ca. 12,000 rpm for 1 min to remove ethanol 
completely and checked that there is no droplet clinging to the bottom of the 
binding column tube.  
13. Now the binding column tube was transferred to a new 1.5 ml tube for elution 
(supplied) and 200 μl of elution buffer (EL, or nuclease-free water) was added 
onto binding column tube and waited for 1min at room temperature (15-25 C) 
until EL was completely absorbed into the glass fibre of binding column tube 
(DNA yield may get increased if waited for 5 min after adding Elution buffer).  
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14. Finally it was centrifuged at 8,000 rpm for 1 min to elute. About 180 μl ~ 200 
μl of eluent can be obtained when using 200 μl of Elution buffer or nuclease-
free water.  
For the improved yield, sample was eluted twice and used after concentration 
process. The eluted genomic DNA is stable and can be used directly, or stored at 4oC 
for later analysis. For long-term DNA storage, it should be eluted with elution buffer 
(EL) and stored at -20oC, because DNA stored in water is subject to acid hydrolysis. 
About 6 μg of DNA in 200 μl of eluent (30 ng/μl) with an A260/A280 ratio of 1.6 ~ 
1.9 can be typically obtained from 200 μl of whole blood (~ 5 X 106 leukocytes/ml). 
 
Flow chart for DNA extraction from whole blood 
 
Whole blood (200 µl) in 1.5 ml tube 
   
Add binding buffer (GC) & proteinase K 
                                        Incubate for 10 min 
Add isopropanol (100 µl) 
 
Transfer binding column tube 
 
Centrifuge at 8,000 rpm, 1 min 
 
Add washing buffer 1 (W1), 2(W2) 
 
Centrifuge at 8,000 rpm for 1 min 
 
Add elution buffer (EL) 
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Fig. 1. Bands showing DNA extracted from the blood samples of patients of 
Plasmodium falciparum  
 
 
Fig. 2. Bands showing DNA extracted from the blood samples of patients of 
Plasmodium vivax 
 
PCR amplification of dhfr gene 
The DNA thus extracted was eluted in Tris EDTA buffer (pH 8.0) and an aliquot was 
used for PCR amplification. A fragment of 1,014-bp fragment of P. vivax, dhfr-ts 
gene was amplified using primers PvDA (5'-ACCGCACCAGTTGATTCCTAC-3') 
(forward) and PvDB (5'-TGTTAAAGCTGAAGTACACGAG-3') (reverse). The 
cycling parameters followed were 10 minutes initial denaturation step at 94ºC 
followed by 35 cycles with a 30 sec denaturation step at 94ºC, one minute annealing 
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step at 58ºC, one minute extension step at 72ºC and a final 10 minutes extension step 
at 72ºC. After diluting 10 times, this priming PCR product was used as a DNA 
template for nested PCR to amplify the 784-bp region, which enclosed the entire 
DHFR domain.  
 
Fig. 3. Gel showing the priming PCR product of DHFR domain . 
 
Primers PvDF (5’-ATGGAGGACCTTTCAGATGT-3’) (Forward) and PvDR 
(5’-AACGCATTGCAGTTCTCCGA-3’) (reverse) were used for nested PCR with  a 
10 minutes initial denaturation step at 94ºC followed by 35 cycles with a 30 sec 
annealing step at 54ºC and a one minute extension step at 72ºC  along with a final 10 
min  extension step at 72°C as the cycling parameters. Primers PvDA (covering -75 to 
-55 bp upstream to the pvdhfr-ts start codon), PvDB, PvDF and PvDR were designed 
from the known pvdhfr-ts sequence of pyrimethamine-sensitive P. vivax isolate 
ARI/Pakistan (98123). DNA was extracted and subjected to PCR amplification of a 
720-bp fragment to the pfdhfr gene using the method described by Ahmad et al. 
(2004). An aliquot of the primary amplicon was diluted and subjected to semi nested 
PCR using primer AMP1 (Plowe et al. 1997) and DHFRR2 (5’-
ACAGAAATAATTTGATACTCA-3’). Only 30 cycles were carried out for semi 
nested PCR under the same conditions as has been used for primary PCR. The PCR 
products were purified and subjected to sequencing according to Mitra et al. (2006), 
using an ABI Big dye terminator Ready Reaction Kit (version 3.1), and the ABI Prism 
310 genetic analyser (PE Applied Biosystems, California, USA).  
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Fig. 4.  Mutated amino acids in DHFR gene by amplification of the first PCR product. 
 Nucleotide Sequencing: 
 Individual band of each PCR product was excised from the agarose gel and purified 
using an Accu Prep gel purification kit (Bioneer Corporation, Korea) according to the 
manufacturer’s instructions. The entire pvdhfr gene was sequenced using primer 
PvDM (5’-GTTAGCGTCTTGTCTTGGAAAGCAC-3’) and PvDR(5’-
AACGCATTGCAGTTCTCCGA-3'), whereas primers for pfdhfr gene sequencing 
were same as described by Ahmad et al. (2006). Sequencing parameters were same as 
described by Jalah et al. (2005). The nucleotide sequences were translated into amino 
acids using the edit sequence program (Lasergene July 1999, version 5.1, DNASTAR
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 Inc., Madison, WI, USA). Gen Doc Multiple Sequence Alignment Editor and 
Shading Utility (Version 2.6.002) was used to align the amino acid sequences. 
Statistical analysis:  
The chi-square test was applied to assess the trends of dhfr mutations in P. falciparum 
and P. vivax infections. A P- value of <0.05 was considered significant. 
 
RESULTS 
Nucleotide sequence of the pfdhfr and pvdhfr genes was analysed from 51 and 46 
isolates of P. falciparum and P. vivax collected from Aligarh, Uttar Pradesh, North 
India during 2011-2013. Sequencing study of pfdhfr and pvdhfr genes showed 
mutations in DNA isolates. The pfdhfr mutations were observed at codons S108N, 
C59R and N51I. Maximum number of isolates (92%) showed mutations at codon 108 
(S108N) (P<0.05) followed by mutations at codon 59 (C59R, 55%) and least (4%) at 
codon 51 (N51I). Majority of the isolates were found to contain double pfdhfr 
mutations (Figures 5,6; Table. 1). The double mutation C59R plus S108N was much 
more common and observed in 28 isolates (55%; n=51) with genotype A16, N51, 
R59, N108, I164 than the N51I plus S108N mutations in 2 isolates (4%; n=51) with 
genotype A16, I51, C59, N108, I164. Single mutation at codon 108 (S108N) was 
detected in 17 isolates (33%; n=51) having genotypes A16, N51, C59, N108, I164. 
Only 4 isolates (8%; n=51) showed wild type amino acids with genotype A16, N51, 
C59, S108, I164.  
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Table1. DHFR genotypes of Plasmodium falciparum in Aligarh, India. 
Genotype No. of mutations No. of isolates 
A16 N51 C59 S108 I164 0 4(8%) 
A16 N51 C59 N108 I164 1 17(33%) 
A16 N51 R59 N108 I164 2 18(55%) 
A16 I51 C59 N108 I164 2 2(4%) 
  Total no.=51 
 
 
Fig. 5. Plasmodium falciparum showing DHFR mutations in Aligarh, India. 
        Mutation analysis by sequencing dhfr gene from 46 P. vivax isolates revealed 
that the mutations occurred at S117N, S93H and S58R codons. Frequency of 
mutation among the isolates from Aligarh, Uttar Pradesh was higher at codon S117N 
followed by the codon S93H. A total of 28 isolates (60.87%; n=46) contained the 
wild type amino acids with genotype at codons F57, S58, T61, S93, S117. Among the 
remaining isolates, the frequency of double mutations of dhfr was highest and 
observed in 12 cases (26.09%; n=46) where genotype was F57, R58, T61, S93, N117. 
Only six isolates (13%; n=46) showed mutations at single codon S93H/S117N of 
6.52% each and the genotypes were F57, S58, T61, H93, S117 and F57, S58, T61, 
S93,  N117. 
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Table 2. DHFR genotypes of Plasmodium vivax in Aligarh, India. 
Genotype No. of mutations No. of isolates 
F57 S58 T61 S93 S117 0 28(61%) 
F57 S58 T61 S93 N117 1 3(6.5%) 
F57 S58 T61 H93 S117 1 3(6.5%) 
F57 R58 T61 S93 N117 2 12(26%) 
  Total no.=46 
 
 
Fig. 6.  Plasmodium vivax showing DHFR mutations in Aligarh, India. 
A-Ala            Alanine 
C- Cys             Cysteine 
F- Phe             Phenylalanine 
H- His             Histidine 
I- Ile               Isoleucine 
N- Asn            Asparagine 
R- Arg            Arginine 
S- Ser             Serine 
T- Thr            Threonine 
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       During the present study, it was observed that rings of P. falciparum, which show 
variations in size and shape in natural course, showed little more prominent variations 
in terms of shape and thickness of cytoplasm of the rings (Fig. 3). In P. falciparum 
having mutations at two codons, rings were much oblong with the thickened 
cytoplasm at one end (Fig. 7.). It remains unclear weather this change in size and 
shape of rings of P. falciparum is a mere coincidence or it is due to the alteration of 
the amino acids in dhfr enzyme.  
 
 
Fig. 7. Ring stage of Plasmodium falciparum showing variations in their size and 
shape.(100x) 
 
DISCUSSION 
Sulfadoxine-pyrimethamine (SP) is an effective synergistic therapeutic agent which 
interferes with folate metabolism. Unfortunately, resistance developed and point 
mutations occurred in dihydrofolate reductase (dhfr) and dihydropteroate synthase 
(dhps) genes against this drug combination. New antifolate combinations that are 
more effective against resistant parasites are being developed. Combinations of these 
antifolates with other drugs having different biochemical targets in the parasite greatly 
enhance their effectiveness and reduce the ongoing development of resistance, as was 
observed by introduction of artesunate plus SP combination (Das et al. 2013, Mishra 
et al. 2014).  
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Antifolate drugs were generally used for the treatment of falciparum malaria 
in developing countries. In India, uncomplicated falciparum malaria cases were 
treated with sulfadoxine-pyrimethamine where chloroquine resistance was already 
proved during the last decade. In regions where resistance due to chloroquine (CQ) 
had reached a very high level, SP was the first-line of treatment for P. falciparum 
infections. Artemisinin based combined therapy was introduced as an alternative 
treatment recently in those cases only which did not respond to SP. Several countries 
have already abandoned chloroquine and SP monotherapy because of emergence and 
worsening rise of CQ and SP-resistance (Rapouda et al. 1997, Bosco et al. 1998, 
Shretta et al. 2000). If P. falciparum and P. vivax coexist in any region, both are at 
risk of being exposed to the antifolate drug (SP) as they have common target enzymes 
(Tjitra et al. 2002, Imwong et al. 2003,  de Pecoulas et al. 2004,  Gregon and Plowe 
2005, Barnadas et al. 2008).  
Single and multiple mutations at codons 51, 59, 108 and 164 of dihydrofolate 
reductase enzyme have usually been associated with pyrimethamine resistance in P. 
falciparum malaria. Enzyme mutants which are present in nature resist pyrimethamine 
and cause in vivo antifolates resistance. Thus, specific combinations of multiple 
mutations at target residues were selected in nature to optimise resistance.  It has also 
been observed that the resistance of multiple mutants was more than the sum of the 
individual mutated components, indicating synergistic as well as intrinsic effects of 
residues selected for resistance (Sirawaraporn et al. 1996).  
In the present study, a low level of SP resistance of 55% pfdhfr mutations was 
recorded at codons 59 and 108 (C59R plus S108N) and 4% at codons 51 and 108 
(N51I plus S108N) from Aligarh in North India where P. vivax dominates over P. 
falciparum. Almost similar findings were obtained in Pakistan where double 
mutations (C59R plus S108N) were recorded without treatment failures (Khatoon et 
al. 2013). Low level of resistance with single mutation ranging from 5-10.5% at 
codon C59R was reported in Yemen and Saudi Arabia (Al-Harthi 2007, Mubjer et al. 
2011), indicating that SP combination is still effective in a few countries at least 
partially in some pockets where malaria transmission is low and seasonal. Mugittu et 
al. (2003) observed prevalence of triple pfdhfr mutant genotype as N51I, C59R and 
S108N in 23.6% isolates with treatment failures in 9.7% patients. These triple mutants 
showed resistance 4 times higher compared to those having moderate mutations in 
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Tanzania. This unusually high rate of mutation indicated synergistic effect of 
component single mutants as earlier postulated by Sirawaraporn et al. (1996). In 
contrast, higher levels of SP resistance and treatment failures were reported from 
Kenya, Malawi, Tanzania, Ethiopia, Sudan and North-Eastern part of India, where 
intense malaria transmission with pfdhfr mutations in  44-82% isolates was observed 
(Pearce et al. 2003, Ahmad et al. 2006a, Schunk et al. 2006, Msyamboza et al. 2007, 
Gesase et al. 2009, Schonfeld et al. 2007, Yousuf et al. 2010, Matondo et al. 2014). A 
few other places such as Tanga and Mbeya of Tanzania showed higher rates of double 
(63-81%)  and quintuple (64-75%)  mutations with widespread treatment failures in P. 
falciparum isolates (Schonfeld et al. 2007, Gesase et al. 2009). Further high rates of 
double, triple and quintuple mutations of around 43-97, 84, and 37.5-80% pfdhfr 
mutations with many treatment failures were recorded in Tanzania (Matondo et al. 
2014).  
Mutation in pvdhfr gene in my study area was less than half of pfdhfr gene. 
This difference in the frequency of mutation might be due to the reason that SP was 
directed specifically against P. falciparum infections. But since P. vivax is the most 
prevalent species having same biochemical target and was exposed to this drug 
because of wrong species diagnosis and/or medications without species identification. 
In my study, sequencing of dhfr gene in P. vivax isolates revealed the mutations at 
codons 117, 93 and 58 (S117N, S93H and S58R). Mutation frequency was highest at 
codon117 (S117N) followed by codon 93 (S93H). 61% isolates contained the wild 
type amino acids with genotype F57, S58, T61, S93, S117. 26% isolates showed 
double mutations with genotypes F57, R58, T61, S93, N117. Rest 13% showed 
mutations at single codon S93H or S117N (6.5% each) with genotypes F57, S58, T61, 
H93, S117 and F57, S58, T61, S93, N117. Since 61% P. vivax isolates showed wild 
type of amino acids, mutation in pvdhfr gene against SP was restricted to only 39% 
cases (26% double and 13% single). Low level of SP resistance in pvdhfr gene was 
detected in 4.1and 12.3% isolates of P. vivax at codons S58R and S117N in 
Afghanistan (Zakeri et al. 2010). Similar low rates of 12, 34 and 2% mutations were 
recorded at codons S58R, S117N and S117T of pvdhfr gene in Iran (Zaman et al. 
2011). Double mutations were located at S58R and S117N in 45.4% isolates in Iran 
(Afsharpad et al. 2012). Slightly higher rates (58%) of double mutations were 
recorded at codons S58R and S117N in Eastern Sudan (Zakeri et al. 2014). Mutations 
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were recorded at codons 58, 61 and 117 in Central China also where single mutations 
were in 34.6% while double mutations were in 43.8% isolates (Huang et al. 2011). In 
Eastern and Central Sudan also mutations were detected at 3 codons (I13L, S58R and 
S117N) where 58% of the isolates had double mutations at codons S58R and S117N 
(Pirahwadi et al. 2014). In Pakistan also antifolates resistance and mutations were 
detected in pvdhfr gene at codons 57, 58 and 117 with highest frequency at codon 117 
accounting for 93.5% (Khatoon et al. 2009). Kaur et al. (2005) detected quadruple 
mutation at codons F57L, S58R, T61M and S117T in two isolates. Thongdee et al. 
(2015) reported that the most prevalent alleles found in samples from the Philippines 
and Bangladesh were triple mutant pvdhfr but those collected from Nepal were 
quadruple mutant pvdhfr.   
The level of pyrimethamine resistance in P. vivax has also increased with the 
sequential addition of each mutation in dhfr gene where S117T mutation was seen in 
the extremely resistant parasites (Hastings et al. 2004, 2005). Valecha et al. (2006) 
reported double mutations in dhfr gene in vitro in Indian isolates of P. vivax.  Alam et 
al. (2007) studied cross species impact of antifolate drug treatment and observed that 
the overall mutation rate of dhfr in P. vivax was lower than that of P. falciparum. 
They concluded that both the species of Plasmodium followed similar trends of dhfr 
mutations which seem true in my case also where both P. falciparum and P. vivax 
showed mutations in dhfr gene. Additional mutations reported in pvdhfr gene were 
I13L, P33L, F57L/I, T61M, S117T, I172V and I173L (Imwong et al. 2003, Brega et 
al. 2004, de Pecoulas et al. 1998, 2004, Hastings et al. 2005, Schunk et al. 2006). 
Various other workers reported similar pvdhfr mutations at above codons except for 
I13L, P33L, I172V and I173L in India (Imwong et al. 2001, Kaur et al. 2006, Valecha 
et al. 2006). 
It seems that there is an association among the degree of malaria transmission, 
number of pfdhfr mutations and treatment failure. It is quite evident from the above 
studies that treatment failures were recorded from the areas where triple and quintuple 
mutations were more frequent. Double mutations showed recrudescence which 
probably lead towards treatment failures, but not in cases having single mutations. 
Mutations in pfdhfr gene have been used as an indicator to predict treatment failure to 
SP in many areas where malaria is endemic. Gregson and Plowe (2005) reported that 
the first mutation occurs at S108N codon followed by C59R, N51I and I164L, which 
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seems true in the present study where mutations occurred at the same codons,  
maximum being at 108 (S108N). However, patient’s response to the treatment is 
significantly dependent on factors such as host immunity profile of treated patients as 
earlier indicated by Happi et al. (2005). In endemic countries where higher doses of 
SP are given, mutations in pfdhfr gene are increasing rapidly and resulting in 
treatment failures. Studies with molecular markers have confirmed rapid development 
of resistance after the drug was used at national level in a number of settings (Sridaran 
et al. 2010, Zakeri et al. 2010). Rapid spread of SP resistant strain has threatened its 
use and therefore, artemisinin based combination therapy was introduced. In India, 
artesunate plus SP combination is also used as reports are coming up regarding 
resistance against SP from different parts of the county. In North-Eastern states where 
artemether plus lumefantrine is being recommended recently as triple and quadruple 
mutations are being recorded from this part of India (Anvikar et al. 2014).          
        Epidemiological and molecular studies on P. falciparum and P. vivax very 
clearly indicate that the dhfr enzyme is the therapeutic target of SP (Nzila et al. 2000, 
Tjitra et al. 2002, Imwong et al. 2003, de Pecoulas et al. 2004, Hastings 2004). 
Resistance to SP is determined by specific point mutations in the parasite dhfr gene. 
These mutations cause alterations of key amino acid residues in the active sites of 
these enzymes reducing the affinity of enzymes for the drug (Foote and Cowman 
1994). Point mutation in pfdhfr reduces its capacity to bind with the drug, resulting in 
the emergence of resistant parasite strains (Cowman et al. 1988, Wang et al. 1997, 
Foote and Cowman 1994, Mbugi et al. 2006, Gesase et al. 2009). P. vivax infections 
are not often treated with SP but this species got exposed to SP because of mixed 
infection and caused mutations as indicated by earlier workers (Snounou and White 
2004, Kaur et al. 2006, Khatoon et al. 2009, Zakeri et al. 2010). The continuous use 
of SP as first-line antimalarial drug in endemic areas, where both P. vivax and P. 
falciparum species coexist, has increased the risk of mutations in the dhfr gene in both 
the species. This may lead towards a higher level of resistance against this 
combination in the near future. Therefore, continuous surveillance of P. vivax and P. 
falciparum molecular markers are needed to monitor the development of resistance to 
SP in endemic foci in poor countries, where this drug is used quite extensively due to 
its cost-effectiveness,  easy availability and taken as a single dose. 
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 With the foregoing discussion it may be concluded that mutations have 
occurred in dhfr gene in P. falciparum and P. vivax infections in Aligarh. Mutations 
were more prominent in the former species as sulfadoxine-pyrimethamine was 
directed towards the treatment of falciparum malaria in my area of study. Double 
mutations were observed in 59% P. falciparum isolates which is more than two times 
high compared to P. vivax. Therefore, to avoid further higher mutations in dhfr 
enzyme of Plasmodium, use of better treatment regimens such as artemisinin based 
combination therapy must be introduced in place of SP combination in my study area.      
 
 
 
 
 
 
 
 
 Chapter 4 
Clinical Manifestations of Malaria 
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INTRODUCTION 
Malaria is one of the most devastating diseases of tropical countries worldwide with 
clinical manifestations such as anaemia, splenomegaly, thrombocytopenia, 
hepatomegaly and acute renal failures. It mainly affects children, pregnant women 
and non-immune adults who frequently die as victims of cerebral manifestations and 
anaemia (Guerra et al. 2009, Quintero et al. 2011). Complications in malaria are 
responsible for a great number of spontaneous abortions, stillbirths, premature 
deliveries and low birth weight (Dicko et al. 2003). Children with impaired 
consciousness and respiratory distress are at the highest risk of death associated with 
malaria (Marsh et al. 1995, Dellinger et al. 2008, Mohan et al. 2008). Neurological 
involvement in Plasmodium falciparum malaria is common and nearly a quarter of 
children who survived cerebral malaria develop neurological sequelae (Idro et al. 
2007). P. vivax is responsible for a significant proportion of malaria cases worldwide 
and is increasingly reported as a cause of severe disease (Lanca et al. 2012). In the 
past few years, P. vivax infection was recognized as a cause of severe malaria in 
young children even causing death (Sharma and Khanduri 2009, Singh et al. 2011, 
Limaye et al. 2012). Symptoms like cerebral malaria, acute kidney injury, liver 
dysfunction, severe respiratory distress, abnormal bleeding, severe anaemia and 
multiple organ failure which had been usually associated with P. falciparum 
infections, were recently reported in vivax malaria also (Prakash et al. 2003, Picot and 
Bienvenu 2009, Sonkar et al. 2011). Recent reports have indicated life threatening, 
complications and even death in P. vivax infection (Rizvi et al. 2013, Douglas et al. 
2014). In view of the above facts, the present study was aimed at assessing the clinical 
manifestations in P. falciparum and P. vivax infections in India. 
 
MATERIALS AND METHODS 
Blood samples were collected from the patients admitted to Jawaharlal Nehru Medical 
College hospital and a few other nursing homes of Aligarh during 2011-2013. Clinical 
profiles of the patients were recorded at the time of sample collection. Patients having 
any pre-existing disease and symptoms resembling malaria were excluded from this 
study. Thin and thick blood smears were prepared on the glass slides by pricking 
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finger of the patients complaining for high fever and headache. These slides were 
stained with Giemsa and Leishman stains and the probabilities of P. falciparum and 
P. vivax were microscopically confirmed at 100x by Nikon Eclipse-600 research 
microscope. Quantitative Buffy Coat (QBC) technique was also used for specific 
diagnosis. Rapid diagnostic test kits were also used during outdoor collections. 
Infectivity was recorded for P. falciparum, P. vivax and mixed infections by 
observing typical ring stages and gametocytes. For liver and kidney function tests 
(LFT and RFT), blood was obtained after taking patients consent by vein puncture 
using a 21 gauge hypodermic sterile needle and syringe. These samples were 
collected in clean sterile glass tubes, allowed to clot for 2 hrs at room temperature and 
then kept in a refrigerator at 5°C for 10 hrs so that clot could get squeezed. Serum was 
picked and transferred to a centrifuge tube with the help of pipette and centrifuged at 
3000 rpm for 5 min to remove any cell contamination. The sera were then stored in 
separate vials for biochemical assay at -20°C until analysed for liver enzymes and 
kidney markers. Changes in liver enzymes, such as aspartate transaminase (AST), 
alanine transaminase (ALT) and alkaline phosphatase (ALP), urea and creatinine of 
the patients were estimated with the help of standard techniques. AST and ALT were 
estimated as per the method described by Wilkinson et al. (1972) whereas ALP was 
estimated as described earlier by Burtis and Asood (1999). Serum bilirubin was 
estimated by the method described by Kalpan (1965). The kidney function markers 
such as creatinine and urea were estimated according to the procedures described by 
Thomas et al. (1998) and Kalpan (1965), respectively. Clinical symptomatic and 
pathological findings were presented in the form of tables and figures. Clinical 
symptoms such as high fever, chills, vomiting, anaemia, splenomegaly, jaundice, 
respiratory distress, convulsions and neurological sequelae were recorded in P. 
falciparum, P. vivax and mixed infections. 
The protocols used to detect the level of enzymes from blood are as follows: 
Aspartate transaminase (AST):  
The reactions involved in the determination of asparate transaminase (AST) activity 
were as follows: 
Aspartate + 2-oxoglutarate                    Glutamate + Oxaloacetate     .............. (1) 
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Oxaloacetate + NADH + H+     Malate dehydrogenase     Malate + NAD+         .............. (2) 
Alanine transaminase (ALT):  
Similar principles were employed in the measurement of alanine transaminase (ALT) 
activity: 
Alanine + 2-oxoglutarate                  Glutamate + Pyruvate         .............. (3) 
Pyruvate + NADH + H+       Lactate    dehydrogenase      Lactate + NAD+      ............... (4) 
Procedure: 
The following mixtures were prepared and incubated for 15 min. at 25°C ± 0.2°C:  
Reagents 
                               Enzymes 
AST (ml) ALT (ml) 
Phosphate buffer (0.1 moles/litre) 1.3 1.3 
Serum 0.2 0.2 
NADH solution 0.2 0.2 
L- aspartate 1.0 - 
L- alanine - 1.0 
Malate dehydrogenase 0.1 - 
Lactate dehydrogenase - 0.1 
Total volume 2.8 2.8 
Optical Density was recorded for absorbance at 340 nm. 
Calculations: 
The rate of change in absorbance per minute was measured (∆A/min), and the 
transaminase activity was calculated in IU per litre: 
Transaminase activity = ∆A/min × 2400 IU/litre  
The normal ranges obtained at 25°C from healthy blood donors by the above methods 
are: 
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 Aspartate transaminase (AST): 0-45 IU/L 
 Alanine transaminase (ALT): 3-60 IU/L 
                                                         
ALP Protocol: 
p- Nitro phenyl phosphate + H2O     
ALP               p-Nitro phenol + phosphate. 
ALP working reagent                    5.5 ml of AMP buffer + 1 vial of pNPP  substrate. 
AMP buffer contains AMP (2-Amino-2-methyl-1-propanol), magnesium acetate and 
zinc sulphate. 
Procedure:  
For the estimation of ALP 20 µl of sample was taken and 1000 µl working ALP 
reagent was added to it. After mixing thoroughly its absorbance was measured at 
405nm. 
 
Calculation: 
ALP activity (IU/L) = ∆A/minute × Kinetic factor 
Kinetic factor (K) = 2712 
Kinetic factor was calculated by using following formula 
 
 
 
M   = Molar extinction coefficient of p-Nitrophenol and is equal to 18.8 × 103 
lit/mol/cm at 405 nm 
TV = Sample volume + working reagent volume 
SV = Sample volume 
P   = Optical path length 
106 = Constant 
Reference range: 
ALP activity in IU/L at 37°C: 30-71 IU/L 
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Serum Bilirubin Protocol:  
Bilirubin combines with diazotized sulfanilic acid to form azobilirubin which is a red-
purple coloured product in acidic medium. The intensity of red-purple colour is 
measured colorimetrically and it is proportional to the concentration of the 
appropriate fraction of bilirubin. This reaction can be represented as:  
                                                                               
Bilirubin + Diazotized Sulfanilic acid                H+                                    Azobilirubin 
                                                                                                                                  H+ 
                                                                                                           Red- Purple Colour 
                                                                                                               (λ max: 540nm) 
Diazo reagents (Diazo A and Diazo B) prepared fresh just before use. 
 
Procedure: 
1. 100 µl of serum was taken in four tubes (T1, T2, D1, D2). 
2. 0.9 ml. distilled water was added in all tubes. 
3. 0.25 ml diazo blank was added in T2, D2. 
4. 0.25 ml diazo reagent was added in T1, D1. 
5. To the Tubes T1 & T2, 1.25 ml methanol was added, mixed well and kept in                                              
    dark for 30 min at room temperature. 
6. O.D. was read after one minute on a spectrophotometer. 
7. To the tubes D1 & D2, 1.25 ml distilled water was added, mixed well and O.D was 
taken  at 540nm on colorimeter using yellow-green filter against distilled water. 
Calculations: 
Bilirubin concentration in mg/100ml: 
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Indirect             = (A) - (B) 
Reference Range: 
Serum Bilirubin :  3-20 µmoles/L of Serum  
 Creatinine Protocol: 
Creatinine reacts with picric acid in an alkaline medium to form an orange coloured 
complex. The rate of formation of this complex is measured by reading the change in 
absorbance at 505 nm in a selected interval of time and is proportional to the 
concentration of creatinine. The reaction time and the concentration of picric acid and 
sodium hydroxide have been optimised to avoid interference of keto acids. 
Creatinine + Picric acid  Alkaline medium   Orange coloured complex 
Procedure: 
 Working Reagents: 
 Equal volume of picrate reagent and sodium hydroxide was added to make up the 
desired volume of the reagent and mixed gently for two minutes. 
 
 Protocol:  
     100µl of serum was taken and 1000µl of working reagent was added to it, 
            mixed well the absorbance was measured at 505nm. 
Calculation: 
 
 
 
Where, 
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AT1:  Initial O.D. of Test 
AT2:  Final O.D. of Test 
AS1:  Initial O.D. of Standard 
AS2:  Final O.D. of Standard 
 
Conversion factor:  
Creatinine concentration in µmol/L=Creatinine concentration in mg/dL × 88.4 
Reference Range:  
Serum creatinine : 72-126 µmoles/L 
Urea Protocol: 
Urea in the presence of water and urease is hydrolysed to produce ammonia and 
carbon dioxide. Under alkaline conditions, ammonia so formed, reacts with 
hypochlorite and phenolic chromogen to form coloured indophenol, which is 
measured at 578 nm (570-600 nm). Sodium nitroprusside acts as a catalyst. The 
intensity of the colour is proportional to the concentration of urea in the sample. 
Urea + H2 O           
Urease           Ammonia + CO2 
Ammonia + Phenolic chromogen + Hypochlorite Sodium Nitroprusside  Indophenol. 
 Working Reagents Solution 1: 
 One vial of urease was added in purified 50 ml of water, dissolved and stored in 
tightly capped reconstitution bottle in dark at 2-8°C. 
 
 Working Reagents Solution 2:  
One part urea chromogen was added in 4 parts of purified water, mixed well and 
stored in tightly capped  reconstitution bottle. 
Procedure:  
1. 10µl of serum was taken and 1000µl of Solution1 was added to it. 
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            2. This solution was incubated at 37°C for 3 minutes. 
            3.  1000 µl of Solution 2 was added and incubated at 37°C for 5 minutes. 
            4. Absorbance was measured at 578 nm. 
Calculation: 
 
 
Conversion formula: 
BUN concentration in mg/dL = Urea concentration in mg/dL × 0.467 
Urea concentration in mmol/L = Urea concentration in mg/dL × 0.1665       
Urea concentration in mg/dL = BUN concentration in mg/dL × 2.14 
Reference Range:  
Serum urea:   3.0-6.0 mmoles/L 
Statistical Analysis: Statistical analysis was performed using SPSS 16.0. (SPSS Inc. 
Chicago, IL, USA). All the clinical variables were examined using Chi-square test 
and level of significance was set at p<0.05. The results were expressed as mean ± 
standard deviation (SD). Graphs were plotted on microsoft excel sheet. 
 
RESULTS 
A total of 360 malaria patients were clinically observed during 2011-2013 from 
Aligarh, India. Among them, 64% (n=231) belonged to P. vivax, 34% (n=122) to P. 
falciparum and 2% (n=7) were the cases of mixed infection. All the patients had fever 
which ranged from 101 to 105º F (38-41ºC), while chills were observed in about 80% 
cases. Other prominent symptoms observed were sweating, headache, nausea, 
dizziness and joint pain in many of the patients (Table 1. & Fig 1.).  
 
=  
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Table 1.  Symptoms in the patients of P. falciparum, P. vivax and mixed infections. 
  
Infection  
                                  
Symptoms 
Plasmodium 
falciparum 
(n=122) (%) 
Plasmodium 
vivax (n=231) 
(%) 
Mixed 
infection (n=7) 
(%) 
Fever 122 (100) 231 (100) 7 (100) 
Chills 98 (80.32) 195 (84.41) 4 (57.14) 
Headache 87 (71.31) 116 (50.21) 3 (42.85) 
Sweating 65 (53.27) 83 (35.93) 2 (28.57) 
Nausea and Vomiting 69 (56.55) 88 (38.09) 3 (42.85) 
Weakness 100 (81.96) 187 (80.95) 4 (57.14) 
Dizziness 59 (48.36) 78 (33.76) 2 (28.57) 
Joint pain 42 (34.42) 79 (34.19) 3 (42.85) 
Abdominal Pain 39 (31.96) 64 (27.70) 1 (14.28) 
 
Fig. 1. Symptoms in the patients of P. falciparum, P. vivax and mixed infections 
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Maximum numbers of malaria patients were recorded from the age group of 21-30 
years, followed by 10-20 years (Table 2 & Fig. 2). Generally, male patients 
dominated in almost all age groups, except 21-30 years where females were more in 
number.  
Table 2. Age-wise distribution of malaria in male and female patients 
 
Age Group 
Sex 
Total (%) p-value 
Male (%) Female (%) 
0 – 10 
11-20 
21-30 
31-40 
41-50 
51-60 
61-70 
70-80 
Total 
23 (6.38) 
47 (13.05) 
46 (12.77) 
32 (8.88) 
26 (7.22) 
12 (3.33) 
3 (0.83) 
0 (-) 
189 (52.50) 
18 (5.00) 
43 (11.95) 
65 (18.05) 
20 (5.55) 
16 (4.44) 
3 (0.83) 
5 (1.38) 
1 (0.27) 
171 (47.50) 
41 (11.38) 
90 (25.00) 
111 (30.83) 
52 (14.44) 
42 (11.66) 
15 (4.16) 
8 (2.22) 
1 (0.27) 
360 
0.435 
0.673 
0.071 
0.096 
0.123 
0.020 
0.480 
- 
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Fig. 2. Agewise distribution of malaria in male and female patients 
 
Pathological findings of both P. falciparum and P. vivax are summarised in 
Table 3 & Fig. 3. There were contrasting differences with respect to 
thrombocytopenia, jaundice, respiratory distress, convulsions, neurological sequelae 
and acute renal failures in terms of percentage which were much higher in P. 
falciparum infections (69, 15, 10, 12, 14 and 11%, respectively) compared to P. vivax 
where the percentage of these parameters were much less (47, 4, 3, 2, 3 and 2%, 
respectively). Splenomegaly was much pronounced and was observed in 40% P. 
falciparum infections compared to P. vivax where it was only in 15% cases. Except 
for haemoglobinaemia, other parameters showed significant differences (P<0.05). 
Haemoglobinaemia was more prominent in P. falciparum patients (35%) than in P. 
vivax malaria patients (22%). 39% of P. falciparum patients were anaemic compared 
to 15% P. vivax patients. Anaemia was rarely observed in healthy individuals or 
patients having mild infection.  
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Table 3. Clinical parameters in P. falciparum and P. vivax malaria 
                  
Parasitaemia 
            
 Parameter      
Plasmodium 
falciparum (n=122) 
 
Plasmodium vivax 
(n=231) 
 
 
 Number Percentage Number Percentage p-value 
Thrombocytopenia 84 69% 108 47% .041 
Haemoglobin(<7g/dl) 43 35% 51 22% .085 
Anaemia  48 39% 35 15% .001 
Splenomegaly  73 60% 81 35% .010 
Jaundice 18 15% 9 4% .012 
Respiratory Distress 12 10% 7 3% .052 
Convulsion 15 12% 5 2% .008 
Neurological 
Sequelae  
24 20% 7 3% .000 
Acute Renal Failure 13 11% 5 2% .013 
 
 
Fig. 3.  Clinical parameters in P. falciparum and P. vivax malaria. 
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 In children splenomegaly, jaundice and neurological sequelae were observed 
in 27, 11 and 9% P. falciparum cases while it was 13, 4 and 5 % in adults. These 
symptoms were 10, 2 and 2% in children infected with P. vivax while in adults,  
infection rates were  5, 2 and 1%.  Both in P. falciparum and P. vivax infections, 
splenomegaly, jaundice and neurological sequelae were almost twice among children 
under the age of ten years compared to older group (Table 4 & Fig. 4). 
Table 4. Splenomegaly, jaundice and neurological sequelae in children(c) under ten 
years of age and older patients (a). 
P.falciparum/ 
P. vivax 
Splenomegaly (%) Jaundice (%) Neurological 
Sequelae (%) 
Pf c 27 11 9 
Pv c 10 2 2 
Pf a 13 4 5 
Pv a 5 2 1 
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Fig. 4. Splenomegaly, jaundice and neurological sequelae in children(c) under ten 
years of age and older patients (a). 
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Liver impairment is common in malaria and its dysfunction enhances sickness.  
Hepatic function was assessed by measurement of bilirubin, aspartate transaminase 
(AST), alanine transaminase (ALT) and alkaline phosphatase (ALP). Normal values 
of AST, ALT and ALP were 0-45, 3-60 and 30-71 IU/L, respectively while the value 
of serum bilirubin was 3-20 µmoles/L. Liver enzymes were elevated in severe cases 
especially in falciparum malaria where parasite density was high (>10 parasites/field). 
AST, ALT and ALP showed raised values of 66.4±6.1, 82.9±5.0, 87.1±3.5 IU/L, 
respectively in patients infected with P. falciparum (Fig. 5), while the values recorded 
for these respective enzymes were 59.7±6.1, 77.6±10.1 and 84.0±9.3 in P. vivax and 
66.5±2.0, 84.9±1.0 and 88.1±0.4, respectively in mixed infection having both P. 
falciparum and P. vivax. Patients with low and mild infections of both P. falciparum 
and P. vivax showed values almost within the normal range. Increased levels of liver 
enzymes clearly indicated liver damage in severe malaria cases having high 
parasitaemia. Serum bilirubin was also raised and ranged between 41.4±7.8 and 
50.6±1.9 µmoles/L in severe malaria cases irrespective of species (Table5 & Fig. 5).  
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Table 5. Liver enzymes, serum bilirubin, creatinine and urea at different levels of parasitaemia in falciparum, vivax and mixed malaria patients 
of Aligarh, India. 
Type of infection  Plasmodium falciparum  (n=122)           Plasmodium vivax (n=231) Mixed Infection (n=7) 
Parameters/ 
Parasitaemia 
Low (n=40) Medium 
(n=44) 
High (n=38) Low (n=79) Medium 
(n=90) 
High (n=62) Low (n=2) Medium 
(n=3) 
High (n=2) 
AST(IU/L)(0-45 
IU/L) 
17.56± 3.70 37.63± 7.35 66.41±6.09 14.15±3.10 31.47± 5.50 59.66± 6.08 17.65± 0.77 35.36± 0.97 66.5± 1.97 
ALT(IU/L) (3-
60IU/L) 
15.82± 3.10 33.80± 5.24 82.85±5.04 13.69±3.97 31.1± 5.75 77.55± 10.09 15.20± 0.45 33.83± 2.31 84.9± 0.98 
ALP(IU/L)(35-
71IU/L) 
52.44± 5.88 73.77± 4.23 87.09±3.51 43.18±5.38 58.78± 4.76 83.95± 9.25 51.05± 0.63 69.56± 0.83 88.1± 0.42 
Serum Bilirubin  
(3.0-
20.0µmoles/L) 
7.17± 2.58 15.60± 3.11 41.38±7.81 7.35± 2.25 15.29± 3.08 49.86± 5.65 7.50± 0.42 16.03± 0.20 50.55± 1.90 
Creatinine(72-
126 µmoles/L) 
74.39± 6.05 92.79± 6.30 145.0± 6.47 70.69±2.74 78.21± 3.99 131.80±7.05 74.20± 0.42 85.26± 2.27 145.1± 0.28 
Urea(3.0-6.0 m 
moles/L) 
3.27± 0.79 4.58± 0.37 7.9± 1.04 4.44± 0.53 6.02± 0.60 8.35± 0.83 4.05± 0.35 6.53± 0.32 10.35± 0.21 
Tabulated values are expressed as Mean±Standard Deviation(±S.D.) 
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Fig. 5.  Liver enzymes and kidney markers in the patients having  P. falciparum,    P. 
vivax and mixed infections.   
 
Impairment of renal function in malaria patients was assessed by measurement 
of serum concentrations of creatinine and urea. In severe malaria patients where 
treatment was delayed especially in P. falciparum, there were indications of renal 
impairments as creatinine and urea values were raised. Patients with high parasitaemia 
showed an increase in the level of creatinine at 145.0±6.5, 131.8±7.1 and 141.5±0.3 
µmoles/L in cases of P. falciparum, P. vivax and mixed infections, respectively, 
compared to the normal range of 72-126 µmoles/L.As far as serum urea is concerned, 
slightly higher values (7.9±1.0, 8.4±0.8 and 10.4±0.2 mmoles/L were recorded in P. 
falciparum, P. vivax and mixed infections against the normal range of 3.0-6.0 
mmoles/L (Table 6 & Fig. 6).  
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Table 6. Liver enzymes, serum bilirubin, creatinine and urea in different age groups of male and female patients of P. falciparum. 
 
Tabulated values are expressed as Mean±Standard Deviation (±S.D.)
Age Group              0-20yrs          20-40yrs           40-60yrs 60 and above 
Sex Male (n=29) Female (n=31) Male (n=22) Female (n=30) Male (n=17) Female (n=9) Male (n=1) Female (n=2) 
AST(IU/L)(0-45 IU/L) 30.45±3.36 26.33±7.07 33.87±8.68 33.10±7.97 54.45±7.84 49.56±6.56 66.50±0.00 62.55±5.16 
ALT(IU/L) (3-60IU/L) 20.89±5.12 17.60±4.14 33.30±8.25 28.92±7.59 56.98±7.89 52.76±8.74 85.9±0.00 81.65±2.19 
ALP(IU/L)(35-71IU/L) 50.88±7.50 48.18±6.14 66.03±7.33 62.81±7.89 85.14±7.65 83.04±7.98 101.2±0.00 93.7±2.33 
SerumBilirubin (3.0-20.0 
µmoles/L) 
15.01±3.1 15.30±3.08 21.41±4.00 19.37±6.34 29.8±6.34 23.97±5.59 35.8±0.00 27.05±7.70 
Creatinine(72-126 
µmoles/L) 
94.68±7.15 93.85±6.53 99.77±9.34 94.59±6.59 120.35±6.94 118.1±11.61 139.6±0.00 132.3±4.80 
Urea(3.0-6.0 m moles/L) 4.50±0.65 4.20±0.71 4.8±0.47 4.69±0.88 5.48±0.79 5.24±0.75 8.6±0.00 7.2±1.55 
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Fig. 6. Liver enzymes, serum bilirubin, creatinine and urea in different age groups of 
male and female patients of P. falciparum. 
In P. falciparum infection, age and sex of the patients showed variations in the 
level of liver enzymes. Elderly people between 40-60 years showed elevated values 
for AST, ALT and ALP which ranged between 49.6-66.5, 52.8-85.9 and 83.0-101.2 
IU/L, respectively, compared to younger patients where values for these enzymes 
were within the normal range (26.3-33.9, 17.6-33.3 and 50.9-66.0 IU/L, respectively). 
Serum bilirubin was also raised in older patients (29.8-35.8 µmoles/L) compared to 
younger ones where values were almost in normal range (15.0-21.4 µmoles/L). In 
most of the patients creatinine and urea were found to be in normal ranges except the 
older patients who showed little higher levels of 139.6µmoles and 8.6mmoles/L, 
respectively (Fig. 6). Almost similar trend was seen in the liver enzymes and kidney 
markers in P. vivax patients, where elevated values were recorded in severely affected 
elderly patients (Fig. 7). In P. vivax, highest values of AST, ALT, ALP and serum 
bilirubin were 66.2, 82.9, 98.9 IU/L and 31.8 µmoles/L, respectively. Creatinine and 
urea were also slightly raised in older patients and were 139.4µmoles/L and 
8.2mmoles/L, respectively. Generally, male patients showed slightly higher levels of 
liver enzymes as well as kidney markers in almost all age groups (Table 7 & Fig. 7). 
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Table 7.  Liver enzymes, serum bilirubin, creatinine and urea in different age groups of male and female patients of P. vivax  
 
Tabulated values are expressed as Mean±Standard Deviation(±S.D.) 
 
Age Group              0-20yrs          20-40yrs           40-60yrs 60 and above 
Sex Male (n=41) Female 
(n=30) 
Male (n=56) Female 
(n=55) 
Male (n=21) Female (n=10) Male (n=2) Female (n=4) 
AST(IU/L)(0-45 IU/L) 29.70±3.94 28.14±4.33 36.70±9.81 33.63±7.12 50.15±10.71 48.56±9.59 66.2±5.09 61.17±6.91 
ALT(IU/L) (3-60IU/L) 18.33±4.83 16.22±3.25 27.15±6.16 29.00±7.84 53.48±11.42 55.2±5.49 82.9±3.81 80.7±6.09 
ALP(IU/L)(35-71IU/L) 49.49±7.78 48.79±7.47 64.14±7.40 62.11±5.81 83.24±5.06 80.26±5.48 98.9±9.47 93.42±5.57 
SerumBilirubin (3.0-
20.0 µmoles/L) 
19.80±4.00 17.68±3.21 22.30±2.82 19.85±4.25 24.30±3.95 23.08±3.37 31.75±5.86 29.3±3.35 
Creatinine(72-126 
µmoles/L) 
93.18±7.03 90.67±7.74 95.23±8.87 94.97±7.66 110.46±10.10 115.06±10.56 138.35±3.46 134.92±10.85 
Urea(3.0-6.0 m moles/L) 4.2±0.87 4.5±0.73 4.6±0.98 4.83±0.92 5.83±0.64 5.78±0.67 8.2±0.42 7.75±0.46 
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Fig. 7. Liver enzymes, serum bilirubin, creatinine and urea in different age groups of 
male   and female patients of P. vivax. 
 
DISCUSSION 
We assessed 360 malaria patients clinically, in which the most frequently implicated 
species was P. vivax, accounting for 64% of cases, while P. falciparum accounted for 
34%. Almost similar results were obtained in central India where P. vivax and P. 
falciparum were reported to be 56.5 and 39.1%, respectively (Gupta et al. 2013). This 
indicates that P. vivax is the most widespread infection in India which results in 
pronounced morbidity (Joshi et al. 2008). Recently, it has been reported that P. vivax 
also has immense potential to cause life threatening complications and even death 
(Rizvi et al. 2013).  
 As far as clinical symptoms are concerned, all the patients had high fever out 
of which 80% had chills as earlier observed in Pakistan (Rasheed et al. 2009). 
Merozoites release certain factors and toxins from the ruptured RBCs such as red cell 
membrane lipid, glycosyl phosphatidyl inositol anchor of a parasite membrane protein 
which directly induce the release of cytokines such as TNF and interleukin-1 from 
macrophages, resulting in chills and high grade fever (Srinivas 2014). Other 
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symptoms, such as headache, sweating, nausea and joint pain were slightly higher in 
P. falciparum cases compared to P. vivax cases. Almost similar clinical pattern for 
most of the above parameters was observed in severe malaria cases in Jazan (Banzal 
et al. 1999). In the present study, cases of P. vivax, P. falciparum and mixed 
infections were observed in 64, 34 and 2% patients, respectively which is almost 
similar to earlier study conducted in Karnataka where  P. falciparum and P. vivax 
were 53 and 34%, and mixed infections were 14% (Muddaiah and Prakash 2006). 
Species composition varies even in the same country having different ecological 
conditions with different types of breeding places and vectors. Age wise distribution 
showed that the maximum number of patients were in the age group 21-30 years 
followed by 11-20 years, indicating that this is the most active age in which maximum 
exposure could take place. This explanation may support higher percentage in males 
of all age groups except 21-30 years where females dominated which could not be 
explained. One of the earlier studies showed maximum number of cases in the 
patients of 21-30 years age group as our results, but with much difference in 
percentage (i.e. 81 and 19%) for males and females, respectively (Muddaiah and 
Prakash 2006).  
 Malaria affects almost all blood components and is a true haematological 
infectious disease. Anaemia and thrombocytopenia are the most frequent malaria 
associated haematological complications and have received much attention due to 
their associated mortality (Wickramasinghe and Abdalla 2000, Rodrigues-Morales et 
al. 2006). Thrombocytopenia is defined by platelet count under 1,50,000/µl and is 
very frequent among malaria patients but there is no report of mortality except in 
cases of severe thrombocytopenia. In our study, thrombocytopenia was detected in 
69% P. falciparum and 47% P. vivax cases, while it was 50% in P. falciparum and 
65% P. vivax malaria from other parts of India (Jadhav et al. 2004).  Slightly lower 
rates of thrombocytopenia, 54.5% and 29.5%, were reported for P. falciparum and P. 
vivax infections in Pakistan (Rasheed et al. 2009). Higher rates of thrombocytopenia 
(53 and 68%) in P. vivax were recorded from Mumbai, India and Saudi Arabia 
(Bashawri et al. 2001, Limaye et al. 2012). Recent data from India has shown an 
increase in thrombocytopenia (43%) in case of severe infection of P. vivax (Kochar et 
al. 2010). This is in agreement with our findings in which we recorded 
thrombocytopenia in 47% P. vivax cases. The exact mechanism of thrombocytopenia 
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in malaria is not clear, but it has been reported that the life span of thrombocytes gets 
reduced due to immunological and non-immunological mechanisms. It has also been 
reported that elevated macrophage colony stimulating factor cause platelet destruction 
(Park et al. 2003). Besides, intravascular coagulation is also thought to consume and 
reduce platelets from the circulation (Jadhav et al. 2004). The variations in values in 
thrombocyte count might be due to drug resistance and endemicity, as drug resistant 
parasites prolong their stay in their host and do more damages resulting in 
thrombocytopenia (Tjitra et al. 2008). These might be the reasons of worldwide 
inconsistent prevalence of thrombocytopenia. The elevated figures of thrombocytes in 
P. vivax infection showed that this species is also moving towards malignancy. 
 P. falciparum and P. vivax both cause destruction of RBCs. Anaemia is an 
inevitable consequence in malaria as  Plasmodium invaded red blood cells lead to 
rigidity and become adherent especially in P. falciparum. The intracellular parasites 
modify the erythrocytes in several ways and cause hypoglycaemia by converting 
glucose into lactic acid by anaerobic glycolysis (Daily et al. 2007). The cell 
membranes become less deformable, resulting in haemolysis and anaemia. Two 
common causes of anaemia are increased haemolysis and decreased rates of 
erythrocyte production from bone marrow. Alteration of uninfected red blood cells by 
addition of glycosyl phosphatidyl inositol (GPI) to membrane causes increased 
clearance of cells in P. falciparum contributing to anaemia (Brattig et al. 2008). 
World Health Organisation criterion for severe malaria is haemoglobin under <7g/dl 
in adults and below <5g/dl in children. Following this criterion we observed anaemia 
in 39 and 15% patients of P. falciparum and P. vivax malaria cases, respectively. In 
contrast, anaemia was recorded in 60% P. falciparum malaria patients in eastern 
region of Saudi Arabia which is comparatively a much higher figure (Bashawri et al. 
2001). High rate of anaemia in P. vivax infection (19%) was also reported in eastern 
Indonesia (Tjitra et al. 2008). Anaemia observed in 12.62% (P. falciparum) and 
2.96% (P. vivax) patients in Mumbai (Limaye et al. 2012), is a low count if compared 
with our findings. This variation might be due to the degree of parasitaemia and the 
level of immunity against P. falciparum and P. vivax in individuals in different types 
of malaria in endemic and non-endemic regions of different countries.                            
 The spleen in malaria plays a crucial role in the immune response against the 
parasite, as well as controls parasitaemia due to phagocytosis of parasitized RBCs 
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(Engwerda et al. 2005). The spleen enlarges more in P. falciparum infections than in 
P. vivax. We observed splenomegaly in 40% and 14% patients of P. falciparum and 
P. vivax malaria cases, respectively. Much higher rate of splenomegaly was recorded 
in falciparum malaria (71%) from Bikaner (Kochar et al. 2006b). In P. falciparum 
infection, splenomegaly reported from Jazan and Asir region of Saudi Arabia was 39 
and 45% (Malik et al. 1998, Banzal et al. 1999), less than what we reported from 
India. In contrast, very low rate of splenomegaly ranging from 6.5 to 13% was 
reported from malaria patients of Saudi Arabia, Colombia and Thailand (Bashawri et 
al. 2001, Echeverri et al. 2003, Tangpukdee et al. 2006). Splenomegaly was nearly 
two times greater in children under ten years of age infected with P. falciparum and 
P. vivax malaria in our study. These variations might be due to the differences in age 
and immune status of the patients from different malaria transmission regions.  
 As far as serum bilirubin is concerned, we observed elevated values of 
41.4±7.8, 49.9±5.7 and 50.6±1.9 µmoles/L in patients severely infected with P. 
falciparum, P. vivax and those having mixed infections, respectively. 46% 
bilirubinaemia was recorded in P. falciparum patients from Karnataka, India (Joseph 
et al. 2011), which is very close to our findings.  Bilirubinaemia was observed in 32% 
and 9% in P. falciparum and P. vivax cases respectively in Pakistan (Rasheed et al. 
2009). However, a relatively low rate of bilirubinaemia (22 and 5%) was observed in 
P. falciparum and P. vivax patients of Mumbai (Limaye et al. 2012). As for jaundice 
is concerned 15% patients infected with P. falciparum in this study were diagnosed 
for jaundice. Other workers from India, Pakistan and Saudi Arabia reported jaundice 
in 17-47% P. falciparum patients (Chawla et al. 1989, Hazra et al. 1998, Banzal et al. 
1999, Mehta et al. 2001, Prakash et al. 2003, Maheshwari et al. 2004, Tripathy et al. 
2007, Abro et al. 2009, Ahsan et al. 2008). In case of vivax malaria we observed 
jaundice in 4%. vivax patients  while other workers reported it in 9-15% patients from 
Colombia, India and Pakistan (Hazra et al. 1998, Echeverri et al. 2003, Kochar et al. 
2006a, Rasheed et al. 2009). The variations in values might be due to the reason that 
in our study area, the level of drug resistance is not that high as in Colombia and 
Bikaner, India. It appears that jaundice is caused by combined effects of haemolysis 
and hyper-bilirubinaemia and raised liver enzymes, and these parameters generally 
increase in severe malaria cases having high parasitaemia.  
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 In P. falciparum infection, the infected RBCs develop protubrance on their 
cell membrane which are sticky. This results in increased adhesion of infected red 
blood cells that clump together. Infected RBCs may also adhere to the wall of the fine 
capillaries, venules and arterioles, thereby blocking the blood flow. This increased 
cytoadherence and clumping which results in occlusions of blood flow, culminating in 
damage to the vital organs like the brain, kidneys, lungs, liver and gastrointestinal 
tract which leads to the various fatally serious complications in falciparum malaria 
(Srinivas 2014). 
 Liver dysfunction is relatively common in severe P. falciparum infections 
compared to P. vivax (Giha et al. 2005, Das 2008, Thanachachartwet et al. 2013). We 
observed mean AST, ALT and ALP values to be 66.4±6.1, 82.9±5.0 and 87.1±3.2 
IU/L, respectively in P. falciparum and 59.7±6.1, 77.6±10.1 and 84.0±9.3 IU/L, 
respectively in P. vivax with high parasitaemia. These enzymes were also above 
normal range in mixed infections (i.e. 66.5±2.0, 84.9±1.0 and 88.1±0.4 IU/L). This 
data clearly indicates the maximum increase in AST, ALT and ALP was recorded in 
severe malaria patients especially in P. falciparum and mixed infections of P. 
falciparum.  Increased liver enzymes may result in liver dysfunction in few patients 
having high parasitaemia. Those who had mild and low parasitaemia, the level of 
enzymes were within the normal ranges. Almost same level of ALP (87-91 IU/L) and 
comparatively lower levels of AST and ALT (33-38 and 21-35 IU/L) were recorded 
for mild infections in Nigeria (Onyesom and Onyemakonor 2011, Uzuegbu and 
Emeka 2011). Elevated levels of AST, ALT and ALP (75, 162 and 265IU/L) were 
also reported for P. vivax patients from New Delhi, India (Anvikar et al. 2010). There 
was a significant difference in the activities of liver enzymes in severe malaria 
infection as compared to low and mild infections (Fig. 4).  Results clearly indicate 
that both P. falciparum and P. vivax can induce changes in liver enzymes, especially 
when parasitaemia is high. Levels of liver enzymes were higher in elderly patients 
compared to younger ones (Figs. 5, 6). It seems that the parasites during their hepatic 
phases destroy membranes of the parasitized cells leading to leakage of the liver 
enzyme into the blood circulation. AST, ALT and ALP are the marker enzymes of 
liver toxicity. Since liver is the major site for drug metabolism, increased level of 
these enzymes in blood might be due to the effect of antimalarials administered to 
treat malaria patients or damage liver and leakage of enzyme. Injury of the cells in 
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elder patients might be due to the abnormal cell activations and autoimmune progress 
induced by the parasites especially when parasitaemia was high.  
 Acute renal failure (ARF) is suspected in patients having creatinine <3.0 
mg/dl. ARF was reported in severe falciparum and vivax malaria cases mostly in 
Southeast Asia and Indian subcontinent where intensity of malaria transmission is 
usually low with occasional micro foci of intense transmission (Mehta et al. 2001). 
ARF is probably caused by mechanical obstruction by infected adherent erythrocytes, 
immune mediated glomerular pathology and alterations in the renal microcirculation 
etc. We observed 11% falciparum patients with ARF, while earlier studies from India 
and Thailand reported ARF in 19 and 21% patients (Manan et al. 2006, Tripathy et al. 
2007, Vannaphan et al. 2010). In P. vivax, we observed only 2% cases of ARF from 
Aligarh. Almost similar findings were reported from Pakistan and India where ARF 
was recorded in 2.5, 3.5 and 5.9% ARF from Pakistan and India (Naqvi et al. 2003, 
Maheshwari et al. 2004, Tripathy et al. 2007). Higher ARFs (12.5% and 20.4%) in P. 
vivax infection had also been reported by other workers from different high 
transmission regions of India (Mehta et al. 2001, Prakash et al. 2003). Increased level 
of creatinine in the range of 131.8-145.1 µmoles/L was recorded in the present study 
in patients having high parasitaemia. Usually ARF occurs in non-immune individuals 
especially in P. falciparum infections with high parasitaemia, but we noticed renal 
failures in P. vivax infections as well which was generally considered as benign 
infection during the past and warrant immediate attention and change in treatment 
strategy. Physiological changes especially in falciparum malaria transform infected 
erythrocytes which makes them adherent to each other as well as to the walls of 
capillary vessels which results in mechanical obstructions. The circulating parasites 
inflame and alter the renal microcirculation by the adherent RBCs thereby causing 
immune mediated glomerular pathology. Increased levels of creatinine in the blood 
damage the kidney tissues, which might be the probable cause of renal failures (Das 
2008). It seems true in my case also where raised levels of creatinine (131-
145µmoles/L) and urea (7.9-10.5 mmoles/L) were recorded in severe patients of P. 
vivax and P. falciparum.   
       We observed acute respiratory distress (ARD) in 10% P. falciparum and 
3% P. vivax cases, respectively.  In other reports of India, ARDs were reported as 
6.6% in P. falciparum and 9.7% in P. vivax infections (Hazra et al. 1998,Gupta et al. 
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2001, Jindal et al. 2002 Rizvi et al. 2013). However, in both the infections, this 
phenomenon occurs as parasites derive energy from anaerobic glycolysis of glucose 
which yields lactic acid, which may contribute to clinical manifestations of 
hypoglycaemia and lactic acidosis leading to respiratory distress in few severely 
infected patients. 
 Basic defect in cerebral malaria is probably clogging of the cerebral 
microcirculation by the parasitised red blood cells. Rosetting of infected and non-
infected red blood cells due to surface knob protein further increases the clogging of 
the microcirculation. Obstruction to the cerebral microcirculation results in hypoxia. 
However, complete obstruction to blood flow is unlikely, since the survivors rarely 
have permanent neurological deficit (Srinivas 2014). Neurological syndrome is the 
most lethal clinical complication of severe P. falciparum malaria. It may manifest as 
impaired consciousness and convulsions which often leads to coma. During this study 
we observed neurological syndrome in 14% of P. falciparum patients but none in 
coma. In other studies, 11-12% patients were reported to have convulsions and other 
neurological deficits after surviving cerebral malaria (Brewster et al. 1990, 
Thanachachartwet et al. 2013) which is very close to our values. In other studies, 12-
21% patients were reported to have convulsions and other neurological deficits after 
surviving cerebral malaria (Giha et al. 2005, Abdullah et al. 2013, Thanachachartwet 
et al. 2013). Still more cases 28-33% presented neurological sequelae just after and a 
few months following cerebral malaria with associated symptoms of bucco-facial 
dyspraxia, diplegia and frontal syndrome, dystonia, seizure, epilepsy and behaviour 
and attention disorder in P. falciparum infection (Ngoungou et al. 2007, Sarkar and 
Bhattacharya  2008). Coma was observed in 5% children suffering from severe 
malaria in Orissa (Tripathy et al. 2007). We observed convulsions in 2% P. vivax 
infection, which is much less than what was reported (14%) from Eastern Sudan 
(Abdullah et al. 2013). We observed convulsions in few patients only which might be 
due to the reason that majority of the patients had low-mild parasitaemia and low 
level of drug resistance. 
 From the foregoing discussion, it may be concluded that higher rates of 
hepatic dysfunction and acute renal failures occurred in severe P. falciparum infection 
as compared to P. vivax. Similarly, splenomegaly, jaundice and neurological sequelae 
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were more common in severe P. falciparum infections, especially among children 
under ten years of age. Some patients with severe vivax malaria showed symptoms 
similar to falciparum malaria, exhibiting hepatic dysfunction and renal impairment 
which is a matter of concern as it was considered as a benign species. It is, therefore, 
suggested that P. vivax patients must also be treated radically in order to avoid 
complications especially among children. 
 
 
 
 
 
 
 
 
 
 Summary  
  
 i 
Malaria is one of the most prevalent parasitic diseases found in 97 countries with 
estimated 198 million clinical cases and 584,000 deaths, representing a major global 
public health problem. Approximately 90% of deaths occur in the African region 
mostly in children under five years of age. A total of 1.07 million cases and 535 
deaths were recorded due to malaria in India (WHO 2014). Majority of malaria 
morbidity and mortality is caused by Plasmodium falciparum. It has been observed 
that P. vivax is also moving towards malignancy which may prove fatal in severe 
cases. Recent reports have indicated life threatening complications and even death in 
P. vivax infection. This disease is managed by antimalarial drugs as no effective 
vaccine is yet available. However, the parasite has developed resistance against most 
commonly used antimalarials, chloroquine and sulfadoxine-pyrimethamine (SP) 
posing a major hurdle in malaria control programme. Malaria has been a serious 
problem in some parts of India due to widespread resistance against sulfadoxine-
pyrimethamine.  
 Prevalence of malaria was studied by observing thick and thin blood smears 
stained with Giemsa and JSB stains under Nikon Eclipse-600 research microscope at 
100x.  Quantitative Buffy Coat test was also performed to see the positivity of 
malaria. P. vivax patients were treated with chloroquine and primaquine and were 
observed for 12 months to study relapse pattern. For recrudescence in P. falciparum, 
patients were treated with standard doses of sulfadoxine-pyrimethamine, artesunate 
plus SP, artemether and artemether plus lumefantrine, and observed for a month after 
the medication was over. Positivity rates for P. falciparum, P. vivax and mixed 
infection during this period were 28.30, 69.39 and 2.29%, respectively. Malaria 
transmission was high in the months of August, September and October, reaching a 
peak in September and October. During peak transmission season, mean temperature 
and relative humidity ranged somewhere around 26-28°C and 77-88%, respectively, 
which favoured vector population. 38.43% P. falciparum cases were uncomplicated 
type with parasitaemia less than 10%, whereas 61.57% were severe having more than 
10% parasitaemia. In P. vivax 58.69% patients were uncomplicated type with 
parasitaemia less than 6%, while rest 41.31% were severe complicated type with more 
than 6% parasitaemia. In mixed infection, majority (70.91%) were of complicated 
type with parasitaemia more than 10%, while 29.09% were uncomplicated type. Male 
predominance was observed in the patients with 59% positivity for malaria.  
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P. vivax patients treated with chloroquine alone showed relapse in 31.48% 
cases, of which 25.92% were of short term and 5.55% long term relapse. But those 
who were treated with 1500 mg chloroquine along with 75 mg primaquine showed 
15% short term and 5% long term relapse. Patients who were administered with 210 
mg primaquine showed only short term relapse in 6.66% patients. Drug resistance in 
P. falciparum against sulfadoxine-pyrimethamine (SP) was recorded in 24.44% cases. 
RI, RII and RIII levels of resistance were recorded in 15.35, 7.50 and 1.58% cases, 
respectively. 
Recent drugs used for the treatment of falciparum malaria were artemisinin 
based combination therapy (ACT). Artemisinin derivatives which are used in Aligarh 
are artesunate plus sulfadoxine-pyrimethamine, artemether and artemether plus 
lumefantrine. Cure rate in P. falciparum cases was 100% with artemisinin plus 
lumefantrine while recrudescence was observed in 2.04% patients who were treated 
with artemether alone. In patients treated with artesunate plus sulfadoxine-
pyrimethamine, recrudescence was observed in 1.25% patients. The rate of 
recrudescence is negligible but it appeared more quickly and therefore, it is predicted 
that its efficacy will decrease in the years to come, if not used judiciously. Among the 
ACTs, artemether-lumifantrine combination was proved the most effective drug 
showing no resistance.  
For mutation studies in dhfr gene, DNA was extracted from the blood of the patients 
who were infected with P. falciparum and P. vivax. The extracted DNA was eluted 
and the aliquot was used for PCR amplification. After diluting, priming PCR product 
was used as a DNA template for nesting PCR to amplify the 784-bp region, which 
covered the entire dhfr domain. Semi nested PCR was carried out under the same 
conditions and the PCR products were purified and subjected to sequencing. The 
nucleotide sequences were translated into amino acids using the edit sequence 
program. Finally, the amino acid sequences were aligned using Gen Doc Multiple 
Sequence Alignment Editor and Shading Utility.  
Sequencing study of pfdhfr and pvdhfr gene showed mutations in DNA isolates. 
pfdhfr mutations were observed at codons S108N, C59R and N51I,  maximum being 
at codon S108N. Double mutations at codons C59R and S108N were observed in 
55% isolates, while mutations at N51I and S108N were observed in only 4% isolates. 
 iii 
Single mutation at codon S108N was detected in 33 isolates, whereas 5% isolates had 
wild amino acids with genotype A16, N51, C59, S108, I164.  
        In P. vivax, majority of the isolates (60.87%) contained the wild type amino 
acids having genotype F57, S58, T61, S93 and S117. Mutations were observed at 
codons S117N, S93H and S58R.  Frequency of mutation was highest at codon S117N 
followed by S93H. Double mutations (S58R and S117N) were noticed in pvdhfr gene 
in 26.09% isolates, while mutations at single locus were detected at codon S93H or 
S117N  in 13% isolates (6.52% each). During the present study variations in size, 
shape and thickness of cytoplasm of the rings were more prominent in P. falciparum 
which had mutations at two loci. This change may be due to the alteration of amino 
acids in dhfr enzyme or a mere coincidence.  
Liver enzymes and kidney markers were analysed from the blood of malaria positive 
patients. These samples were collected, allowed to clot and centrifuged to remove any 
cell contamination. The sera were then analysed for liver enzymes and kidney 
markers with the help of standard techniques. Clinical symptoms such as high fever, 
chills, vomiting, anaemia, splenomegaly, jaundice, respiratory distress, convulsions 
and neurological sequelae were recorded in P. falciparum, P. vivax and mixed 
infections. As far as symptoms are concerned, all the patients had fever but chills 
were observed in only 80% patients. Other symptoms such as sweating, headache, 
nausea, dizziness were more prominent in P. falciparum. Maximum numbers of 
malaria patients belonged to the age group of 21-30 years, followed by 10-20 years. 
Male patients dominated over females in almost all age groups except 21-30 years 
where females were more in number.  
As far as clinical features are concerned, thrombocytopenia, jaundice, respiratory 
distress, convulsions, neurological sequelae and acute renal failures were much higher 
in P. falciparum infections compared to P. vivax. Splenomegaly was observed in 40% 
P. falciparum infections compared to 15% in P. vivax. In P. falciparum patients, 
splenomegaly, jaundice and neurological sequelae were more pronounced in children 
compared to adults. In P. vivax these symptoms were present but in a comparatively 
less number of patients. Both in P. falciparum and P. vivax infections, splenomegaly, 
jaundice and neurological sequelae were almost twice among children under the age 
of ten years compared to the older group.  
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Haemoglobinaemia was more prominent in P. falciparum patients (35%) than in P. 
vivax malaria patients (22%). Liver enzymes and kidney markers were elevated in 
severe complicated cases of P. falciparum, P. vivax and mixed infections where 
parasitaemia was more than 10% compared to patients having low and mild 
infections. Elevated liver enzymes clearly indicated liver and kidney damage in a few 
severe malaria patients having high parasitaemia. Serum bilirubin was also raised in 
severe malaria cases irrespective of the species. Elderly people between 40-60 years 
showed higher elevated levels of AST, ALT and ALP compared to younger patients. 
Serum bilirubin was also raised in older patients compared to younger ones, the 
values being almost in normal range in the latter. In most of the patients creatinine 
and urea were found to be in normal ranges except in the older patients where these 
were at a slightly higher side.  Almost similar trend was seen in the liver enzymes and 
kidney markers in P. vivax patients, where elevated values were recorded in severely 
affected elderly. Creatinine and urea were also slightly raised in older patients. 
Generally, male patients showed slightly higher levels of liver enzymes as well as 
kidney markers in almost all age groups. 
From the results obtained during this study, it has become evident that prevalence of 
P. vivax has increased from 65.40 to 76.95% if 2011 data is compared with that of 
2013. In the mean time, prevalence of P. falciparum has decreased from 32.26 to 
21.24% during the same years which may be correlated with creation of more 
breeding places by developmental project in and around Aligarh which increased the 
vector population and thereby increased transmission of vivax malaria. Decrease in 
the prevalence of P. falciparum may be correlated with the introduction of artesunate 
and sulfadoxine-pyrimethamine which contained the P. falciparum infection to some 
extent. In P. falciparum  and mixed infections, severe cases ranged between 62-71%, 
while in P. vivax situation was just reverse and only 41% cases were severe with a 
few complicated cases. The probable reason for more complications in P. falciparum 
may be its higher rate of multiplication during pre-erythrocytic schizogony and its 
ability to infect all the RBCs whether young or old which results in higher 
parasitaemia and more damage to the vital organs such as liver, spleen and brain. In 
the present study, resistance was observed in 2.04 and 1.28% patients treated with 
artemether and artesunate plus sulfadoxine-pyrimethamine combination, respectively. 
The low percentage in the resistance rate of these drugs is indicative of the fact that 
artemether alone as well as (AS+SP) combination are still quite effective in my study 
 v 
area and therefore, may be considered as safe and comparatively much effective drug 
for the treatment of acute uncomplicated as well as severe resistant falciparum malaria 
as a viable alternative of sulfadoxine-pyrimethamine.  
 In P. falciparum infection, all the erythrocytic stages, except early ring stage develop 
in the capillaries of internal organs which probably damage them. As a result of this, 
serum bilirubin, liver enzymes and kidney markers get increased which might have 
resulted in liver dysfunctions and kidney failures in some severe cases. Anaemia and 
thrombocytopenia were other prominent features of malaria which were recorded in 
more patients of falciparum malaria compared to those of P. vivax. Neurological 
deficits which were more prominent in P. falciparum infection were also recorded 
from P. vivax patients, but in a comparatively less number. P. vivax produces less 
number of merozoites while undergoing pre-erythrocytic schizogony in the liver and 
infects only younger RBCs. This species completes its erythrocytic schizogony in 
peripheral blood only and generally does not migrate to inner vital organs and results 
in less pathogenicity.  But probably some patients receive higher inoculums of 
sporozoites which results in higher rates of parasitaemia and damage of the vital 
organs like that of P. falciparum. In such heavy infections almost similar comparable 
pathological conditions such as splenomegaly, liver dysfunction and neurological 
deficits are observed in P. vivax infection. It has also become clear that the efficacy of 
both curative as well as anti-relapse drugs has decreased, as recrudescence and 
treatment failures were observed along with relapse in P. vivax in the patients who 
received chloroquine and primaquine. Relapse cases were more in the patients who 
were given 75 mg primaquine for 5 days compared to those received 210 mg 
primaquine for 14 days. Those given primaquine for 14 days showed 6.66% short 
term relapse, indicating its decreasing efficacy. 
As far as mutation in pfdhfr gene is concerned, in P. falciparum double mutations 
were recorded in 59% compared to 26% in P.vivax. Probable reason for higher 
mutations in falciparum malaria is continuous long exposure of P. falciparum to 
sulfadoxine-pyrimethamine which was given for about last two decades either alone 
or in combination with amodiaquine or artesunate which made this drug susceptible 
and resulted in a higher level of resistance due to mutations in pfdhfr gene. Higher 
rates of double and single mutations in P. falciparum were due to the reason that SP 
was directed against this species and mutations which were reported in a few P. vivax 
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patients were probably due to the reason that clinicians generally do not wait for the 
species diagnosis and give a medicine which covers both P. falciparum and P. vivax 
infections to cure the patients. This resulted in mutation of P. vivax also as both P. 
falciparum and P. vivax co-exist in the same area and have the same biochemical 
target in the form of dihydrofolate reductase (dhfr) enzyme. 
From the results obtained during this study, it may be concluded that peak 
transmission of malaria occurs in Aligarh during the months of September and 
October. Cases of resistance and relapse are increasing due to decreased efficacy of 
curative and antirelapse drugs. Single and double mutations were observed in dhfr 
genes of both P. falciparum and P. vivax which were exposed to sulfadoxine-
pyrimethamine for many years. This long exposure of parasite to antifolates resulted 
in mutations which caused recrudescence and a few treatment failures especially in P. 
falciparum which is a malignant species causing damage to vital organs such as brain, 
liver and spleen etc. and may prove fatal in severe cases. P. vivax is also moving 
towards malignancy in severe infections showing pathology in aforesaid organs. It is 
therefore, need of the hour that SP should not be given alone in Aligarh as it may 
cause more mutations and treatment failures. In the meantime, ACT such as 
artemether plus lumefantrine should not be given to every falciparum patient in this 
area as artesunate plus SP is still quite effective with recrudescence in only 1.28% 
cases. Artemether plus lumefantrine should be treated as emergency drug and may 
only be given in severe complicated cases as it has 100% efficacy rate in this area. 
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INTRODUCTION
Malaria is endemic in 104 countries with estimated 207 mil-
lion clinical cases and 627,000 deaths, representing a major 
global public health problem [1]. It mainly affects children, 
pregnant women, and non-immune adults who frequently die 
as victims of cerebral manifestations and anemia [2]. Both of 
these malarial complications are responsible for a great num-
ber of spontaneous abortions, stillbirths, premature deliveries, 
and low birth weight [3]. Children with impaired conscious-
ness and respiratory distress are at the highest risk of death as-
sociated with malaria [4]. Among the 4 Plasmodium species re-
sponsible for human malaria, P. falciparum has been the most 
prevalent overall, particularly in Africa. Neurological involve-
ment in P. falciparum malaria is common and nearly a quarter 
of children who survived cerebral malaria develop neurologi-
cal sequelae [5]. P. vivax is responsible for a significant propor-
tion of malaria cases worldwide and is increasingly reported as 
a cause of severe disease [6]. In the past few years, P. vivax in-
fection was recognized as a cause of severe malaria in young 
children even causing death [7-9]. 
In India, 60-65% of the malaria infections are reported due 
to P. vivax, while 30-35% due to P. falciparum [10]. India is one 
of the major contributors to malarial morbidity and mortality 
in the world [11]. Malaria has been a serious problem in some 
parts of India due to the slow progress in its control. During 
the past decade, most malaria-endemic countries shifted their 
national treatment policies to artemisinin combination thera-
py (ACT). Keeping above facts in view, the present study aimed 
to determine the prevalence and clinical manifestations of ma-
laria in Aligarh, India.
MATERIALS AND METHODS
This study is based on the confirmed cases of malaria admit-
ted in the hospitals and nursing homes of Aligarh, India dur-
ing 2011-2013. Blood samples were collected from the patients 
admitted to the Jawaharlal Nehru Medical College hospital 
and a few other nursing homes of Aligarh. Clinical profiles of 
the patients were recorded at the time of sample collection. 
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Abstract: Malaria is one of the most widespread infectious diseases of tropical countries with an estimated 207 million 
cases globally. In India, there are endemic pockets of this disease, including Aligarh. Hundreds of Plasmodium falciparum 
and P. vivax cases with severe pathological conditions are recorded every year in this district. The aim of this study is to 
find out changes in liver enzymes and kidney markers. Specific diagnosis for P. falciparum and P. vivax was made by mi-
croscopic examination of Giemsa stained slides. Clinical symptoms were observed in both of these infections. Liver en-
zymes, such as AST, ALT, and ALP, and kidney function markers, such as creatinine and urea, were estimated by standard 
biochemical techniques. In Aligarh district, P. vivax, P. falciparum, and mixed infections were 64%, 34%, and 2%, respec-
tively. In case of P. falciparum infection, the incidences of anemia, splenomegaly, renal failure, jaundice, and neurological 
sequelae were higher compared to those in P. vivax infection. Recrudescence and relapse rates were 18% and 20% in P. 
falciparum and P. vivax infections, respectively. Liver dysfunctions and renal failures were more common in P. falciparum 
patients, particularly in elderly patients. Artesunate derivatives must, therefore, be introduced for the treatment of P. falci-
parum as they resist to chloroquine as well as sulfadoxine-pyrimethamine combinations.
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Clinico-pathological studies of Plasmodium falciparum 
and Plasmodium vivax – malaria in India and Saudi Arabia
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Abstract
Malaria is one of the most devastating diseases of tropical countries with clinical manifestations such as anaemia, splenomegaly,
thrombocytopenia, hepatomegaly and acute renal failures. In this study, cases of thrombocytopenia and haemoglobinemia were
more prominent in subjects infected with Plasmodium falciparum (Welch, 1897) than those with Plasmodium vivax (Grassi et
Feletti, 1890). However, anaemia, jaundice, convulsions and acute renal failure were significantly high (3–4 times) in subjects in-
fected with P. falciparum than those infected with P. vivax. The incidence of splenomegaly and neurological sequelae were 2 and
6 times higher in P. falciparum infections compared to the infections of P. vivax. Both in P. vivax and P. falciparum malaria, the
cases of splenomegaly, jaundice and neurological sequelae were almost double in children (<10 years) compared to older patients.
The liver enzymes were generally in normal range in cases of low and mild infections. However, the AST, ALT, ALP activities and
serum bilirubin, creatinine, and the urea content were increased in P. falciparum and P. vivax malaria patients having high para-
sitaemia, confirming liver dysfunction and renal failures in few cases of severe malaria both in India and Saudi Arabia.
Keywords
Pathology, liver enzymes, splenomegaly, malaria, India, Saudi Arabia
Introduction
Malaria is one of the most widespread infectious diseases 
of tropical and sub-tropical countries which continue to
claim around 655,000 lives throughout the WHO African 
region (WHO, 2011). There are 99 countries and territories
with ongoing malaria transmission. Globally, an estimated
3.3 billion people are at risk of malaria, with maximum cases
recorded from sub-Saharan Africa. It mainly affects children,
pregnant women and non-immune adults who frequently die
as victims of cerebral manifestations and anaemia (Quintero
et al. 2011). In the African region, approximately 90% of
deaths among children under the age of five occur due to
malaria. Children with impaired consciousness and respira-
tory distress are at the highest risk of death associated with
malaria (Marsh et al. 1995). Neurological involvement in 
P. falciparum malaria is common and nearly a quarter of
children who survive cerebral malaria, develop neurological
sequelae (Idro et al. 2007). P. vivax infection is responsible
for a significant proportion of malaria cases worldwide and
is increasingly reported as a cause of severe disease (Lanca
et al. 2012). However in the past few years, P. vivax infec-
tion has been increasingly recognized as a cause of severe
malaria in young children even causing death (Sharma and
Khanduri 2009, Singh et al. 2011, Limaye et al. 2012). 
Despite having lower densities than P. falciparum, P. vivax
causes similar absolute reduction in red blood cell mass 
because it results in proportionately greater removal of 
uninfected red blood cells (Douglas et al. 2012). Recent find-
ings indicate that P. vivax is also responsible for a dramatic
toll in many endemic areas other than Africa. Cerebral
malaria, acute kidney injury, liver dysfunction, severe respi-
ratory distress, abnormal bleeding, severe anaemia and mul-
tiple organ failure were the recently reported symptoms of
P. vivax – malaria (Prakash et al. 2003, Picot and Bienvenu
2009, Sonkar et al. 2011). In view of above facts, the pres-
ent study was aimed at assessing the clinico-pathological
symptoms of malaria in India and Saudi Arabia. 
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Malaria is the most prevalent parasitic disease world-
wide, responsible for an estimated 225 million clinical 
cases each year. it mainly affects children, pregnant wom-
en and non-immune adults who frequently die as victims 
of cerebral manifestations and anaemia (Quintero et al. 
2011). it is major cause of death in tropical and sub-tropi-
cal countries where it claims approximately 655 thousand 
lives each year (World Health organization 2010). this 
disease is managed by anti-malarial drugs as no effective 
vaccine is yet available. However, the parasite has devel-
oped resistance against most commonly used antimalarial 
chloroquine (cQ), posing a major problem for malaria 
control programme (Mitra et al. 2006). 
in case of doubtful species diagnosis, sulfadoxine-
pyrimethamine (sP) combination is usually prescribed 
by clinicians to avoid any risk on the life of patient and, 
thereby, increases sP pressure on parasite population. 
With the spread of chloroquine resistant malaria in dif-
ferent countries including india and saudi Arabia, sP 
alone or in combination with artesunate is used as an al-
ternate drug. this drug combination targets the folate bio-
synthetic pathway of Plasmodium species; blocking the 
nucleic acid biosynthesis and thus causing parasite death 
(Peterson et al. 1988, triglia et al. 1997). Pyrimethamine 
acts on the dihydrofolate reductase enzyme of Plasmo-
dium falciparum (Welch, 1897) (PFDHFr) and inhibits 
the folate biosynthesis pathway of the parasite (gregon 
and Plowe 2005). Point mutation in PFDHFr reduces its 
capacity to bind with the drug, resulting in the emergence 
of resistant parasite strains (Mbugi et al. 2006, gesase et 
al. 2009). there are mutations at more than three loci in 
the parasite enzyme in endemic countries (Peterson et al. 
1988, sirawaraporn et al. 1997). 
Pyrimethamine resistance develops in a progressive 
manner and treatment failure occurs. since both P. fal-
ciparum and P. vivax (grassi et Feletti, 1890) contain 
the same target enzymes, the antifolate drug also affects 
P. vivax – see imwong et al. (2003), Hastings et al. (2004), 
de Pecoulas et al. (2004), Kaur et al. (2006), Barnadas 
et al. (2008). Keeping these facts in mind, study on the 
prevalence of mutations and phenotypic expressions as-
sociated with sulfadoxine-pyrimethamine resistance in 
P. falciparum and P. vivax is attempted in the samples ob-
tained from india and saudi Arabia.
Materials and Methods
Blood samples collected from the patients with fever who 
attended the Medical college and other malaria clinics of Ali-
garh, india during 2011–2012, and the communicable Diseases 
control centre, taif, saudi Arabia, from the patients who vis-
ited Jazan and Yemen earlier, were included in this study. thick 
and thin blood smears of these patients were screened by E-600 
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abstract: therapeutic efficacy of sulfadoxine-pyrimethamine (sP), which is commonly used to treat falciparum malaria, was as-
sessed in isolates of Plasmodium falciparum (Welch, 1897) and Plasmodium vivax (grassi et Feletti, 1890) of Aligarh, Uttar Pradesh, 
North india and taif, saudi Arabia during 2011–2012. Both the species showed mutations in dihydrofolate reductase (DHFr) 
enzyme as they have common biochemical drug targets. Mutation rate for pfdhfr was higher compared to pvdhfr because the drug 
was mainly given to treat falciparum malaria. since both the species coexist, P. vivax was also exposed to sP due to faulty species 
diagnosis or medication without specific diagnosis. low level of mutations against sP in P. falciparum of saudi isolates indicates 
that the sP combination is still effective for the treatment of falciparum malaria. since sP is used as first-line of treatment because of 
high level of resistance against chloroquine (cQ), it may result in spread of higher level of mutations resulting in drug resistance and 
treatment failure in near future. therefore, to avoid further higher mutations in the parasite, use of better treatment regimens such as 
artesunate combination therapy must be introduced against sP combination. 
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